---
layout: report
---

<nav class="navbar bg-light fixed-top flex-md-nowrap p-0 shadow">
	<a class="navbar-brand col-sm-3 col-md-2 mr-0 transition" href="{{ site.baseurl }}/index">{% include logo.html %}</a>
	<span id="message" class="col-lg-6 alert alert-success-fade">Please read feedback on this page and click next to continue</span>
	<div class="wizard-steps col-lg-4">
		<ul>
			<li class="">1. Select audit</li>
			<li class="active">2. Review Report</li>
			<li class="">3. Complete survey</li> 
		</ul>
	</div>	
	<!--<ul class="navbar-nav px-3">
		<li class="nav-item text-nowrap">
			{% include progress-bar.html %}
		</li>
	</ul>-->
</nav>
<div class="container-fluid">
	<div class="row">
		<nav class="col-md-2 d-none d-md-block bg-light sidebar">
			<div class="sidebar-sticky">
				<ul class="nav flex-column">
					<!--<li class="nav-item">
						<a class="nav-link" href="#">
						  <i class="far fa-arrow-alt-circle-up"></i>Back to top 
						</a>
					</li>-->
					<li class="nav-item" id="blocka-link">
						<a class="nav-link" href="#block-a">
						  <i class="fas fa-chart-bar mr-2"></i>Results
						</a>
					</li>
					<li class="nav-item" id="blockc-link">
						<a class="nav-link" href="#block-c">
						  <i class="fas fa-check mr-2"></i>Recommendations for action 
						</a>
					</li>
					<li class="nav-item" id="blockd-link">
						<a class="nav-link" href="#block-d">
						  <i class="fas fa-search mr-2"></i>Patient experience 
						</a>
					</li>
					<li class="nav-item" id="blocke-link">
						<a class="nav-link" href="#block-e">
						  <i class="far fa-star mr-2"></i>Participation and benchmarking 
						</a>
					</li>
					<li class="nav-item" id="blockf-link">
						<a class="nav-link" href="#block-f">
						  <i class="far fa-comment-alt mr-2"></i>A patient account 
						</a>
					</li>
				</ul>
			</div>
		</nav>
		<main role="main" class="col-md-9 ml-sm-auto col-lg-10 px-4">
			<div class="d-flex justify-content-between flex-wrap flex-md-nowrap align-items-center pt-3 pb-2 mb-3 border-bottom">
				<h1 class="h2">National Diabetes Audit<small class="text-muted">2017-2018</small>
				      <!--<label class="switch pull-right">
					<input type="checkbox" id="toggleSwitch" onclick="toggleSwitch()">
					<span class="slider round"></span>
				      </label>-->
				</h1>
			</div><!--end d-flex--->
			<div id="audit-standard" class="audit-standard" title="Audit Standard">
			      <blockquote class="blockquote" style="border-left:5px,blue">
				      <p class="mb-0"><strong>Audit Standard: </strong>Adults with type 2 diabetes whose HbA1c level is 58mmol/mol 7.5% or above after 6 months with single-drug treatment are offered dual therapy.</p>
			      </blockquote>
			</div><!--audit standard--->
			<h2 id="blocka-header">Results</h2>
			      <p>Your practice achieved this standard of care for <strong>86% (318/370) of patients</strong>.</p>
			<div id="block-a" title="mod-7">
			      <p class="toggle-mod" style="display:block">The top 25% of practices achieved this for <strong>93.7% or better</strong> of patients.</p>
			      <p class="toggle-mod" style="display:none">This compares to the national achievement of <strong>79%.</strong></p>
			</div><!--end block a-->
			<div id="block-b" title="mod-9">
			      <div class="toggle-mod" style="display:block">
				    <p>This chart shows your performance in comparison with other general practices.</p>
				    {% include mod-9-svg.html %}  
			      </div>
			      <div class="toggle-mod" style="display:none">
				    <!--Off contains no content-->  
			      </div>
			</div><!--end block b-->
			<div id="block-c" title="mod-3" class="section">
			      <div class="toggle-mod">
				    <h2 id="blockc-header">Recommendations for action</h2>
				    <ul class="list-group">
					  <li class="list-group-item">
						<i class="fas fa-check-circle mr-1"></i>Identify adult patients with type 2 diabetes whose HbA1c level is 58mmol/mol or above.
					  </li>
					  <li class="list-group-item">
						<i class="fas fa-check-circle mr-1"></i>Identify which of these patients have been treated with a single drug for 6 months or longer.
					  </li>
					  <li class="list-group-item">
						<i class="fas fa-check-circle mr-1"></i>Invite these patients for a consultation to discuss HbA1c test results.
					  </li>
					  <li class="list-group-item">
						<i class="fas fa-check-circle mr-1"></i>Discuss treatment options and offer dual-therapy, if appropriate.
					  </li>                
				    </ul>
			      </div>
			      <div class="toggle-mod" style="display:none">
				    <!--Off contains no content--> 
			      </div>
			</div><!--end block c-->
			<div id="block-d" title="mod-12" class="section">
				<h2 id="blockd-header">Patient experience </h2>
			      <div class="row">
				      <div class="col-md-4">
					      	<ul class="nav nav-pills flex-column" id="myTab" role="tablist" aria-orientation="vertical">
							<li class="nav-item">
								<a class="nav-link active" id="home-tab" data-toggle="tab" href="#evidence" role="tab" aria-controls="evidence" aria-selected="true">What is the evidence base for HbA1c target levels?</a>
							</li>
							<li class="nav-item">
								<a class="nav-link" id="therapies-tab" data-toggle="tab" href="#therapies" role="tab" aria-controls="therapies" aria-selected="false">What are the options if single drug therapy if the HbA1c level is 58mmol/mol or above?</a>
							</li>
							<li class="nav-item">
								<a class="nav-link" id="patients-tab" data-toggle="tab" href="#patients" role="tab" aria-controls="patients" aria-selected="false">Which of our patients with type 2 diabetes have an HbA1c level of 58mmol/mol or above?</a>
							</li>
						</ul>
				      </div>
				      <div class="col">
						<div class="tab-content">
					  <div class="tab-pane active" id="evidence" role="tabpanel" aria-labelledby="evidence-tab">
						<div class="col-lg-12">
						    <h4></h4>
						</div>
						<div class="col-lg-12 col-sm-12 col-md-12 col-xs-12">
						  <ul>
						    <li style="display:block; text-align:left"><a href="" class="circle circle-md bg-warning di" data-toggle="tooltip" title="" data-original-title="More">48+</a> mmol/mol HbA1c levels risk for <strong>microvascular complications</strong> increases significantly</li><br>
						    <li style="display:block; text-align:left"><a href="" class="circle circle-md bg-danger di" data-toggle="tooltip" title="" data-original-title="More">53+</a> mmol/mol HbA1c levels risk for <strong>mortality and macrovascular complications</strong> increases significantly</li>
						  </ul>
						</div>
						<div class="">
							<a href="#" class="btn btn-outline-secondary" data-toggle="modal" data-target="#Modal1">View NICE guidance</a>
                        			</div> 
						  <a href="#therapies" aria-controls="patients" title="" data-toggle="tooltip" data-placement="top" class="btn btn-primary m-l-20 hidden-xs hidden-sm waves-effect waves-light pull-right" data-original-title="Needs to link to patient list">View at risk patients</a>
					  </div>
					  <div class="tab-pane" id="patients" role="tabpanel" aria-labelledby="patients-tab">
					      <div class="col-sm-12">
						  <h4></h4>
					      </div>
						<div class="table-responsive manage-table">
						    <table class="table">
							<thead>
							    <tr>
								<th>NAME</th>
								<th>NHS Number</th>
								<th>Last HbA1c level</th>
								<th>Actions</th>
							    </tr>
							</thead>
							<tbody>
							    <tr class="advance-table-row">
								<td>Andrew Simons</td>
								<td>434 897 2136</td>
								<td>69</td>
								<td><button type="button" class="btn btn-outline-secondary" data-toggle="tooltip" data-placement="top" title="In a real audit report this would link to a table containing individual patient records">
								  Patient details
								</button></td>
							    </tr>
							    <tr class="advance-table-row">
								<td>Hanna Gover</td>
								<td>434 765 3241</td>
								<td>76</td>
								<td><button type="button" class="btn btn-outline-secondary" data-toggle="tooltip" data-placement="top" title="In a real audit report this would link to a table containing individual patient records">
								  Patient details
								</button></td>
							    </tr>
							    <tr class="advance-table-row">
								<td>Joshi Nirav</td>
								<td>434 456 1101</td>
								<td>72</td>
								<td><button type="button" class="btn btn-outline-secondary" data-toggle="tooltip" data-placement="top" title="In a real audit report this would link to a table containing individual patient records">
								  Patient details
								</button></td>
							    </tr>
							    <tr class="advance-table-row">
								<td>Joshi Sunil</td>
								<td>434 456 1101</td>
								<td>65</td>
								<td><button type="button" class="btn btn-outline-secondary" data-toggle="tooltip" data-placement="top" title="In a real audit report this would link to a table containing individual patient records">
								  Patient details
								</button></td>
							    </tr>
							</tbody>
						    </table>

						    <!-- Patient info modals -->
						    <div class="modal fade" id="Modal1" tabindex="-1" role="dialog" aria-labelledby="exampleModalLabel" aria-hidden="true">
						      <div class="modal-dialog" role="document">
							<div class="modal-content">
							  <div class="modal-header">
							    <h5 class="modal-title" id="exampleModalLabel">Andrew Simons</h5>
							    <button type="button" class="close" data-dismiss="modal" aria-label="Close">
							      <span aria-hidden="true">×</span>
							    </button>
							  </div>
							  <div class="modal-body">
							    <div class="topic">
            <header id="displayheader" class="topic-header">
                <a class="toggle-offcanvas" data-toggle="offcanvas"><span class="icon-nice-hamburger"></span></a>

                <div class="navbar share-links pull-right">
                    <div class="navbar-inner">
                        <ul class="nav">
                            <li class="dropdown">
                                <a href="#" id="nice-share" class="dropdown-toggle icon-stack" data-toggle="dropdown" title="Share"><i class="icon-nice-circle icon-stack-base"></i><i class="icon-nice-share"></i></a>
                                <ul class="dropdown-menu pull-right addthis_toolbox" role="menu" aria-labelledby="nice-share">
                                    <li class="nav-header"><b>Share</b></li>
                                    <!-- AddThis Button BEGIN -->
                                    <li><a data-category="social - linkedin" class="addthis_button_linkedin addthis_event" target="_blank" title="LinkedIn" href="#"><i class="icon-linkedin"></i> Linked In</a></li>
                                    <li><a data-category="social - twitter" class="addthis_button_twitter addthis_event" title="Twitter" href="#"><i class="icon-nice-twitter"></i> Twitter</a></li>
                                    <li><a data-category="social - facebook" class="addthis_button_facebook addthis_event" title="Facebook" href="#"><i class="icon-nice-facebook"></i> Facebook</a></li>
                                    <li><a data-category="social - email" class="addthis_button_email addthis_event" target="_blank" title="Email" href="#"><i class="icon-nice-email-closed"></i> Email</a></li>
                                    <li><a class="addthis_button_more" target="_blank" title="More" href="#"><i class="icon-nice-plus"></i> More...</a></li>
                                    <!-- AddThis Button END -->
                                <div class="atclear"></div></ul>
                            </li>
                            <li><a id="printVersionLink" href="javascript:window.print()" class="icon-stack" title="Print friendly version" rel="nofollow"><i class="icon-nice-circle icon-stack-base"></i><i class="icon-nice-print"></i></a></li>
                        </ul>
                    </div>
                </div>
            <h1 property="name">Diabetes - type 2</h1><span class="last_revision" style="display: block;">Last revised in August 2017
</span></header>

            <article prefix="dcterms: http://purl.org/dc/terms/ dc: http://purl.org/dc/elements/1.1/" vocab="http://schema.org/" about="-350333" typeof="MedicalScholarlyArticle" class="topic"><header></header><span property="dc:title" class="hidden">Diabetes - type 2</span><div property="about" typeof="MedicalCondition" class="hidden"><div property="code dcterms:MESH" typeof="MedicalCode"><div><span property="codeValue">D003924</span><span class="term">Diabetes Mellitus, Type 2</span></div></div></div><div class="clinical_specialities hidden"><span class="clinical_speciality">Preventative medicine</span><span class="clinical_speciality">Cardiovascular</span><span class="clinical_speciality">Kidney disease and urology</span><span class="clinical_speciality">Eyes</span><span class="clinical_speciality">Endocrine and metabolic</span></div><span property="dateModified dcterms:modified" content="2018-10-25" class="hidden">2018-10-25</span><section class="changes hidden" id="-350356"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Changes</h2></header><span class="last_revision">Last revised in August 2017
</span><p>
          <b>August&nbsp;2017</b>&nbsp;— minor update. Bullous pemphigoid added as an adverse effect&nbsp;of gliptins as per updates to the manufacturer's summary of product characteristics.&nbsp;</p><p>
          <b>May 2017</b>&nbsp;— minor update. Information added on&nbsp;sodium–glucose cotransporter 2 (SGLT-2) inhibitors to reflect&nbsp;changes to NICE &nbsp;guideline&nbsp;<i>Type 2 diabetes in adults: management.</i></p><p>
          <b>January 2017</b>&nbsp;— minor update. Information added on organic cation transporters in the metformin prescribing section as per the<b>&nbsp;</b>manufacturer's Summary of Product Characteristics for glucophage. Information also added on drug interaction with St John's wort as per an update to the&nbsp;manufacturer's Summary of Product Characteristics for Diamicron.</p><p>
          <b>December 2016</b> — minor updates.</p><ul><li class="level1">Information added on use of pioglitazone in patients with active bladder cancer following FDA review&nbsp;[<a rel="citation" resource="1090203#A1404805" href="/diabetes-type-2#!references/1090203">FDA, 2016</a>].</li><li class="level1">The adverse effects section for pioglitazone has&nbsp;been updated with information that bone fractures have been reported in both men and women&nbsp;[<a rel="citation" resource="1090203#A1314693" href="/diabetes-type-2#!references/1090203">ABPI, 2016</a>].</li><li class="level1">Information from&nbsp;a systematic review has&nbsp;been added to the basis for recommendation in the section on managing cardiovascular risk [<a rel="citation" resource="1090203#A1404546" href="/diabetes-type-2#!references/1090203">BMJ, 2016</a>].</li><li class="level1">The adverse effects and interactions sections have been updated to reflect changes to the manufacturer's Summary of Product Characteristics for vildagliptin [<a rel="citation" resource="1090203#A1404967" href="/diabetes-type-2#!references/1090203">ABPI, 2016b</a>].</li></ul><p><b>November 2016 </b>—&nbsp;minor updates.</p><ul><li class="level1">The National Institute for Health and Care Excellence (NICE) quality standards for diabetes in children&nbsp;and young people have been added to this topic [<a rel="citation" resource="1090203#A1402667" href="/diabetes-type-2#!references/1090203">NICE, 2016</a>]. &nbsp;</li><li class="level1">Additional information regarding referral to the diabetic eye screening programme has been added to reflect the November 2016 update to the NICE guideline.&nbsp;</li><li class="level1">A recommendation from a&nbsp;Medicines and Healthcare products Regulatory Agency (MHRA) Drug safety update&nbsp;<i>SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis</i>&nbsp;[<a rel="citation" resource="1090203#A1403259" href="/diabetes-type-2#!references/1090203">MHRA, 2016</a>]&nbsp;has been added to this topic.</li><li class="level1">The adverse effects section for sulfonylureas has been updated to include information about skin and subcutaneous tissue disorders and&nbsp;drug rash with eosinophilia and systemic symptoms (DRESS) with gliclazide [<a rel="citation" resource="1090203#A1403667" href="/diabetes-type-2#!references/1090203">ABPI, 2016c</a>].</li></ul><p><b>October 2016&nbsp;</b>— minor update.&nbsp;Increased lipase and increased amylase added as common adverse effects of liraglutide.&nbsp;</p><p><b>April to July 2016 </b>— reviewed. A literature search was conducted in April 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The recommendations have been updated in line with recommendations in the National Institute for Health and Care Excellence (NICE) guidelines&nbsp;<i>Type 2 diabetes in adults: management (2015)</i>&nbsp;and&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management (2015)</i>.</p><section class="previouschanges" id="-391419"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Previous changes</h3></header><p><b>October 2015</b> —&nbsp;minor updates:</p><ul><li class="level1">Immune-mediated necrotizing myopathy (IMNM) has been included as a very rare adverse effect of some statins based on updates to manufacturers' Summaries of Product Characteristics (SPCs).</li><li class="level1">The prescribing information section has been updated to reflect the US Food and Drug Administration (FDA) adverse event database, which now includes severe joint pain as an adverse effect of DPP-4 inhibitors.</li></ul><p><b>September 2015 </b>— minor updates. The prescribing information section has been updated to include:</p><ul><li class="level1">Pruritus, arthropathy, and bullous pemphigoid as adverse effects of sitagliptin based on an update to the manufacturer's SPC.</li><li class="level1">Advice from the Medicines and Healthcare products Regulatory Agency (MHRA) and the drug manufacturers that combination use of drugs from two classes of the renin-angiotensin system (RAS) blocking agents (for example an angiotensin-converting enzyme [ACE] inhibitor plus an angiotensin-II receptor antagonist or aliskiren) is not recommended.</li><li class="level1">Other common adverse effects of ACE inhibitors and a drug interaction between ramipril tablets (Tritace®) and vildagliptin, based on updates to the SPC for Tritace®.</li></ul><p><b>August 2015 </b>— minor update. The prescribing information section on clarithromycin has been updated to&nbsp;reflect&nbsp;changes to the manufacturer's SPC.</p><p><b>July 2015 </b>— minor update. Based on an update to the manufacturer's SPC, constipation has been added as an adverse effect of saxagliptin.</p><p><b>April 2015 </b>—&nbsp;minor update. Update to the text to clarify the MHRA warning that aliskiren should not be prescribed with different classes of RAS blocking drugs.</p><p><b>March 2015 </b>—&nbsp;minor update. Update to the text to reflect the adverse effect of rapid weight loss resulting in cholelithiasis for exenatide, based on the manufacturer's SPC.</p><p><b>February 2015 </b>— minor update. Update to reflect the National Institute for Health and Care Excellence (NICE) guideline and address differences between this and the current Clinical Knowledge Summaries (CKS) type 2 diabetes topic.</p><p><b>September 2014 </b>—&nbsp;two minor updates:</p><ul><li class="level1">The recommendations in the scenario on managing&nbsp;lipids&nbsp;have been updated in line with the revised NICE guideline <i>Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (2014)</i>.</li><li class="level1">The World Health Organization (WHO) recommendation to use HbA1c to confirm the diagnosis of diabetes type 2 has been included.</li></ul><p><b>August 2014 </b>— minor update to reflect additional caution of history of pancreatitis for saxagliptin and vildagliptin, based on the manufacturers' SPCs.</p><p><b>July 2014 </b>— two minor updates:&nbsp;</p><ul><li class="level1">The evidence section on lipid modification therapy has been deleted because it is currently being updated in line with the NICE guideline on lipid modification.</li><li class="level1">Advice from the MHRA to not prescribe medicines from different classes of RAS blocking agents in combination (for example an ACE inhibitor plus an AIIRA) has been incorporated into the topic.</li></ul><p><b>March 2014 </b>—&nbsp;minor update. Information on the pharmacological treatment of neuropathic pain has been removed and a link to the CKS topic on Neuropathic pain - drug treatment inserted.</p><p><b>January 2014 </b>— minor update. The prescribing information regarding antiplatelet drugs has been removed and a link to the CKS topic on Antiplatelet treatment inserted.</p><p><b>December 2013 </b>— two minor updates:</p><ul><li class="level1">Prescribing information has been updated in line with the SPC for perindopril.</li><li class="level1">Text has been removed from the section on antiplatelet treatment and links added to the updated CKS topic on Antiplatelet treatment.</li></ul><p><b>September 2013</b> — minor update to the text to reflect current European Medicines Agency (EMA) recommendations regarding metoclopramide.</p><p><b>July 2013 </b>— minor update. Links to the&nbsp;Driver and Vehicle Licensing Agency (DVLA)&nbsp;website have been updated.</p><p><b>June 2013 </b>— minor update. The 2013&nbsp;Quality and Outcomes Framework (QOF)&nbsp;options for local implementation have been added to this topic.</p><p><b>February 2013 </b>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><b>January 2013 </b>— minor update. Removed the black triangle status from sitagliptin as this is no longer a black triangle drug. Change to the text to reflect safety advice issued by the MHRA regarding gliptins. Update to the text to reflect safety advice issued by the MHRA for simvastatin.</p><p><b>November 2012 </b>— minor update. The links to the electronic medicines website (www.medicines.org.uk) have been updated.</p><p><b>October 2012 </b>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><b>July 2012 </b>— minor update. The section on goals and outcome measures has been updated to reflect changes to the NICE <i>Diabetes in adults</i> quality standards.</p><p><b>March 2012 </b>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><b>February 2012 </b>— minor update. Issued in April 2012. This topic has been updated to include:&nbsp;</p><ul><li class="level1">A section on management of a person with type 2 diabetes during periods of fasting (such as during Ramadan).</li><li class="level1">Information from guidelines commissioned by NHS Diabetes on 'Recognition, treatment and prevention of hypoglycaemia in the community'.</li><li class="level1">New information about doses, contraindications, and adverse effects of gliptins.</li></ul><p><b>January 2012 </b>— minor updates. Issued in February 2012. This topic has been updated to include:</p><ul><li class="level1">Information from the MHRA about the slight risk of hyperglycaemia and diabetes with statin use.</li><li class="level1">Update to the manufacturers' SPCs to clarify that although liraglutide is not licensed for use in combination with insulin, Levemir® (insulin detemir [recombinant human insulin analogue]) is licenced to be used as add-on therapy to liraglutide treatment.</li></ul><p><b>October to December 2011</b>— updated. Issued in January 2012. This topic has been updated to include:&nbsp;</p><ul><li class="level1">The MHRA warning on the interaction between systemic fusidic acid and statins.</li><li class="level1">Information on saxagliptin (Onglyza®) and linagliptin (Trajenta®), two new dipeptidyl peptidase-4 inhibitors licensed for the treatment of adults with type 2 diabetes to improve glycaemic control.</li><li class="level1">Information on the NICE technology appraisal&nbsp;<i>Liraglutide for the treatment of type 2 diabetes mellitus</i>.</li><li class="level1">Information on fitness to drive from the DVLA's&nbsp;<i>At a glance guide to the current medical standards of fitness to drive</i>.</li><li class="level1">A tabulated version of the treatment recommendations for blood glucose control, to aid navigation.</li></ul><p><b>August 2011</b>— minor update. There is a small increased risk of bladder cancer associated with pioglitazone use. This information is based on advice from the MHRA and the EMA. Issued in September 2011.</p><p><b>July 2011</b>— minor update. Cough is included as a very rare but possible adverse effect of candesartan. This information is based on the updated SPC for Amias®. Issued in September 2011.</p><p><b>May 2011</b>— minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><b>March 2011</b>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made. The NICE quality standards on the management of diabetes have been added.</p><p><b>November 2010 </b>— minor update. CKS is aware that some primary care trusts are still recommending gabapentin over pregabalin due to the significant price differences between these two drugs. Based on feedback from CKS external reviewers, gabapentin is also offered by CKS as an alternative to pregabalin if there is a local decision to prefer gabapentin over pregabalin for painful diabetic neuropathy. Issued in November 2010.</p><p><b>October 2010 </b>— minor update. Information on fitness to drive from the DVLA's <i>At a glance guide to the current medical standards of fitness to drive </i>has been added. Issued in October 2010.</p><p><b>September 2010 </b>— minor update. The topic has be amended to reflect information in the MHRA guidance&nbsp;<i>Rosiglitazone (Avandia, Avandamet): Recommended withdrawal from clinical use updated</i>. Rosiglitazone is no longer available. The UK marketing authorisation has been suspended because the benefits are no longer considered to outweigh the increase in cardiovascular risk associated with its use. Issued in September 2010.</p><p><b>September 2010 </b>— minor update. The supporting evidence section on Antiplatelet drugs has been updated. Issued in September 2010.</p><p><b>August 2010 </b>— minor update. The MHRA has issued a reminder that the current cardiovascular restrictions on rosiglitazone must be followed whilst the EMA review on the safety of rosiglitazone is ongoing. Issued in August 2010.</p><p><b>July 2010 </b>— updated to include new recommendations on the management of painful diabetic neuropathy published in the NICE guideline <i>Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings</i>.</p><p><b>June 2010 </b>— minor update. Advice that vitamin B12 deficiency may sometimes be caused by long-term treatment with metformin has been added to the adverse effects section. Issued in June 2010.</p><p><b>April 2010 </b>— minor update. The recommendations from the NHS Diabetes Working Group on when to recommend self-monitoring of blood glucose has been included in the relevant sections. It supports the advice that self-monitoring of blood glucose should only be offered with appropriate education and clear objectives in specific circumstances. Advice from the Scottish Intercollegiate Guidelines Network&nbsp;(SIGN)&nbsp;that aspirin should not be offered for primary prevention of cardiovascular disease (CVD) in people with diabetes has also been added. Issued in April 2010.</p><p><b>December 2009 </b>— minor update. The recommendations on when to consider antiplatelet therapy for primary prevention of CVD have been updated. Issued in December 2009.</p><p><b>July to October 2009 </b>— updated to include evidence and recommendations from the NICE short guideline T<i>ype 2 diabetes: newer agents for blood glucose control in type 2 diabetes</i> and new information on reporting HbA1c levels. A reminder from the MHRA that aspirin is not licensed for primary prevention of CVD has also been added. Issued in October 2009.</p><p><b>July 2009 </b>— minor update to clarify the advice from the MHRA on the use of ACE inhibitors and AIIRAs in women who are breastfeeding. Issued in July 2009.</p><p><b>May 2009 </b>— minor update to include drug safety advice from the MHRA on the use of&nbsp;ACE inhibitors and AIIRAs&nbsp;in women who are breastfeeding. Issued in June 2009.</p><p><b>April 2009 </b>— updated to include the indicators related to diabetes mellitus in the QOF of the General Medical Services contract in the section on goals and outcome measures section. Issued in May 2009.</p><p><b>March 2009 </b>— minor update. Losartan has been reclassified as a black triangle drug by the MHRA. However, this is due to harmonisation of the SPCs across the European Union, not because of any newly identified safety issues. Issued in April 2009.</p><p><b>July to December 2008 </b>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. This CKS topic replaces previous topics on <i>Diabetes — foot disease</i>, <i>Diabetes — glycaemic control</i>, <i>Diabetes — hypertension</i>, <i>Diabetes — renal disease</i>, and <i>Diabetes — retinopathy</i>. Significant changes include:&nbsp;</p><ul><li class="level1">The recommendation to prescribe aspirin to all people with diabetes over the age of 50 years.</li><li class="level1">The recommendation to start insulin (before triple therapy with oral antidiabetic drugs) in primary care, providing the expertise and support are available.</li><li class="level1">The rapid-acting insulin secretagogues (nateglinide and repaglinide) are recommended as an alternative to sulphonylureas for people with irregular mealtimes. Prescriptions are included.</li><li class="level1">Recommendations for management of hypertension have altered — all people with type 2 diabetes should now be started on an ACE inhibitor first-line (unless contraindicated).</li><li class="level1">The decision on when to prescribe a lipid-modifying drug is more clearly expressed.</li><li class="level1">Treatment targets for lipids have changed.</li><li class="level1">Ezetimibe is now recommended, in addition to simvastatin, as an alternative to a higher-intensity statin for people with CVD or microalbuminuria who have not reached lipid targets on a lower-intensity statin. Prescriptions are included.</li></ul></section></section><section class="annual_know_upd hidden" id="-350359"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Update</h2></header><section class="annual_know_new_evidence" id="-511708"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>New evidence</h3></header><h5>Evidence-based guidelines</h5><ul><li class="level1">IDF (2017) <i>IDF diabetes atlas - 6th edition</i>. International Diabetes Federation. <a href="http://www.idf.org/">www.idf.org</a>. [<a href="https://www.idf.org/news/94:new-idf-figures-show-continued-increase-in-diabetes-across-the-globe,-reiterating-the-need-for-urgent-action.html">Free Full-text</a>]</li><li class="level1">Qaseem, A., Barry, M.J., Humphrey, L.L., and Forciea, M.A. (2017)&nbsp;Oral pharmacologic treatment of type 2 diabetes mellitus: a&nbsp;clinical practice guideline update from the American College of Physicians. <i>Annals of Internal Medicine</i> epub ahead of print. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/22312141">Abstract</a>] [<a href="http://annals.org/aim/article/2595888/oral-pharmacologic-treatment-type-2-diabetes-mellitus-clinical-practice-guideline">Free Full-text</a>]</li><li class="level1">NICE (2016)&nbsp;<i>Dapagliflozin in triple therapy for treating type 2 diabetes (technology appraisal)</i>. National Institute for Health and Care Excellence. <a href="https://www.nice.org.uk/">www.nice.org.uk</a> [<a href="https://www.nice.org.uk/guidance/ta418">Free Full-text</a>]</li><li class="level1">NICE (2017)&nbsp;Type 2 diabetes: prevention in people at high risk.&nbsp;National Institute for Health and Care Excellence. <a href="https://www.nice.org.uk/">www.nice.org.uk</a> [<a href="https://www.nice.org.uk/guidance/ph38">Free Full-text</a>]</li><li class="level1">SIGN (2017) <i>Management of diabetes. A national clinical guideline</i>. <a href="http://www.sign.ac.uk/">www.sign.ac.uk</a>&nbsp;[<a href="http://www.sign.ac.uk/assets/sign116.pdf">Free Full-text</a>]</li><li class="level1">SIGN (2017) <i>Pharmacological management of glycaemic control in people with type 2 diabetes</i>. <a href="http://www.sign.ac.uk/">www.sign.ac.uk</a>&nbsp;[<a href="http://www.sign.ac.uk/assets/sign154.pdf">Free Full-text</a>]</li><li class="level1">Diabetes UK (2018) <i>Improving care for people with diabetes and a learning difficulty.</i> Diabetes UK [<a href="https://www.diabetes.org.uk/Professionals/Resources/shared-practice/for-people-with-learning-disability">Free Full-Text</a>]</li><li class="level1">ADA (2018) Standards of medical care in diabetes. American Diabetes Association. <a href="http://care.diabetesjournals.org/">www.care.diabetesjournals.org.uk</a> [<a href="http://care.diabetesjournals.org/content/41/Supplement_1">Free Full-text</a>]</li><li class="level1">PHE (2018) Diabetes foot care profiles: annual update, 2018. Public Health England. <a href="https://www.gov.uk/">www.gov.uk</a> [<a href="https://www.gov.uk/government/statistics/diabetes-foot-care-profiles-annual-update-2018">Free Full-Text</a>]</li><li class="level1">PHE (2018) <i>Health matters: preventing Type 2 diabetes</i>. Public Health England. <a href="https://www.gov.uk/">www.gov.uk</a> [<a href="https://www.gov.uk/government/publications/health-matters-preventing-type-2-diabetes/health-matters-preventing-type-2-diabetes">Free Full-text</a>]</li><li class="level1">McKee, S. (2018)&nbsp;<i>Novo’s oral </i><i>semaglutide</i><i> beats Lilly/Boehringer’s Jardiance.&nbsp;</i>Pharma Times. <a href="http://www.pharmatimes.com/">www.pharmatimes.com</a> [<a href="http://www.pharmatimes.com/news/novos_ozempic_beats_lillyboehringers_jardiance_1237555">Free Full-text</a>]</li><li class="level1">The Lancet (2018) Incidence and progression of diabetic retinopathy: a systematic review. <a href="https://www.thelancet.com/journals/landia/issue/current">www.thelancet.com</a> [<a href="https://www.thelancet.com/journals/landia/article/PIIS2213-8587(18)30128-1/fulltext">Free Full-text</a>]</li><li class="level1">Davies, M., et al (2018)&nbsp;<i>Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). </i>Diabetes Care. <a href="http://care.diabetesjournals.org/">www.care.diabetesjournals.org</a> [<a href="http://care.diabetesjournals.org/content/early/2018/09/27/dci18-0033">Free Full-text</a>]</li></ul><h5>HTAs (Health Technology Assessments)</h5><p>No new HTAs since 1 May 2016.</p><h5>Economic appraisals</h5><p>No new economic appraisals relevant to England since 1 May 2016.</p><h5>Systematic reviews and meta-analyses</h5><ul><li class="level1">Zaccardi, F., Dhalwani, N. N., Dales, J. et al. (2018) <i>Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials</i>. Diabetes, Obesity and Metabolism.&nbsp;<b>epub ahead of print</b>. [<a href="http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13185/abstract">Free Full Text</a>]</li><li class="level1">Du, Y. T., Rayner, C. K., Jones, K. L., et al (2018) <i>Gastrointestinal symptoms in diabetes: prevalence, assessment, pathogenesis and management</i>. American Diabetes Association. <a href="http://care.diabetesjournals.org/">care.diabetesjournals.org&nbsp;</a>&nbsp;[<a href="http://care.diabetesjournals.org/content/41/3/627">Free Full-Text</a>]</li><li class="level1">NPDA (2018)&nbsp;<i>National Paediatric Diabetes Audit Report 2016-17 Care processes and outcomes. </i>[<a href="https://www.rcpch.ac.uk/sites/default/files/2018-07/npda_annual_report_2016_-_2017_april_2018_final_updated_3.pdf">Free Full-text</a>]</li></ul><h5>Primary evidence</h5><p>No new primary evidence since 1 May 2016.</p></section><section class="annual_know_policies" id="-350361"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>New policies</h3></header><p>No new policies since 1 May 2016.</p></section><section class="annual_know_safety" id="-350362"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>New safety alerts</h3></header><p>No new safety alerts published since 1 May 2016.</p></section><section class="annual_know_product" id="-350363"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Changes in product availability</h3></header><ul><li class="level1">Qtern 5 mg/10 mg film-coated tablets is available and is&nbsp;licensed for adults with type 2 diabetes when metformin and/or sulphonylurea and one of the components of Qtern do not provide adequate glycaemic control and the patient is already on the combination of dapagliflozin and saxagliptin. See the manufacturer's summary of product characteristics here:&nbsp;<a href="http://www.medicines.org.uk/emc/medicine/32750">http://www.medicines.org.uk/emc/medicine/32750</a>.</li><li class="level1">Suliqua is licensed for use with metformin for adults with type 2 diabetes mellitus to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin. See the manufacturer's summary of product characteristics here:&nbsp;<a href="http://www.medicines.org.uk/emc/medicine/33221">http://www.medicines.org.uk/emc/medicine/33221</a>.</li><li class="level1">Glucophage SR is now licensed for reduction in risk or delay of onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance or impaired fasting glucose, and/or increased HbA1C who are at high risk for developing overt type 2 diabetes mellitus. See the manufacturer's summary of product characteristics here:&nbsp;<a href="http://www.medicines.org.uk/emc/medicine/20952">http://www.medicines.org.uk/emc/medicine/20952</a>.</li><li class="level1">The manufacturer's summary of product characteristics for saxagliptin has been updated to include information on&nbsp;saxagliptin add on to dapagliflozin plus metformin therapy&nbsp;and on saxagliptin and dapagliflozin added on to metformin therapy:&nbsp;<a href="http://www.medicines.org.uk/emc/medicine/22315">http://www.medicines.org.uk/emc/medicine/22315</a>.</li><li class="level1">Biosimilar insulin glargine approved in the EU - Semglee is a biosimilar medicinal product that has comparable quality, safety and efficacy to the reference product Lantus (insulin glargine). It will be available as a 100 units/mL 3 mL prefilled disposable pen. See more <a href="https://www.biospace.com/article/releases/mylan-and-biocon-receive-approvals-from-the-european-commission-and-tga-australia-for-semglee-biosimilar-insulin-glargine/">here</a>.&nbsp;</li></ul></section></section><section class="goals hidden" id="-350390"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Goals</h2></header><p>To support primary healthcare professionals to:&nbsp;</p><ul><li class="level1">Make a diagnosis of type 2 diabetes in adults, and know when to suspect type 2 diabetes in a child or young person</li><li class="level1">Provide appropriate care, education, and support for people with type 2 diabetes and/or their family/carers</li><li class="level1">Manage the adverse effects of antidiabetic drugs, including hypoglycaemia</li><li class="level1">Manage people with type 2 diabetes during periods of illness&nbsp;</li><li class="level1">Promptly identify and manage acute complications of diabetes, such as dyslipidaemia&nbsp;</li><li class="level1">Minimize the risk of, and screen for, long-term complications of diabetes, such as cardiovascular disease, nephropathy, retinopathy, neuropathy, and psychological problems</li></ul></section><section class="outcomemeasures hidden" id="-505411"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Outcome measures</h2></header><p>No outcome measures were found during the review of this topic.</p></section><section class="cksauditcriteria hidden" id="-498690"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Audit criteria</h2></header><p>No audit criteria were found during the review of this topic.</p></section><section class="cksgmsquality hidden" id="1090185"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>QOF indicators</h2></header><p><b>Table 1. </b>Indicators related to diabetes mellitus in the Quality and Outcomes Framework (QOF) of the General Medical Services (GMS) contract.</p><div class="table-responsive"><table class="tableholder table table-striped table-bordered">
          
		<tbody><tr>
			<th colspan="1"><span class="tableheading">Indicator</span></th>
			<th colspan="1"><span class="tableheading">Points</span></th>
			<th colspan="1"><span class="tableheading">Achievement thresholds</span></th>
		</tr>
		<tr>
			<th colspan="1"><span class="tableheading">Records</span></th>
			<th colspan="1"><span class="tableheading">&nbsp;</span></th>
			<th colspan="1"><span class="tableheading">&nbsp;</span></th>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM017. The contractor establishes and maintains a register of all patients aged 17 or over with diabetes mellitus, which specifies the type of diabetes where a diagnosis has been confirmed</span></td>
			<td colspan="1"><span class="tablerow">6</span></td>
			<td colspan="1"><span class="tablerow">&nbsp;</span></td>
		</tr>
		<tr>
			<th colspan="1"><span class="tableheading">Ongoing management</span></th>
			<th colspan="1"><span class="tableheading">&nbsp;</span></th>
			<th colspan="1"><span class="tableheading">&nbsp;</span></th>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM002. The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</span></td>
			<td colspan="1"><span class="tablerow">8</span></td>
			<td colspan="1"><span class="tablerow">53-93%</span></td>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM003. The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 140/80 mmHg or less</span></td>
			<td colspan="1"><span class="tablerow">10</span></td>
			<td colspan="1"><span class="tablerow">38-78%</span></td>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM004. The percentage of patients with diabetes, on the register, whose last measured total cholesterol (measured within the preceding 12 months) is 5 mmol/L or less</span></td>
			<td colspan="1"><span class="tablerow">6</span></td>
			<td colspan="1"><span class="tablerow">40-75%</span></td>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM006. The percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARB)</span></td>
			<td colspan="1"><span class="tablerow">3</span></td>
			<td colspan="1"><span class="tablerow">57-97%</span></td>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM007. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 59 mmol/mol or less in the preceding 12 months</span></td>
			<td colspan="1"><span class="tablerow">17</span></td>
			<td colspan="1"><span class="tablerow">35-75%</span></td>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM008. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 64 mmol/mol or less in the preceding 12 months</span></td>
			<td colspan="1"><span class="tablerow">8</span></td>
			<td colspan="1"><span class="tablerow">43–83%</span></td>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM009. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months</span></td>
			<td colspan="1"><span class="tablerow">10</span></td>
			<td colspan="1"><span class="tablerow">52–92%</span></td>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM012. The percentage of patients with diabetes, on the register, with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes in previous ulcer) or 4) ulcerated foot within the preceding 12 months</span></td>
			<td colspan="1"><span class="tablerow">4</span></td>
			<td colspan="1"><span class="tablerow">50–90%</span></td>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM014. The percentage of patients newly diagnosed with diabetes, on the register, in the preceding 1 April to 31 March who have a record of being referred to a structured education programme within 9 months after entry on to the diabetes register</span></td>
			<td colspan="1"><span class="tablerow">11</span></td>
			<td colspan="1"><span class="tablerow">40–90%</span></td>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow">DM018. The percentage of patients with diabetes, on the register, who have had influenza immunisation in the preceding 1 August to 31 March</span></td>
			<td colspan="1"><span class="tablerow">3</span></td>
			<td colspan="1"><span class="tablerow">55–95%</span></td>
		</tr>
		<tr>
			<td colspan="1"><span class="tablerow"><b>Data from:</b>&nbsp;[<a rel="citation" resource="1090203#A1299764" href="/diabetes-type-2#!references/1090203">BMA and NHS Employers, 2015</a>]</span></td>
			<td colspan="1"><span class="tablerow">&nbsp;</span></td>
			<td colspan="1"><span class="tablerow">&nbsp;</span></td>
		</tr>
	

        </tbody></table></div></section><section class="qipp hidden" id="1090189"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>QIPP - Options for local implementation</h2></header><p>No QIPP indicators were found during the review of this topic.</p></section><section class="nicequalitystandards hidden" id="1090188"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>NICE quality standards</h2></header><ul><li class="level1">People with diabetes and/or their carers receive a structured educational programme that fulfils the nationally agreed criteria from the time of diagnosis, with annual review and access to ongoing education.</li><li class="level1">People with diabetes receive personalised advice on nutrition and physical activity from an appropriately trained healthcare professional or as part of a structured educational programme.</li><li class="level1">People with diabetes participate in annual care planning which leads to documented agreed goals and an action plan.</li><li class="level1">People with diabetes agree with their healthcare professional a documented personalised HbA1c target, and receive an ongoing review of treatment to minimise hypoglycaemia.</li><li class="level1">People with diabetes agree with their healthcare professional to start, review and stop medications to lower blood glucose, blood pressure and blood lipids in accordance with NICE guidance.</li><li class="level1">Trained healthcare professionals initiate and manage therapy with insulin within a structured programme that includes dose titration by the person with diabetes.</li><li class="level1">Women of childbearing age with diabetes are regularly informed of the benefits of preconception glycaemic control and of any risks, including medication that may harm an unborn child. Women with diabetes planning a pregnancy are offered preconception care and those not planning a pregnancy are offered advice on contraception.</li><li class="level1">People with diabetes receive an annual assessment for the risk and presence of the complications of diabetes, and these are managed appropriately.</li><li class="level1">People with diabetes are assessed for psychological problems, which are then managed appropriately.</li><li class="level1">People with diabetes who are at risk of foot ulceration receive regular review by a foot protection service in accordance with NICE guidance.</li><li class="level1">People with diabetes with a limb-threatening diabetic foot problem are referred immediately to acute services, and the multidisciplinary foot care service is informed.&nbsp;</li><li class="level1">People with diabetes with an active foot problem that is not limb-threatening or life-threatening are referred to the multidisciplinary foot care service within 1 working day and triaged within 1 further working day.</li><li class="level1">People with diabetes admitted to hospital are cared for by appropriately trained staff, provided with access to a specialist diabetes team, and given the choice of self-monitoring and managing their own insulin.</li><li class="level1">People admitted to hospital with diabetic ketoacidosis receive educational and psychological support prior to discharge and are followed up by a specialist diabetes team.&nbsp;</li><li class="level1">People with diabetes who have experienced hypoglycaemia requiring medical attention are referred to a specialist diabetes team.</li></ul><p>[<a rel="citation" resource="1090203#A1299775" href="/diabetes-type-2#!references/1090203">NICE, 2011</a>]</p><ul><li class="level1">Children and young people presenting in primary care with suspected diabetes are referred to and seen by a multidisciplinary paediatric diabetes team on the same day.</li><li class="level1">Children and young people with type&nbsp;1 or type&nbsp;2 diabetes are offered a programme of diabetes education from diagnosis that is updated at least annually.</li><li class="level1">Children and young people with type&nbsp;1 diabetes are offered intensive insulin therapy and level&nbsp;3 carbohydrate-counting education at diagnosis.</li><li class="level1">Children and young people with type&nbsp;1 diabetes who have frequent severe hypoglycaemia are offered ongoing real-time continuous glucose monitoring with alarms.</li><li class="level1">Children and young people with type&nbsp;1 diabetes are offered blood ketone testing strips and a blood ketone meter.</li><li class="level1">Children and young people with type&nbsp;1 or type&nbsp;2 diabetes are offered access to mental health professionals with an understanding of diabetes.</li></ul><p>[<a rel="citation" resource="1090203#A1402667" href="/diabetes-type-2#!references/1090203">NICE, 2016</a>]</p></section><section class="backgroundsub hidden" id="-350395"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Definition</h2><h3>What is it?</h3></header><ul><li class="level1"><b>Diabetes mellitus is&nbsp;a&nbsp;group of metabolic disorders in which persistent hyperglycaemia (random plasma glucose more than 11 mmol/L) is caused by deficient insulin secretion, resistance to the action of insulin, or both.</b>

	
	</li><ul><li class="level2">Insulin deficiency and&nbsp;insulin&nbsp;resistance lead to the abnormalities of carbohydrate, fat, and protein metabolism that are&nbsp;characteristic of diabetes mellitus.&nbsp;&nbsp;</li></ul><li class="level1"><b>Diabetes mellitus is classified as:</b>
	
	</li><ul><li class="level2">Type&nbsp;1 diabetes&nbsp;— an absolute insulin deficiency causes persistent hyperglycaemia (insulin activity is normal).&nbsp;See the CKS topic on <a href="/diabetes-type-1">Diabetes - type 1</a>&nbsp;for more information.</li><li class="level2">Type&nbsp;2 diabetes&nbsp;— insulin resistance and a relative insulin deficiency result in persistent hyperglycaemia.&nbsp;</li><li class="level2">Gestational diabetes&nbsp;— hyperglycaemia develops during pregnancy and usually resolves after delivery, although the woman is at increased risk for overt type 2 diabetes in the future.</li><li class="level2">Other specific types of diabetes, including:
		
		</li><ul><li class="level3">Monogenic diabetes (due to a single gene defect; previously known as 'maturity-onset diabetes in the young').</li><li class="level3">Diabetes secondary to pathological conditions or diseases (such as pancreatitis), trauma, or pancreatic surgery.</li><li class="level3">Drug- or chemically-induced diabetes (such as from long-term corticosteroid treatment).</li></ul></ul><li class="level1">The term 'type 2 diabetes' has replaced the older terms 'non-insulin-dependent diabetes mellitus (NIDDM)' and 'adult-onset diabetes'. The older terms are potentially misleading because people with type 2 diabetes may require insulin, and type 2 diabetes is increasingly being diagnosed in children and young people.</li></ul><p>[<a rel="citation" resource="1090203#A1299518" href="/diabetes-type-2#!references/1090203">WHO, 2006</a>; <a rel="citation" resource="1090203#A63987" href="/diabetes-type-2#!references/1090203">Holt and Kumar, 2010</a>; <a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>]</p></section><section class="backgroundsub hidden" id="1307619"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Causes</h2><h3>What causes it?</h3></header><ul><li class="level1"><b>Type 2 diabetes is caused by a combination of insulin resistance/insensitivity (where the body is unable to respond to normal levels of insulin) and&nbsp;insulin deficiency&nbsp;(where the pancreas is unable to secrete enough insulin to compensate for this resistance).</b>
	
	</li><ul><li class="level2">People with type&nbsp;2 diabetes can differ in the balance of importance of increased insulin resistance and decreased insulin secretion that contributes to their disease.</li><li class="level2">Insulin resistance&nbsp;is exacerbated by overeating, inactivity, and other&nbsp;<a href="/diabetes-type-2#!backgroundsub:2">risk factors</a>.</li></ul></ul><p>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>]</p></section><section class="backgroundsub hidden" id="1307622"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Risk factors</h2><h3>What are the risk factors?</h3></header><ul><li class="level1"><b>Risk factors for type 2 diabetes include:</b>

	
	</li><ul><li class="level2"><b>Obesity and inactivity </b>— people who are overweight or obese (especially central obesity)&nbsp;and/or have inactive lifestyles are at increased risk of developing type 2 diabetes, as overeating and inactivity can exacerbate insulin resistance. Obesity accounts for&nbsp;80–85% of the overall risk of developing type 2 diabetes.&nbsp;</li><li class="level2"><b>Family history </b>— type 2 diabetes tends to cluster in families. People with a family history of diabetes are 2–6&nbsp;times more likely to have diabetes than people without a family history. The risk of developing type 2 diabetes is about 15% if one parent has type 2 diabetes and 75% if both parents have type 2 diabetes.</li><li class="level2"><b>Ethnicity </b>— people of Asian, African, and Black communities are 2–4 times more likely to develop type 2 diabetes than white people.</li><li class="level2"><b>History of gestational diabetes </b>— this confers a sevenfold increased risk of developing type 2 diabetes later in life.&nbsp;Children born to mothers with gestational diabetes have a&nbsp;sixfold increased risk of developing type 2 diabetes.</li><li class="level2">
		<b>Poor dietary habits </b>—low fibre, high glycaemic index (GI) diet&nbsp;may increase the risk of being overweight or obese, which in turn increases the risk of developing type 2 diabetes.

		
		</li><ul><li class="level3">High-GI foods contain carbohydrates that&nbsp;are broken down quickly and cause a rapid increase in blood glucose levels. Examples include sugary foods and drinks, white rice, white bread, and&nbsp;potatoes.</li></ul><li class="level2">
		<b>Drug treatments&nbsp;</b>—certain drug treatments, for example statins, corticosteroids, and combined treatment with a thiazide diuretic plus a beta-blocker, can increase the risk of developing hyperglycaemia and type 2 diabetes.
		</li><li class="level2"><b>Polycystic ovarian syndrome </b>—&nbsp;this&nbsp;increases the risk of impaired glucose regulation and hence type 2 diabetes.</li><li class="level2">
		<b>Metabolic syndrome&nbsp;</b>— insulin resistance is commonly associated with the metabolic syndrome, defined as a combination of&nbsp;raised blood pressure, a disturbance of blood lipid levels,&nbsp;fatty liver, abdominal adiposity (increased waist circumference), and&nbsp;a tendency to develop thrombosis.&nbsp;
		</li><li class="level2"><b>Low birth weight for gestational age&nbsp;</b>— there is some evidence that preterm birth before 35 weeks of gestation is associated with an increased risk of type 2 diabetes&nbsp;developing&nbsp;in adult life.</li></ul></ul><p>[<a rel="citation" resource="1090203#A23356" href="/diabetes-type-2#!references/1090203">MeReC, 2004</a>]&nbsp;&nbsp;[<a rel="citation" resource="1090203#A1314577" href="/diabetes-type-2#!references/1090203">Kajantie et al, 2010</a>]&nbsp;&nbsp;[<a rel="citation" resource="1090203#A68615" href="/diabetes-type-2#!references/1090203">MHRA, 2012</a>; <a rel="citation" resource="1090203#A1299577" href="/diabetes-type-2#!references/1090203">Diabetes UK, 2015</a>; <a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>]</p></section><section class="backgroundsub hidden" id="1307625"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Incidence and prevalence</h2><h3>How common is it?</h3></header><ul><li class="level1"><b>Diabetes is one of the most common chronic diseases in the UK, and its prevalence is increasing&nbsp;</b>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>]<b>.&nbsp;</b>

	
	</li><ul><li class="level2">Diabetes UK estimates that in the UK, there are&nbsp;[<a rel="citation" resource="1090203#A1299577" href="/diabetes-type-2#!references/1090203">Diabetes UK, 2015</a>]:&nbsp;

		
		</li><ul><li class="level3">About 3.5 million people with diagnosed diabetes, including 31,500 children and young people under the age of 19 years.&nbsp;</li><li class="level3">Over half a million (549,000) people with undiagnosed diabetes.&nbsp;</li></ul><li class="level2">The National Institute for Health and Care Excellence (NICE) estimates that by 2025, more than 5 million people in the UK will be diagnosed with diabetes&nbsp;[<a rel="citation" resource="1090203#A1299588" href="/diabetes-type-2#!references/1090203">NICE, 2015c</a>].</li></ul><li class="level1"><b>Type 2 diabetes&nbsp;can occur in all age groups and is increasingly being diagnosed in children </b>(due to the rise in obesity)&nbsp;[<a rel="citation" resource="1090203#A1299577" href="/diabetes-type-2#!references/1090203">Diabetes UK, 2015</a>].
	
	</li><ul><li class="level2">About&nbsp;90% of adults currently diagnosed have type 2 diabetes.&nbsp;</li><li class="level2">About 1.9% of children and young people currently diagnosed have type 2 diabetes.&nbsp;</li></ul></ul></section><section class="backgroundsub hidden" id="1307628"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Prognosis</h2><h3>What is the prognosis?</h3></header><ul><li class="level1"><b>With optimal management, </b>people with type 2 diabetes&nbsp;can participate normally in the usual activities of daily life but are at risk of&nbsp;<a href="/diabetes-type-2#!backgroundsub:5">complications</a>.&nbsp;

	
	</li><ul><li class="level2">Insulin deficiency in type 2&nbsp;diabetes&nbsp;progresses with time and usually worsens over a period of years.</li><li class="level2">Initially, lifestyle interventions (such as diet and physical activity) are used to manage type 2 diabetes. However, over time, many people will require antidiabetic drug treatments (including insulin).</li></ul></ul><p>[<a rel="citation" resource="1090203#A1299577" href="/diabetes-type-2#!references/1090203">Diabetes UK, 2015</a>; <a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>]</p></section><section class="backgroundsub hidden" id="1307631"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Complications</h2><h3>What are the complications?</h3></header><ul><li class="level1"><b>Complications of type 2 diabetes include:</b>
	
	</li><ul><li class="level2"><b>Macrovascular complications —</b> cardiovascular disease (CVD, for example myocardial infarction), cerebrovascular disease (for example stroke and transient ischaemic attack), and peripheral arterial disease (for example intermittent claudication).
		
		</li><ul><li class="level3">CVD is a major cause of death and disability in people with diabetes. In the World Health Organization (WHO) <i>Multinational study of vascular disease in diabetes</i>, CVD accounted for 52% of deaths in people with type 2 diabetes&nbsp;[<a rel="citation" resource="1090203#A64340" href="/diabetes-type-2#!references/1090203">Morrish et al, 2001</a>].</li><li class="level3">People with type&nbsp;2 diabetes have a twofold increased risk of stroke within the first five years of diagnosis compared with the general population.&nbsp;</li><li class="level3">About 20% of hospital admissions for&nbsp;heart failure, myocardial&nbsp;infarction, and stroke are in&nbsp;people with diabetes (type 1 or 2).</li></ul><li class="level2"><b>Microvascular complications —&nbsp;</b>nephropathy, retinopathy, and neuropathy.
		
		</li><ul><li class="level3">Nephropathy — kidney damage is the largest cause of renal failure in people of working age in the UK. About 3 in 4&nbsp;people with diabetes will develop some stage of chronic kidney disease (CKD) during their lifetime. Kidney disease accounts for 11% of deaths in people with type 2 diabetes.</li><li class="level3">Retinopathy — diabetes is the leading cause of preventable blindness in people of working age in the UK, and diabetic retinopathy accounts for 7% of people who are registered blind in England and Wales.&nbsp;Within 20 years of diagnosis, about 60%<b>&nbsp;</b>of people with type&nbsp;2 diabetes will have some degree of retinopathy.</li><li class="level3">Chronic painful neuropathy — this is estimated to affect up to 26% of people with diabetes, and people with diabetes are estimated to be up to 30 times more likely to have an amputation compared with the general population.&nbsp;</li><li class="level3">Autonomic neuropathy — this presents in different ways and affects a variety of organs, including the skin (sweating), blood vessels (postural hypotension), gastrointestinal tract (gastroparesis and diarrhoea), heart, bladder function, and sexual function (35–90% of men with diabetes have erectile dysfunction). It may also blunt the symptoms of&nbsp;<a href="/diabetes-type-2#!diagnosissub:3">hypoglycaemia</a>.</li></ul><li class="level2"><b>Metabolic complications —</b>&nbsp;dyslipidaemia and&nbsp;diabetic ketoacidosis (DKA).
		
		</li><ul><li class="level3">Dyslipidaemia is a risk factor for CVD. See the CKS topic on <a href="/cvd-risk-assessment-and-management">CVD risk assessment and management</a>&nbsp;for more information.</li><li class="level3">DKA (the metabolic state characterized by the triad of marked hyperglycaemia, acidosis, and ketonaemia)&nbsp;is more common in type 1 diabetes but may occur in people with type 2 diabetes&nbsp;[<a rel="citation" resource="1090203#A79929" href="/diabetes-type-2#!references/1090203">BSPED, 2013</a>; <a rel="citation" resource="1090203#A79928" href="/diabetes-type-2#!references/1090203">Joint British Diabetes Societies Inpatient Care Group, 2013</a>].&nbsp;See the section on&nbsp;<a href="/diabetes-type-2#!diagnosissub:2">When to suspect diabetic ketoacidosis</a>&nbsp;for more information.</li></ul><li class="level2"><b>Psychological complications —</b> these include anxiety and depression. In addition, in children and young people, behavioural and conduct disorders, family/relationship difficulties, and risk-taking behaviour (including non-adherence to recommended treatment).</li><li class="level2"><b>Reduced quality of life —</b> people with diabetes face significant challenges to daily living, for example managing episodes of hypoglycaemia and hyperglycaemia, self-monitoring of blood glucose, and the need to plan normal daily activities (such as eating and exercising).&nbsp;</li><li class="level2"><b>Infections —</b> people with diabetes are prone to infections, particularly of the urinary tract and skin.</li><li class="level2"><b>Reduced life expectancy — </b>it is estimated that diabetes accounts for about 15–16% of deaths in England, with life expectancy for people with type 2 diabetes reduced by an average of up to 10 years. Diabetes UK estimates that in people with type 2&nbsp;diabetes, the risk of death is 32% greater than expected and is mostly in younger people and females&nbsp;[<a rel="citation" resource="1090203#A1299577" href="/diabetes-type-2#!references/1090203">Diabetes UK, 2015</a>].</li><li class="level2"><b>Dementia —</b>&nbsp;people with type&nbsp;2 diabetes have a 1.5–2.5-fold increased risk of dementia; the exact reason for this is currently unknown&nbsp;[<a rel="citation" resource="1090203#A1299577" href="/diabetes-type-2#!references/1090203">Diabetes UK, 2015</a>].
		&nbsp;</li></ul></ul><p>[<a rel="citation" resource="1090203#A1299577" href="/diabetes-type-2#!references/1090203">Diabetes UK, 2015</a>; <a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>; <a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>]</p></section><section class="diagnosissub hidden" id="-350398"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Diagnosis - adults</h2><h3>How should I diagnose type 2 diabetes in an adult?</h3></header><ul><li class="level1"><b>Suspect type 2 diabetes in an adult who presents with:</b>

	
	</li><ul><li class="level2">Persistent hyperglycaemia (HbA1c more than 48 mmol/mol [6.5%] or&nbsp;random plasma glucose more than 11 mmol/L)&nbsp;— be aware that&nbsp;the characteristic features (thirst, polyuria, blurred vision, weight loss, recurrent infections, and tiredness) are not usually severe and may be absent.</li><li class="level2"><a href="/diabetes-type-2#!backgroundsub:2">Risk factors</a>&nbsp;for type 2 diabetes (such as a&nbsp;strong family history, obesity, or&nbsp;Black or Asian family origin).</li><li class="level2">Evidence of insulin resistance (for example acanthosis nigricans).</li></ul><li class="level1"><b>Diabetes&nbsp;is usually diagnosed by an HbA1c of 48 mmol/mol (6.5%) or more.&nbsp;</b>If the use of HbA1c is&nbsp;<a href="/diabetes-type-2#!diagnosisadditional">inappropriate</a>&nbsp;(for example in people with end-stage chronic kidney disease),&nbsp;type 2 diabetes is diagnosed by a fasting plasma glucose level of 7.0 mmol/L or greater.
	
	</li><ul><li class="level2"><b>In an asymptomatic person,</b> the diagnosis of diabetes should never be based on a single abnormal HbA1c or fasting&nbsp;plasma glucose level; at least one additional abnormal HbA1c or&nbsp;plasma glucose level&nbsp;is essential. If the second test results are normal, it is prudent to arrange regular review of the person.</li><li class="level2"><b>In a symptomatic person,</b> diabetes can be diagnosed with more confidence on the basis of a single abnormal HbA1c or fasting&nbsp;plasma glucose level (although a second test may be prudent). Be aware that severe hyperglycaemia in people with an acute infection, trauma, or circulatory (other stress) may be transitory and should not be regarded as diagnostic of diabetes.</li></ul><li class="level1"><b>Type 2 diabetes is more likely in a person with:</b>
	
	</li><ul><li class="level2">No&nbsp;additional features of type 1 diabetes (such as rapid onset, often in childhood, insulin dependence, or ketoacidosis)&nbsp;— see the CKS topic on <a href="/diabetes-type-1">Diabetes - type 1</a>&nbsp;for more information.</li><li class="level2">No features of monogenic diabetes or diabetes secondary to a pathological condition or disease, drug treatment, trauma, or pancreatic surgery.</li></ul></ul><section class="diagnosisadditional" id="1307664"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>When to avoid HbA1c or interpret results with caution</h3></header><ul><li class="level1"><b>HbA1c should not be used to diagnose diabetes mellitus&nbsp;in the following groups:</b>

	
	</li><ul><li class="level2">Children and young people (younger than 18 years of age).&nbsp;</li><li class="level2">Pregnant women or women who are two months postpartum.&nbsp;</li><li class="level2">People with symptoms of diabetes for less than 2 months.&nbsp;</li><li class="level2">People at high diabetes risk who are acutely ill.</li><li class="level2">People taking medication that may cause hyperglycaemia (for example corticosteroids).&nbsp;</li><li class="level2">People with acute pancreatic damage, including pancreatic surgery.</li><li class="level2">People with end-stage chronic kidney disease.</li><li class="level2">People with HIV infection.</li></ul><li class="level1"><b>HbA1c should be interpreted&nbsp;with caution&nbsp;in people with:</b>&nbsp;
	
	</li><ul><li class="level2">Abnormal haemoglobin.</li><li class="level2">Anaemia (any cause).</li><li class="level2">Altered red cell lifespan (for example post-splenectomy).&nbsp;</li><li class="level2">A recent blood transfusion.</li></ul></ul><p>[<a rel="citation" resource="1090203#A79177" href="/diabetes-type-2#!references/1090203">WHO, 2011</a>; <a rel="citation" resource="1090203#A79176" href="/diabetes-type-2#!references/1090203">Kilpatrick and Atkin, 2014</a>]</p></section><section class="diagnosisbasis" id="-491849"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Basis for recommendation</h3></header><p>These recommendations are largely based on the World Health Organization (WHO) reports&nbsp;<i>Definition, diagnosis and classification of diabetes mellitus and its complications&nbsp;</i>[<a rel="citation" resource="1090203#A1314592" href="/diabetes-type-2#!references/1090203">WHO, 1999</a>]&nbsp;and&nbsp;<i>Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus&nbsp;</i>[<a rel="citation" resource="1090203#A79177" href="/diabetes-type-2#!references/1090203">WHO, 2011</a>],&nbsp;and&nbsp;the&nbsp;British Medical Journal (BMJ) review article <i>Using haemoglobin A1c to diagnose type 2 diabetes or to identify people at high risk of diabetes&nbsp;</i>[<a rel="citation" resource="1090203#A79176" href="/diabetes-type-2#!references/1090203">Kilpatrick and Atkin, 2014</a>]. The National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Type 2 diabetes in adults: management&nbsp;</i>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>]&nbsp;does not cover the diagnosis of type 2 diabetes in adults.</p><p><b>When to suspect type 2 diabetes</b></p><ul><li class="level1">The WHO report on the diagnosis and classification of diabetes mellitus&nbsp;generally&nbsp;describes diabetes as a state of high blood glucose levels that is sufficient to put a person at risk of microvascular complications&nbsp;[<a rel="citation" resource="1090203#A1314592" href="/diabetes-type-2#!references/1090203">WHO, 1999</a>].</li><li class="level1">Although the NICE guideline does not cover the diagnosis of type 2 diabetes in adults, it&nbsp;acknowledges the WHO report and adds that&nbsp;type 2 diabetes should be suspected in a person who does not have type 1 diabetes, monogenic diabetes, or other medical conditions or treatment suggestive of secondary diabetes&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].</li><li class="level1">Other recommendations on when to suspect type 2 diabetes are&nbsp;extrapolated from the&nbsp;NICE guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li></ul><p><b>Measuring HbA1c</b></p><ul><li class="level1">
	In the past, the diagnosis of diabetes mellitus was largely based on measurement of fasting plasma glucose concentration and, when indicated, a glucose concentration two hours after an oral glucose load&nbsp;[<a rel="citation" resource="1090203#A79176" href="/diabetes-type-2#!references/1090203">Kilpatrick and Atkin, 2014</a>].&nbsp;However, in recent years, HbA1c has been introduced&nbsp;as an alternative test to glucose concentration for diagnosing diabetes (including type 2 diabetes) or identifying people at high risk of developing the disease (for example people with impaired glucose regulation). HbA1c is preferred because&nbsp;[<a rel="citation" resource="1090203#A79177" href="/diabetes-type-2#!references/1090203">WHO, 2011</a>; <a rel="citation" resource="1090203#A79176" href="/diabetes-type-2#!references/1090203">Kilpatrick and Atkin, 2014</a>]:

	
	</li><ul><li class="level2">It does not require the person to fast, take a glucose solution (which can sometimes cause nausea), or return for a second blood test after two hours.</li><li class="level2">It assesses glycaemia over 8–12 weeks.</li><li class="level2">There is lower biological variability with HbA1c than with fasting glucose or two hour post-glucose load concentration.</li><li class="level2">There are fewer pre-analytical concerns with HbA1c, including time to analysis.</li><li class="level2">It is already used to guide management of diabetes.</li><li class="level2">It is thought that standardization of HbA1c measurement will help harmonize results between laboratories.</li></ul><li class="level1">WHO recommends&nbsp;HbA1c as&nbsp;a diagnostic test for diabetes, providing there are no conditions present which preclude its accurate measurement&nbsp;[<a rel="citation" resource="1090203#A79177" href="/diabetes-type-2#!references/1090203">WHO, 2011</a>].&nbsp;</li><li class="level1">WHO states that an HbA1c of 48 mmol/mol (6.5%) should be used as the cut-off point for diagnosing diabetes, although a lower value does not exclude diabetes diagnosed using glucose tests&nbsp;[<a rel="citation" resource="1090203#A79177" href="/diabetes-type-2#!references/1090203">WHO, 2011</a>].</li></ul></section></section><section class="diagnosissub hidden" id="1309397"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Diagnosis - children and young people</h2><h3>When should I suspect type 2 diabetes in a child or young person?</h3></header><ul><li class="level1"><b>Think about the possibility of type 2 diabetes in a child or young person who presents with:</b>
	
	</li><ul><li class="level2">Persistent hyperglycaemia (random plasma glucose more than 11 mmol/L)&nbsp;— be aware that the characteristic features (thirst, polyuria, blurred vision, weight loss, recurrent infections, and tiredness) are not usually severe and may be absent.</li><li class="level2"><a href="/diabetes-type-2#!backgroundsub:2">Risk factors</a>&nbsp;for type 2 diabetes (such as a strong family history, obesity, or Black or Asian origin).</li><li class="level2">Evidence of insulin resistance (for example acanthosis nigricans).</li><li class="level2">No additional features of type 1 diabetes — see the CKS topic on <a href="/diabetes-type-1">Diabetes - type 1</a> for more information.</li><li class="level2">No features of monogenic diabetes or diabetes secondary to a pathological condition or disease, drug treatment, trauma, or pancreatic surgery.</li></ul><li class="level1"><b>If type 2 diabetes is suspected,</b> refer the child or young person immediately (on the same day) to a multidisciplinary paediatric diabetes care team with the competencies needed to confirm the diagnosis and provide immediate care.</li></ul><section class="diagnosisbasis" id="1309398"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Basis for recommendation</h3></header><p><b>When to suspect type 2 diabetes in a child or young person</b></p><ul><li class="level1">The information on the characteristic features of type 2 diabetes in children and young people are based on expert opinion in the&nbsp;National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].&nbsp;</li></ul><p><b>Arranging immediate referral&nbsp;</b></p><ul><li class="level1">NICE recommends immediate referral to a paediatric specialist diabetes team for confirmation of diagnosis and provision of immediate care for children and young people with type 1 diabetes, based on expert opinion&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li><li class="level1">CKS has extrapolated this recommendation to children and young people with suspected type 2 diabetes as they also require specialist management.&nbsp;</li></ul></section></section><section class="diagnosissub hidden" id="1309415"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>When to suspect diabetic ketoacidosis</h2><h3>When should I suspect diabetic ketoacidosis?</h3></header><p>
          <b>Diabetic ketoacidosis (DKA)</b> is the metabolic state characterized by the triad of marked hyperglycaemia, acidosis, and ketonaemia. It is a medical emergency because it leads to dehydration and electrolyte imbalances. Although more common in type 1 diabetes, people with type 2 diabetes can also develop DKA.</p><ul><li class="level1"><b>Suspect DKA in a person with</b> known diabetes or significant hyperglycaemia (finger-prick blood glucose level greater than 11 mmol/L) <i>and</i> the following:&nbsp;

	
	</li><ul><li class="level2"><b><a href="/diabetes-type-2#!diagnosisadditional:1">Clinical features</a>&nbsp;of DKA.&nbsp;</b></li><li class="level2"><b>Precipitating factors, such as:&nbsp;</b>
		
		</li><ul><li class="level3">Infection (for example pneumonia or a urinary tract infection).&nbsp;</li><li class="level3">Physiological stress (such as trauma or surgery).</li><li class="level3">Inadequate insulin or non-adherence with insulin treatment.&nbsp;</li><li class="level3">Other medical conditions (such as hypothyroidism or pancreatitis).&nbsp;</li><li class="level3">Drugs (such as corticosteroids, diuretics, and sympathomimetic drugs [for example salbutamol]).&nbsp;</li></ul><li class="level2"><b>Ketones in the urine or blood.&nbsp;</b>
		
		</li><ul><li class="level3">In an adult with suspected DKA, test for urine or blood ketones, even if plasma glucose levels are near-normal.&nbsp;</li><li class="level3">In a child or young person with suspected DKA, test for blood ketones using a ketone testing meter and strips, even if plasma glucose levels are near-normal. If this is not possible, arrange immediate admission to a hospital with acute paediatric facilities.&nbsp;</li><li class="level3">Ketones are high if above 2+ in the urine or above 3 mmol/L in the blood.&nbsp;</li><li class="level3">See the section on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes#!scenariorecommendation:2">Accessories for insulin therapy</a>&nbsp;in the CKS topic on <a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>&nbsp;for information on ketone testing meters and strips.&nbsp;</li></ul><li class="level2"><b>Consider the possibility of DKA in all people with type 2 diabetes who are unwell, bearing in mind that:&nbsp;</b>
		
		</li><ul><li class="level3">Low blood ketone levels (less than 3 mmol/L) do not always exclude DKA.</li><li class="level3">Hyperglycaemia may not always be present — children and young people on insulin therapy may develop DKA with normal blood glucose levels.&nbsp;</li></ul></ul></ul><section class="diagnosisadditional" id="1311269"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Clinical features of diabetic ketoacidosis</h3></header><p><b>Symptoms of diabetic ketoacidosis (DKA) include:</b></p><ul><li class="level1">Increased thirst and urinary frequency.</li><li class="level1">Weight loss.</li><li class="level1">Inability to tolerate fluids.</li><li class="level1">Persistent vomiting and/or diarrhoea.</li><li class="level1">Abdominal pain.</li><li class="level1">Lethargy and/or confusion.</li></ul><p><b>Signs of DKA include:</b></p><ul><li class="level1">Fruity smell of acetone on the breath.</li><li class="level1">Acidotic breathing — deep sighing (Kussmaul) respiration.</li><li class="level1">Dehydration, which can be classified as:
	
	</li><ul><li class="level2">Mild — only just clinically detectable.&nbsp;</li><li class="level2">Moderate — dry skin and mucus membranes; reduced skin turgor.&nbsp;</li><li class="level2">Severe — sunken eyes and prolonged capillary refill time.&nbsp;</li><li class="level2">Shock — the person is severely ill with:
		
		</li><ul><li class="level3">Tachycardia, poor peripheral perfusion, and (as a late sign) hypotension (indicating decreased cardiac output).</li><li class="level3">Lethargy, drowsiness, or decreased level of consciousness (indicating decreased cerebral perfusion).</li><li class="level3">Reduced urine output (indicating decreased renal perfusion).</li></ul></ul></ul><p>[<a rel="citation" resource="1090203#A79929" href="/diabetes-type-2#!references/1090203">BSPED, 2013</a>; <a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>; <a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>]</p></section><section class="diagnosisbasis" id="1309417"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Basis for recommendation</h3></header><p>These recommendations are based on (and in some cases extrapolated from)&nbsp;the&nbsp;National Institute for Health and Care Excellence (NICE)&nbsp;guidelines&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>]&nbsp;and&nbsp;<i>Type 1 diabetes in adults: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>]&nbsp;the&nbsp;Joint British Diabetes Societies Inpatient Care Group guideline&nbsp;<i>The management of diabetic ketoacidosis in adults&nbsp;</i>[<a rel="citation" resource="1090203#A1299786" href="/diabetes-type-2#!references/1090203">Joint British Diabetes Societies Inpatient Care, 2013</a>], the American Diabetes Association guideline&nbsp;<i>Hyperglycemic crises in adult patients with diabetes&nbsp;</i>[<a rel="citation" resource="1090203#A79927" href="/diabetes-type-2#!references/1090203">Kitabchi et al, 2009</a>], the British Society&nbsp;for Paediatric Endocrinology and Diabetes (BSPED) guideline&nbsp;<i>BSPED recommended DKA guidelines 2009 (minor review 2013)&nbsp;</i>[<a rel="citation" resource="1090203#A79929" href="/diabetes-type-2#!references/1090203">BSPED, 2013</a>],&nbsp;and a Medicines and Healthcare products Regulatory Agency (MHRA) Drug safety update&nbsp;<i>SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis </i>[<a rel="citation" resource="1090203#A1403259" href="/diabetes-type-2#!references/1090203">MHRA, 2016</a>]<i>.</i>&nbsp;The NICE guideline&nbsp;<i>Type 2 diabetes in adults: management</i>&nbsp;does not cover the management of diabetic ketoacidosis (DKA).</p></section></section><section class="diagnosissub hidden" id="1311271"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>When to suspect hypoglycaemia</h2><h3>When should I suspect hypoglycaemia in a person with type 2 diabetes?</h3></header><ul><li class="level1"><b>Hypoglycaemia (low blood glucose) is generally defined as being present when blood glucose levels decrease to less than 3.5 mmol/L.</b> It is the main adverse effect of insulin treatment.&nbsp;</li><li class="level1">See the section on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes#!scenariorecommendation:8">Hypoglycaemia</a>&nbsp;in the CKS topic on <a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>&nbsp;for further information on when to suspect (and how to manage) hypoglycaemia.</li></ul><section class="diagnosisbasis" id="1311273"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Basis for recommendation</h3></header><p>The definition of hypoglycaemia is taken from the National Institute for Health and Care Excellence (NICE) guideline <i>Type 1 diabetes in adults: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>].</p></section></section><section class="scenario active" id="-350369"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Scenario: Management - adults</h2></header><p class="age">Age from 18 years onwards</p><section class="scenariorecommendation" id="-350384"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Initial care and support</h3></header><ul><li class="level1"><b>Ensure that an individual care plan is set up for all adults with type 2 diabetes, </b>taking into account&nbsp;their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.</li><li class="level1"><b>Offer a&nbsp;structured group education programme, </b>for example the <a href="http://www.desmond-project.org.uk/">DESMOND</a> (Diabetes Education for Self-Management for Ongoing and Newly Diagnosed) programme,&nbsp;to the person and/or their family/carers.
	
	</li><ul><li class="level2">Offer this programme at or around the time of diagnosis, with annual reinforcement and review.</li><li class="level2">Explain to the person and/or their family/carers that structured education is an integral part of diabetes care.</li><li class="level2">Provide an alternative of equal standard for a person unable or unwilling to participate in group education, depending on local availability.</li></ul><li class="level1"><b>Ensure&nbsp;that the person and/or their family/carers know how to contact the diabetes team&nbsp;</b>during working hours and out of hours, as available.&nbsp;</li><li class="level1"><b>Provide information on government disability benefits, </b>if needed — <a href="https://www.gov.uk/benefits-calculators">Benefits calculators</a> are available at <a href="https://www.gov.uk/">www.gov.uk</a>.</li><li class="level1"><b>Manage lifestyle issues, </b>such as diet and exercise.&nbsp;See the section on&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:3">Lifestyle management</a>&nbsp;for more information.</li><li class="level1"><b>Screen for complications of type 2 diabetes, </b>such as retinopathy and diabetic foot problems.&nbsp;See the section on&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:6">Screening for complications</a>&nbsp;for more information.</li><li class="level1"><b>Provide up-to-date information (including written information) on diabetes support groups (local and national),</b> including information on how to contact them and the benefits of membership.&nbsp;
	
	</li><ul><li class="level2">For example, <a href="https://www.diabetes.org.uk/?gclid=CPqHpMedkMsCFckV0wod0qoJoQ">Diabetes UK</a> (a charity which provides information, support, and advocacy for people with diabetes) has a support helpline (0345 123 2399 or 0141 212 8710 [for Scotland])&nbsp;for people with diabetes and their family/carers.&nbsp;</li><li class="level2">Provide this information at the time of diagnosis and periodically thereafter.&nbsp;</li></ul></ul><section class="scenariobasis" id="-493023"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are largely based on the&nbsp;National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Type 2 diabetes in adults: management&nbsp;</i>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].&nbsp;The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng28/evidence">full NICE guideline</a>.</p><p><b>Individual care plans</b></p><ul><li class="level1">NICE recommends an individualized approach to diabetes care that is tailored to the needs and circumstances of the person with type 2 diabetes&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].</li><li class="level1">Expert opinion in the&nbsp;American Diabetes Association's <i>Standards of Medical Care in Diabetes </i>is&nbsp;that the&nbsp;management of people with diabetes should include developing a written plan with input from the person with diabetes and/or their family/carers[<a rel="citation" resource="1090203#A1300251" href="/diabetes-type-2#!references/1090203">ADA, 2016</a>]. &nbsp;</li></ul><p><b>Offering a structured education programme</b></p><ul><li class="level1">The NICE guideline development group (GDG) found limited robust evidence of the effectiveness of structured educational programmes for people with type 2 diabetes. However, in their expert opinion, understanding diabetes, making an informed choice on management opportunities, and the acquisition of relevant skills for successful self-management are vital for achieving optimal outcomes in people with type 2 diabetes and/or their family/carers&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].

	
	</li><ul><li class="level2">These can be achieved through structured education programmes, which the GDG defined as programmes that&nbsp;have been designed to improve the knowledge and skills of the person with diabetes and to help motivate and sustain them in taking control of their condition and in delivering effective self-management&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].</li></ul><li class="level1">NICE does not make any recommendations on the choice of educational programme. However, the GDG noted that evidence from the DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) study showed changes in health beliefs, reduction in depression, increases in self-reported physical activity and weight reduction, and improvement in smoking status.&nbsp;</li><li class="level1">The GDG concluded that well-designed and well-implemented programmes were likely to be clinically- and cost-effective interventions for adults with type 2 diabetes for whom group education is appropriate.</li></ul><p><b>Providing information on government disability benefits, if needed</b></p><ul><li class="level1">CKS has extrapolated this recommendation from the NICE guideline <i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>]&nbsp;as it may also be relevant for adults with type 2 diabetes and their family/carers.</li></ul><p><b>Providing information on support groups</b></p><ul><li class="level1">CKS has extrapolated this recommendation from the NICE guideline&nbsp;<i>Type 1 diabetes in adults: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>]&nbsp;as it is also relevant for adults with type 2 diabetes and their family/carers.

	
	</li><ul><li class="level2">The GDG of the NICE type 1 diabetes guideline found evidence that&nbsp;people with type 1 diabetes who do not have access to a community of support, especially the young or elderly living alone, may be less likely to be compliant with their medication regimen, putting them at risk of suboptimal blood glucose control and complications.</li></ul></ul></section></section><section class="scenariorecommendation" id="1307667"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Treatment targets</h3></header><ul><li class="level1"><b>Offer&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:3">lifestyle advice</a>&nbsp;and&nbsp;<a href="/diabetes-type-2#!scenarioclarification">drug treatment(s)</a>&nbsp;to support adults with type 2 diabetes to achieve&nbsp;a target HbA1c level to minimize the risk of long-term vascular&nbsp;<a href="/diabetes-type-2#!backgroundsub:5">complications</a>.</b></li><li class="level1">The recommended HbA1c treatment targets are:
	
	</li><ul><li class="level2">For people who are&nbsp;managed by lifestyle and diet: 48 mmol/mol (6.5%).&nbsp;</li><li class="level2">For people who are managed by&nbsp;lifestyle and diet combined with a single drug not associated with hypoglycaemia (such as metformin): 48 mmol/mol (6.5%).&nbsp;</li><li class="level2">For people who&nbsp;are taking a drug associated with hypoglycaemia (such as a sulphonylurea): 53 mmol/mol (7.0%).</li></ul><li class="level1">Involve the person in decisions about their individual HbA1c target.
	
	</li><ul><li class="level2">Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.&nbsp;</li><li class="level2">For guidance on HbA1c targets for women who are pregnant, planning a pregnancy, or breastfeeding, see the&nbsp;National Institute for Health and Care Excellence (NICE) guideline&nbsp;<a href="https://www.nice.org.uk/guidance/ng3?unlid=898185477201622043720">Diabetes in pregnancy: management from preconception to the postnatal period</a>.</li></ul><li class="level1">Measure HbA1c levels at&nbsp;3–6-monthly intervals (tailored to individual needs) until the HbA1c is stable on unchanging treatment, then at 6-monthly intervals.</li><li class="level1">If HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol/mol (7.5%) or higher:&nbsp;
	
	</li><ul><li class="level2">Reinforce advice on diet, lifestyle, and adherence to antidiabetic drug treatment.</li><li class="level2">Support the person to aim for an HbA1c level of 53 mmol/mol (7.0%).</li><li class="level2">Intensify antidiabetic drug treatment.&nbsp;</li></ul><li class="level1">Consider relaxing the target HbA1c level on a case-by-case basis (with particular consideration for people who are older or frail) if:
	
	</li><ul><li class="level2">The person is unlikely to achieve longer-term risk-reduction benefits, for example they have a reduced life expectancy.</li><li class="level2">Tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example in people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job.</li><li class="level2">Intensive management would be inappropriate, for example in a person with significant comorbidities.</li></ul><li class="level1">If the person achieves an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it. However, be aware that there are other possible reasons for a low HbA1c level, for example deteriorating renal function or sudden weight loss.&nbsp;</li><li class="level1"><b>Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes.</b>
	
	</li><ul><li class="level2">Take the Driver and Vehicle Licensing Agency (DVLA) document&nbsp;<a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/526635/assessing-fitness-to-drive-a-guide-for-medical-professionals.pdf">Assessing fitness to drive - a guide for medical professionals</a>&nbsp;into account when offering advice on self-monitoring of blood glucose levels.</li><li class="level2">Advise self-monitoring of blood glucose levels if:
		
		</li><ul><li class="level3">The person is on insulin therapy, <i>or&nbsp;</i></li><li class="level3">There is evidence of hypoglycaemic episodes, <i>or&nbsp;</i></li><li class="level3">The person is taking a drug that may increase their risk of hypoglycaemia while driving or operating machinery (such as a sulfonylurea), <i>or</i>&nbsp;</li><li class="level3">The person is pregnant or is planning to become pregnant. For more information, see the&nbsp;NICE&nbsp;guideline&nbsp;<a href="https://www.nice.org.uk/guidance/ng3?unlid=898185477201622043720">Diabetes in pregnancy: management from preconception to the postnatal period</a>.&nbsp;</li></ul><li class="level2">Consider advising short-term self-monitoring of blood glucose levels (and review treatment as necessary):&nbsp;
		
		</li><ul><li class="level3">When starting treatment with corticosteroids, <i>or</i></li><li class="level3">To confirm suspected&nbsp;<a href="/diabetes-type-2#!diagnosissub:3">hypoglycaemia</a>.</li></ul><li class="level2">Be aware that adults with type 2 diabetes who have an acute intercurrent illness or infection are at risk of worsening hyperglycaemia. Review their treatment as necessary.</li><li class="level2">If routine self-monitoring of blood glucose is indicated, ensure that a structured assessment is carried out at least annually. The assessment should include checking:
		
		</li><ul><li class="level3">Self-monitoring skills, the quality and frequency of testing, and&nbsp;the equipment used.</li><li class="level3">That the person knows how to interpret the blood glucose results and what action to take if they are too high or too low.</li><li class="level3">The impact of self-monitoring on the person's quality of life and the continued benefit to the person.&nbsp;</li></ul><li class="level2">See the section on <a href="/insulin-therapy-in-type-2-diabetes#!scenariorecommendation:2">Accessories for insulin therapy</a>&nbsp;in the CKS topic on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>&nbsp;for information on blood glucose meters, lancets, and strips.</li></ul></ul><section class="scenariobasis" id="1307668"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are largely based on the&nbsp;National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Type 2 diabetes in adults: management&nbsp;</i>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].&nbsp;The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the&nbsp;<a href="https://www.nice.org.uk/guidance/ng28/evidence">full NICE guideline</a>.</p><p><b>HbA1c target levels</b></p><ul><li class="level1">The NICE guideline development group (GDG) reviewed the available evidence to determine the optimal target HbA1c level for adults with type 2 diabetes and the effects of different HbA1c levels on mortality risk and the risk of developing microvascular and macrovascular complications&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].

	
	</li><ul><li class="level2">Moderate-quality evidence from one study found that the risk for microvascular complications increased significantly with HbA1c levels above 48 mmol/mol (6.5%), and the risk for mortality and macrovascular complications increased significantly with HbA1c levels above 53 mmol/mol (7%).&nbsp;</li><li class="level2">Moderate- to high-quality evidence showed that all-cause mortality risk increased with increasing baseline levels of HbA1c.</li><li class="level2">Very low- to high-quality evidence showed that rising levels of HbA1c increase the risk of mortality and of developing macrovascular and microvascular complications, with critical thresholds ranging from 42–53 mmol/mol (6.0–7.0%).</li></ul><li class="level1">The NICE GDG recognized the trade-off between the increased benefits of setting target values for blood glucose to protect against long-term complications and the possible associated harms (for example hypoglycaemia). Based on the evidence identified, the NICE GDG agreed that:
	
	</li><ul><li class="level2">A mid-range value of 48 mmol/mol (6.5%) would be achievable for most adults with type 2 diabetes who are managed by lifestyle and diet and/or one oral antidiabetic drug not associated with hypoglycaemia.&nbsp;&nbsp;</li><li class="level2">Antidiabetic drug treatment should be intensified if HbA1c levels rise to 58 mmol/mol (7.5%) and considering the risk of hypoglycaemia, a realistic target of 53 mmol/mol (7.0%) should be set to achieve blood glucose control.&nbsp;</li><li class="level2">Special consideration of appropriate target values should be given to people at risk of hypoglycaemia, to achieve an acceptable balance between good blood glucose control and the likely negative impact on quality of life of this adverse effect.&nbsp;</li></ul></ul><p><b>Self-monitoring of blood glucose levels</b></p><p>The NICE GDG was aware of the debate surrounding the routine use of self-monitoring of blood glucose in people with type 2 diabetes, and assessed the available evidence (from systematic reviews and randomized controlled trials) to determine whether self-monitoring should be used to manage blood glucose levels in this group of people.&nbsp;</p><ul><li class="level1">The GDG noted that while self-monitoring of blood glucose provides the potential for tight blood glucose control and therefore reduced the risk of diabetes-related complications, the possible impact of such control on hypoglycaemic events is important in determining the safety and acceptability to people with type 2 diabetes.&nbsp;</li><li class="level1">Based on the evidence identified (which was generally of low quality), the GDG agreed that although a&nbsp;statistically significant difference was generally observed in HbA1c levels&nbsp;in favour of self-monitoring, the small reduction of less than 5 mmol/mol&nbsp;(0.5%; the threshold for minimal important difference) was not clinically significant.</li><li class="level1">The GDG agreed that self-monitoring would not be beneficial to people with type 2 diabetes, with the exception of certain groups of people, for example people on insulin therapy.&nbsp;</li><li class="level1">The GDG also highlighted clinical scenarios that may benefit from short-term self-monitoring of blood glucose, for example people being treated with drugs that can cause hyperglycaemia (such as corticosteroids). For people with acute intercurrent illness or infection, the&nbsp;GDG agreed that no evidence had been identified to indicate that short-term self-monitoring would be beneficial; however, it was agreed that it is useful to make clinicians aware of the potential risk of worsening hyperglycaemia during acute intercurrent illnesses in people with type 2 diabetes.</li><li class="level1">Due to a lack of evidence, the NICE GDG was unable to make any recommendations on&nbsp;the frequency of self-monitoring of blood glucose or on specific target values for people with type 2 diabetes.</li></ul></section></section><section class="scenariorecommendation" id="1308458"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Antidiabetic drugs</h3></header><section class="scenarioclarification" id="1312930"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Long-term antidiabetic treatment options</h4></header><ul><li class="level1"><b>Offer standard-release metformin as the initial treatment for adults with type 2 diabetes, unless it is&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:4">contraindicated</a>.&nbsp;</b>

	
	</li><ul><li class="level2">Gradually increase the dose of standard-release metformin over several weeks to minimize the risk of&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:5">adverse effects</a>, such as gastrointestinal (GI) adverse effects.&nbsp;

		
		</li><ul><li class="level3">If GI adverse effects are intolerable,&nbsp;consider a trial of modified-release metformin.</li><li class="level3">Monitor renal function before and during treatment with metformin. See the section on&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:3">Initiation and monitoring</a>for more information.</li></ul><li class="level2"><b>If metformin is&nbsp;contraindicated or not tolerated,&nbsp;</b>consider initial treatment with one of the following, unless contraindicated:
		
		</li><ul><li class="level3">A&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:7">gliptin</a>&nbsp;(dipeptidyl peptidase-4 inhibitor).</li><li class="level3"><a href="/diabetes-type-2#!prescribinginfosub:14">Pioglitazone</a>.</li><li class="level3">A&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:21">sulfonylurea</a>.</li><li class="level3">A <a href="/diabetes-type-2#!prescribinginfosub:35">Sodium-glucose cotransporter 2 inhibitors (SGLT-2i)</a>.</li></ul></ul><li class="level1"><b>If the first-line treatment is ineffective,&nbsp;</b>consider the following second-line treatment options:
	
	</li><ul><li class="level2">For people who can take metformin, consider dual therapy with:&nbsp;
		
		</li><ul><li class="level3">Metformin plus a gliptin,&nbsp;<i>or&nbsp;</i></li><li class="level3">Metformin plus pioglitazone, <i>or&nbsp;</i></li><li class="level3">Metformin plus a sulfonylurea.&nbsp;</li><li class="level3">Metformin plus an SGLT-2i&nbsp;</li></ul><li class="level2">For people in whom metformin is contraindicated or not tolerated, consider the following:&nbsp;
		
		</li><ul><li class="level3">A gliptin plus pioglitazone,&nbsp;<i>or&nbsp;</i></li><li class="level3">A gliptin plus a sulfonylurea,&nbsp;<i>or&nbsp;</i></li><li class="level3">Pioglitazone plus a sulfonylurea.</li><li class="level3">An SGLT-2i instead of a gliptin if a sulfonylurea or pioglitazone is not appropriate</li></ul></ul><li class="level1"><b>If the second-line treatment option is ineffective,</b>&nbsp;consider one of the following third-line treatment options:
	
	</li><ul><li class="level2">For&nbsp;people who can take metformin:
		
		</li><ul><li class="level3">Triple therapy with metformin, a gliptin, and a sulfonylurea, <i>or</i></li><li class="level3">Triple therapy with&nbsp;metformin, pioglitazone, and a sulfonylurea, <i>or</i></li><li class="level3">Triple therapy with metformin, pioglitazone or a sulfonylurea and an SGLT-2i. (The SGLT-2i dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea NOT pioglitazone), <i>or </i></li><li class="level3">Starting insulin-based treatment. See the CKS topic on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>&nbsp;for more information.</li></ul><li class="level2">For people in whom metformin is contraindicated or not tolerated:
		
		</li><ul><li class="level3">Consider starting insulin-based treatment.&nbsp;</li></ul></ul><li class="level1"><b>If the third-line treatment option is ineffective, not tolerated, or contraindicated:</b>
	
	</li><ul><li class="level2">For people on&nbsp;triple therapy with metformin and two other oral antidiabetic drugs, consider combination treatment with metformin, a sulfonylurea, and a&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:28">glucagon-like peptide-1(GLP-1) mimetic</a>&nbsp;for:
		
		</li><ul><li class="level3">Adults who have a body mass index (BMI) of 35 kg/m<sup>2</sup>&nbsp;or higher (adjust accordingly for people from Black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity,&nbsp;<i>or&nbsp;</i></li><li class="level3">Adults who have a BMI&nbsp;lower than 35 kg/m<sup>2</sup>&nbsp;and insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities.&nbsp;</li></ul><li class="level2">For people on&nbsp;insulin-based treatment:
		
		</li><ul><li class="level3">Seek specialist advice (or refer the person to their diabetes team) for consideration of treatment with&nbsp;a GLP-1 mimetic plus insulin.&nbsp;</li></ul></ul><li class="level1"><b>Be aware that:</b>
	
	</li><ul><li class="level2">If metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes. However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.</li><li class="level2">GLP-1 mimetic therapy should only be continued if the person has had a beneficial metabolic response (a reduction of at least 11 mmol/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months).</li></ul></ul></section><section class="scenarioclarification" id="1312927"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Immediate treatment of symptomatic hyperglycaemia</h4></header><ul><li class="level1"><b>If an adult with type 2 diabetes is symptomatically hyperglycaemic, </b>consider insulin therapy or a sulfonylurea. Review treatment when blood glucose control has been achieved.&nbsp;</li></ul></section><section class="scenariobasis" id="1308460"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are largely based on the&nbsp;National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Type 2 diabetes in adults: management&nbsp;</i>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].&nbsp;The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the&nbsp;<a href="https://www.nice.org.uk/guidance/ng28/evidence">full NICE guideline</a>.</p><p>In May 2017 NICE added text on sodium–glucose cotransporter 2 (SGLT-2) inhibitors to the section on <a href="https://www.nice.org.uk/guidance/ng28/chapter/1-Recommendations#initial-drug-treatment">initial drug treatment</a> and updated the algorithm for <a href="https://www.nice.org.uk/guidance/ng28/resources/">blood glucose lowering therapy in adults with type 2 diabetes</a>&nbsp;to revise footnote b with links to relevant NICE guidance on SGLT-2 inhibitors. They also added new information on SGLT-2 inhibitors to the box on action to take if metformin is contraindicated or not tolerated.</p><p><b>The use of antidiabetic drugs</b></p><ul><li class="level1">The NICE guideline development group (GDG) reviewed the available evidence to determine&nbsp;optimal drug treatment strategies for adults with type 2 diabetes. The GDG acknowledged the&nbsp;progressive nature of the condition and assumed that augmenting existing drug treatments with additional drugs will provide better blood glucose control as the&nbsp;added drug will have a different mode of action that is complementary to the existing drug treatment.</li><li class="level1">A series of 4 network meta-analyses (NMAs) were proposed for the NICE update, and the GDG agreed that the critical outcomes to consider were blood glucose control (change in HbA1c), hypoglycaemia, and adverse events, and an important outcome to consider was change in body weight.</li></ul><p><b>First-line treatment options</b></p><ul><li class="level1"><b>For people who can take metformin:</b>

	
	</li><ul><li class="level2">The NICE GDG discussed that although standard-release metformin was not associated with the greatest reduction in HbA1c in the reviewed evidence, the additional cardiovascular benefits associated with its use are very important in the overall long-term management of people with type 2 diabetes. In addition, metformin was associated with fewer hypoglycaemic events and with weight loss at 12&nbsp;and 24 months, which are considered important for people’s quality of life.</li><li class="level2">Although there was limited evidence on alternative forms of metformin for people who cannot tolerate the standard-release formulation, the GDG agreed that based on clinical experience, a trial of modified-release metformin should be considered as an alternative for people who are unable to tolerate standard-release metformin because of gastrointestinal adverse effects.&nbsp;</li></ul><li class="level1"><b>For people who cannot take metformin:</b>
	
	</li><ul><li class="level2">The GDG did not identify any studies that investigated the effects of different drug treatments in this group of people.&nbsp;</li><li class="level2">The GDG discussed the evidence surrounding the remaining drug interventions within the NMAs and agreed that in the absence of specific data on people for whom metformin is contraindicated or not tolerated, the effectiveness of alternative treatments in the analyses should be extrapolated to inform equal treatment options, depending on tolerability.</li><li class="level2">In particular for sulfonylureas, which were associated with clinically important reductions in HbA1c in the short term at 3 and 6 months but were consistently associated with greater hypoglycaemic events and weight gain at 12 and 24 months, the&nbsp;GDG recommended that the balance of good blood glucose control and the risk of poor weight outcomes and hypoglycaemia should be considered (and discussed with the person) before treatment is started and that treatment should be reviewed once agreed targets have been met.</li></ul></ul><p><b>Second-line treatment options&nbsp;</b></p><ul><li class="level1"><b>For people who can take metformin:</b></li><li class="level1">Metformin plus a gliptin was moderately effective in controlling blood glucose levels and was associated with fewer hypoglycaemic events and weight loss.</li><li class="level1">Metformin plus pioglitazone was most effective at reducing HbA1c levels at 24 months and preventing nausea, but was associated with weight gain.</li><li class="level1">Metformin plus a sulfonylurea was moderately effective in reducing HbA1c levels but was strongly associated with more hypoglycaemic events.</li><li class="level1"><b>For people who cannot take metformin:</b>

	
	</li><ul><li class="level2">The GDG recognized that there was limited evidence for treatment intensification options for this group of people, but noted that sitagliptin combined with a sulfonylurea was associated with high rankings in change in HbA1c at 6 months, and pioglitazone combined with a sulfonylurea was associated with weight gain at 24 months.</li></ul></ul><p><b>Third-line treatment options</b></p><ul><li class="level1">The GDG acknowledged that there was generally less evidence for this treatment level.</li><li class="level1">The GDG discussed the evidence surrounding three non-insulin based drug combinations and noted that while they were not the most effective in decreasing HbA1c levels, they were associated with fewer hypoglycaemic events and, for some combinations, weight loss.</li><li class="level1">Starting insulin therapy was given as an option (including for people who cannot take metformin), but the GDG acknowledged that many people are generally unwilling to start insulin therapy because of a fear of injections, hypoglycaemia, and its potential impact on quality of life.&nbsp;</li></ul><p><b>Fourth-line treatment options</b></p><p><b>For people in whom triple therapy with metformin and 2 other oral drugs is ineffective, not tolerated, or contraindicated:</b></p><ul><li class="level1">The GDG considered that GLP-1 mimetic combinations may be a cost-effective option for people with high body mass index (BMI) who would require high doses (and therefore costs) of insulin or for whom other treatment options were not tolerated or were contraindicated.</li><li class="level1">The GDG advised that due to the lack of evidence for combinations of GLP-1 mimetics and insulin, this&nbsp;treatment&nbsp;option should only be&nbsp;offered in a specialist care setting.&nbsp;</li><li class="level1">&nbsp;NICE technology appraisal guidance <a href="https://www.nice.org.uk/guidance/ta288/chapter/1-guidance?unlid=829855762016128162">288</a>, <a href="https://www.nice.org.uk/guidance/ta418">418</a>, <a href="https://www.nice.org.uk/guidance/ta315/chapter/1-guidance">315</a> and <a href="https://www.nice.org.uk/guidance/ta336/chapter/1-guidance?unlid=737496412016297152">336</a>&nbsp;on dapagliflozin, canagliflozin and empagliflozin. All three SGLT-2i are recommended as options in dual therapy regimens with metformin under certain conditions, as options in triple therapy regimens and in combination with insulin. All three are also options as monotherapies in adults in whom metformin is contraindicated or not tolerated. Serious and life-threatening cases of diabetic ketoacidosis have been reported in people taking SGLT-2i or shortly after stopping SGLT-2i. <a href="https://www.gov.uk/drug-safety-update/sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin-risk-of-diabetic-ketoacidosis">MHRA guidance&nbsp; 2015</a>&nbsp;advises testing for raised ketones in people with symptoms of diabetic ketoacidosis, even if plasma glucose levels are near normal.  </li></ul></section></section><section class="scenariorecommendation" id="1307673"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Lifestyle advice</h3></header><ul><li class="level1"><b>See the sections on&nbsp;<a href="/diabetes-type-2#!scenarioclarification:2">Diet</a>,&nbsp;<a href="/diabetes-type-2#!scenarioclarification:3">Exercise</a>,&nbsp;<a href="/diabetes-type-2#!scenarioclarification:4">Alcohol intake</a>, and&nbsp;<a href="/diabetes-type-2#!scenarioclarification:5">Smoking and substance misuse</a>&nbsp;for information on managing these lifestyle issues.</b></li><li class="level1">For detailed information on managing other lifestyle and cultural issues, such as driving, fasting, holiday and travel, insurance, and shift work, see the section on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes#!scenariorecommendation:7">Additional information and advice</a>&nbsp;in the CKS topic on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>.</li></ul><section class="scenarioclarification" id="1307679"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Diet</h4></header><ul><li class="level1"><b>Provide appropriate, individualized, and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition </b>to the person with&nbsp;type 2 diabetes and/or their family/carers.</li><li class="level1">Emphasize the importance of a healthy balanced diet that:
	
	</li><ul><li class="level2">Includes plenty of fibre, low-glycaemic-index sources of carbohydrate (such as fruit, vegetables, wholegrain, and pulses), low-fat dairy products, and oily fish, <i>and</i></li><li class="level2">Controls the intake of foods containing saturated and trans fatty acids.</li><li class="level2">Individualize recommendations for carbohydrate and alcohol intake, and meal patterns, to reduce the risk of hypoglycaemia, especially in people being treated with insulin or an insulin secretagogue.</li><li class="level2">Advise that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowed, but care should be taken to avoid excess energy intake.</li><li class="level2">Discourage the use of foods marketed specifically for people with diabetes.</li></ul><li class="level1"><b>Integrate dietary advice with a personalized diabetes management plan, including aspects of lifestyle modification (such as increasing physical activity and weight loss, as appropriate).</b>
	
	</li><ul><li class="level2">If the person is overweight, set an initial body weight loss target of 5–10% (smaller weight losses may still be beneficial).&nbsp;</li><li class="level2">Consider referring the person to&nbsp;a dietitian, or see the CKS topic on &nbsp;<a href="http://cks.nice.org.uk/obesity">Obesity</a>, for further information on weight management.</li></ul></ul></section><section class="scenarioclarification" id="1308397"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Exercise and physical activity</h4></header><ul><li class="level1"><b>Advise adults with type 2 diabetes that regular exercise may lower blood glucose levels, </b>as exercise increases the amount of glucose used by the muscles for energy.&nbsp;
	
	</li><ul><li class="level2">Provide information (or refer the person to the specialist diabetes team for information) on types and duration of exercise.&nbsp;The current <a href="https://www.gov.uk/government/publications/uk-physical-activity-guidelines">UK physical activity guidelines</a>&nbsp;state that:
		
		</li><ul><li class="level3">All adults aged 19&nbsp;years and over should aim to be active daily.</li><li class="level3">Over a week, this should add up to at least 150&nbsp;minutes (2.5&nbsp;hours) of moderate intensity physical activity (such as brisk walking or cycling) in bouts of 10&nbsp;minutes or more.</li><li class="level3">Alternatively, comparable benefits can be achieved through 75&nbsp;minutes of vigorous intensity activity (such as running or playing football) spread across the week or combinations of moderate and vigorous intensity activity.</li><li class="level3">All adults should also undertake physical activity to improve muscle strength on at least 2&nbsp;days a week.</li><li class="level3">Time spent being sedentary should be minimized.</li><li class="level3">Older adults (65&nbsp;years and over) who are at risk of falls should incorporate physical activity to improve balance and coordination on at least 2 days a week.</li></ul><li class="level2">Also provide information on the following (if appropriate):
		
		</li><ul><li class="level3">The&nbsp;interaction&nbsp;of exercise and alcohol.</li><li class="level3">The effect of exercise and physical activity on blood glucose levels when insulin levels are adequate (risk of hypoglycaemia).&nbsp;</li><li class="level3">The effect of exercise and physical activity on blood glucose levels when the person is hyperglycaemic or hypoinsulinaemic (risk of worsening of hyperglycaemia and ketonaemia).</li><li class="level3">The appropriate adjustments of insulin dosage and/or nutritional intake for exercise and post-exercise periods, and the next 24 hours.&nbsp;</li><li class="level3">Further contacts and sources of information. For example, information on <a href="https://www.diabetes.org.uk/keeping-active">Getting active and staying active</a> for people with diabetes is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/">www.diabetes.org.uk</a>).&nbsp;&nbsp;</li></ul></ul><li class="level1"><b>Also advise that regular exercise can:</b>
	
	</li><ul><li class="level2">Reduce&nbsp;their increased cardiovascular risk in the medium and longer term.&nbsp;</li><li class="level2">Help with weight management (when combined with a healthy diet) — see the CKS topic on <a href="/obesity">Obesity</a> for more information.</li></ul></ul></section><section class="scenarioclarification" id="1309404"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Alcohol intake</h4></header><ul><li class="level1"><b>Give information on the recommended maximum alcohol intake. </b>See the section on 'Safer drinking limits'&nbsp;in the CKS topic on&nbsp;<a href="/alcohol-problem-drinking">Alcohol - problem drinking</a> for more information.</li><li class="level1"><b>Advise the person with type 2 diabetes and/or their family/carers:</b>
	
	</li><ul><li class="level2">To avoid drinking alcohol on an empty stomach (as the alcohol will be absorbed faster).
		
		</li><ul><li class="level3">They should eat a snack that contains carbohydrate (such as a sandwich) before and after drinking alcohol.&nbsp;</li></ul><li class="level2">That alcohol may exacerbate or prolong the hypoglycaemic effect of antidiabetic drugs.
		
		</li><ul><li class="level3">The signs of hypoglycaemia may become less clear, and delayed hypoglycaemia may occur up to several hours after alcohol consumption.</li><li class="level3">See the section on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes#!scenariorecommendation:8">Hypoglycaemia</a>&nbsp;in the CKS topic on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>&nbsp;for more information.&nbsp;</li></ul><li class="level2">To always wear some form of diabetes identification&nbsp;(as the reduced awareness of hypoglycemia may be confused with alcohol intoxication). Examples of diabetes identification include:&nbsp;
		
		</li><ul><li class="level3">A MedicAlert® bracelet, necklace, or watch (available from&nbsp;<a href="http://www.medicalert.org.uk/">www.medicalert.org.uk</a>).&nbsp;</li><li class="level3">Diabetes ID Card (available from&nbsp;<a href="http://www.diabetes.co.uk/shop/productdetails.aspx?pid=1739">www.diabetes.co.uk</a>).</li></ul></ul></ul></section><section class="scenarioclarification" id="1309406"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Smoking and substance misuse</h4></header><ul><li class="level1"><b>Explain that smoking is a risk factor for cardiovascular disease.</b>

	
	</li><ul><li class="level2">Give adults with type 2 diabetes who smoke&nbsp;advice on smoking cessation and the use of smoking cessation&nbsp;services. See the&nbsp;CKS topic on&nbsp;<a href="/smoking-cessation">Smoking cessation</a>&nbsp;for more information.

		
		</li><ul><li class="level3">Reinforce this advice annually for people who currently do not plan to stop smoking, and at all clinical contacts if there is a prospect of the person stopping.&nbsp;</li></ul><li class="level2">Advise young adult non-smokers&nbsp;never to start smoking.</li></ul><li class="level1"><b>Explain about the general dangers of substance misuse and the possible effects on blood glucose control.</b>&nbsp;
	
	</li><ul><li class="level2">Information, advice, and support on substance misuse are available on the Talk to Frank website (<a href="http://www.talktofrank.com/">www.talktofrank.com</a>).</li></ul></ul></section><section class="scenariobasis" id="1307674"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <i>Type 2 diabetes in adults: management&nbsp;</i>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].&nbsp;The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the&nbsp;<a href="https://www.nice.org.uk/guidance/ng28/evidence">full NICE guideline</a>.</p><p><b>Advice on diet</b></p><ul><li class="level1">In the expert opinion of the NICE guideline development group (GDG), good dietary habits should be encouraged in people with type 2 diabetes as this can help them:
	
	</li><ul><li class="level2">Achieve and maintain blood glucose levels and blood pressure in the normal range (or as close to normal as is safely possible).</li><li class="level2">Maintain a lipid and lipoprotein profile that reduces the risk of vascular disease.&nbsp;</li></ul><li class="level1">The GDG noted that there was little new evidence to warrant any change to previous recommendations on diet and that a&nbsp;dietary plan for people with diabetes should follow the principles of healthy eating in the general population. The GDG also noted that&nbsp;major consensus-based recommendations from the UK and US emphasize sensible practical implementation of nutritional advice for people with type 2 diabetes.</li><li class="level1">The GDG discouraged the use of:
	
	</li><ul><li class="level2">'Diabetic foods' because although they may be low in classical sugars, most are high in calories and are therefore unsuitable as well as unnecessary for people who are overweight.</li><li class="level2">Low-carbohydrate diets due to a lack of evidence of long-term safety.</li><li class="level2">High-protein diets&nbsp;due to a lack of evidence of long-term safety, although&nbsp;these were acknowledged as being effective for&nbsp;short-term weight loss.</li></ul></ul><p><b>Advice on exercise and physical activity</b></p><ul><li class="level1">NICE does not make specific recommendations on exercise and physical activity for adults with type 2 diabetes but refers to the NICE guideline&nbsp;<i>Physical activity: brief advice for adults in primary </i><i>care&nbsp;</i>[<a rel="citation" resource="1090203#A1314603" href="/diabetes-type-2#!references/1090203">NICE, 2013</a>], which includes the <a href="https://www.gov.uk/government/publications/uk-physical-activity-guidelines">UK physical activity guidelines</a> published by the Department of Health.&nbsp;</li><li class="level1">CKS has extrapolated the recommendations on exercise and physical activity from the NICE guideline <i>Type 1 diabetes in adults: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>].</li></ul><p><b>Advice on alcohol intake</b></p><ul><li class="level1">NICE does not make specific recommendations on alcohol intake for adults with type 2 diabetes but states that people with type 2 diabetes who are overweight or&nbsp;prone to hypoglycaemia through use of insulin secretagogues or insulin should be advised on alcohol intake&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].</li><li class="level1">The recommendations on alcohol intake are based on (and in some cases extrapolated from) expert opinion in the&nbsp;Royal College of Nursing guideline <i>Starting injectable treatment in adults with Type 2 diabetes&nbsp;</i>[<a rel="citation" resource="1090203#A79868" href="/diabetes-type-2#!references/1090203">RCN, 2012</a>],&nbsp;the NICE guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>], and&nbsp;the&nbsp;Diabetes UK website (<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Enjoy-food/what-to-drink-with-diabetes/Alcohol-and-diabetes/">www.diabetes.org.uk</a>).</li></ul><p><b>Advice on substance misuse</b></p><ul><li class="level1">NICE does not make specific recommendations on substance misuse for adults with type 2 diabetes.</li><li class="level1">CKS has extrapolated the recommendations on substance misuse from the NICE guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management </i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>]&nbsp;as it is recognized that substance misuse can also be a problem in the adult population.</li></ul></section></section><section class="scenariorecommendation" id="1312534"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Managing suspected diabetic ketoacidosis</h3></header><p><b>Diabetic ketoacidosis (DKA) is more common&nbsp;in type 1 diabetes but can occur in people with type 2 diabetes.</b></p><ul><li class="level1"><b>If DKA is&nbsp;<a href="/diabetes-type-2#!diagnosissub:2">suspected</a>,&nbsp;</b>admit the person immediately for confirmation of the diagnosis and emergency treatment with intravenous insulin and fluids.</li><li class="level1"><b>After the person has recovered from an episode of DKA:</b>
	
	</li><ul><li class="level2">Discuss with them and/or their family/carers the&nbsp;<a href="/diabetes-type-2#!diagnosissub:2">factors</a>that may have led to the episode.</li><li class="level2">Consider the possibility of non-adherence to treatment, especially if the DKA is recurrent.&nbsp;</li><li class="level2">Give advice on how to reduce the risk of future episodes. In particular, advise on the importance of appropriately managing&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:5">intercurrent illness</a>.</li></ul><li class="level1"><a href="https://www.diabetes.org.uk/Guide-to-diabetes/Complications/Diabetic_Ketoacidosis/">Information on DKA</a> for people with diabetes and their family/carers is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/">www.diabetes.org.uk</a>).</li></ul><section class="scenariobasis" id="1312536"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><ul><li class="level1">The&nbsp;National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Type 2 diabetes in adults: management</i>&nbsp;does not cover the management of diabetic ketoacidosis (DKA), and&nbsp;CKS did not identify any guidelines on the primary care management of DKA in adults with type 2 diabetes.&nbsp;</li><li class="level1">The recommendation to admit adults with suspected DKA and the advice on&nbsp;how to manage the person after&nbsp;an episode of DKA have been&nbsp;extrapolated from the NICE guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li></ul></section></section><section class="scenariorecommendation" id="1312540"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Managing intercurrent illness</h3></header><ul><li class="level1"><b>Consider the need for&nbsp;<a href="/diabetes-type-2#!scenarioclarification:6">hospital admission or seeking specialist advice</a>.</b>
	
	</li><ul><li class="level2">Use clinical judgement, taking into account the person's age, any underlying comorbidities and complications, and the presence of&nbsp;hyperglycaemia and ketosis.</li></ul><li class="level1"><b>If the person can be managed in primary care:</b>
	
	</li><ul><li class="level2">Assess and manage the intercurrent illness(es).</li><li class="level2">Assess how well blood glucose has been managed with diet and antidiabetic treatment (if relevant).
		
		</li><ul><li class="level3">For people on antidiabetic treatment, review their treatment as necessary.</li></ul><li class="level2">Warn the person and/or their family/carers that illness may affect blood glucose control:
		
		</li><ul><li class="level3">Some illnesses (especially if associated with fever) can raise blood glucose levels.</li><li class="level3">In contrast, illnesses associated with vomiting and diarrhoea (such as gastroenteritis) can lower blood glucose levels, possibly leading to hypoglycaemia (generally defined as blood glucose levels less than 3.5 mmol/L).</li></ul><li class="level2">Consider the need for&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:1">self-monitoring of blood glucose</a>&nbsp;levels.</li><li class="level2">Provide the person with clear individualized oral and written advice (<a href="/diabetes-type-2#!scenarioclarification:7">'sick-day rules'</a>)&nbsp;on managing type 2 diabetes during intercurrent illness or episodes of hyperglycaemia.
		
		</li><ul><li class="level3">Reiterate the advice at least annually.</li></ul><li class="level2">Ensure that the person has written contact details of their diabetes specialist team.</li><li class="level2">Ensure that the person has sick day foods and hydration supplies readily accessible at home, including:
		
		</li><ul><li class="level3">Easily digestible food and sugary drinks (to provide energy and to prevent further ketosis).</li><li class="level3">Oral rehydration salt sachets (to prevent dehydration).</li><li class="level3">Glucose tablets or oral gel (to prevent hypoglycaemia).</li><li class="level3">Equipment for self-monitoring of blood glucose and ketones.&nbsp;</li><li class="level3">Additional supplies of insulin (if the person is on insulin therapy).</li><li class="level3">A glucagon kit (if appropriate).</li></ul><li class="level2">See the section on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes#!scenariorecommendation:2">Accessories for insulin therapy</a>&nbsp;in the CKS topic on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>&nbsp;for information on blood glucose and ketone monitoring meters, glucose oral gels, and other accessories.</li></ul></ul><section class="scenarioclarification" id="1312547"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Admission or specialist advice</h4></header><p><b>The decision to admit a person or seek specialist advice will depend on clinical judgement, taking into account the person's age, underlying&nbsp;comorbidities and complications, and the presence of hyperglycaemia and ketosis.</b></p><ul><li class="level1"><b>Arrange immediate hospital admission if:</b>

	
	</li><ul><li class="level2">There is an immediate risk of&nbsp;<a href="/diabetes-type-2#!diagnosissub:2">diabetic ketoacidosis</a>&nbsp;(DKA).</li><li class="level2">There is moderate ketonuria (2+ on urine dipstick) or ketonaemia (1.5–2.9&nbsp;mmol/L) with or without hyperglycaemia and the person cannot eat or drink, as there is a risk of DKA.</li><li class="level2">A person treated with insulin does not improve rapidly with insulin treatment.</li></ul><li class="level1"><b>Consider arranging hospital admission or seeking urgent specialist advice if:</b>
	
	</li><ul><li class="level2">The underlying condition is unclear.</li><li class="level2">The person is dehydrated or at risk of dehydration.</li><li class="level2">Vomiting persists beyond 2&nbsp;hours.</li><li class="level2">The person and their family/carers are unable to keep the blood glucose level above 3.5&nbsp;mmol/L.</li><li class="level2">The person and their family/carers are exhausted, for example due to repeated night-time waking.</li></ul></ul></section><section class="scenarioclarification" id="1312550"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>'Sick-day rules'</h4></header><ul><li class="level1"><b>During a period of illness that does not require&nbsp;<a href="/diabetes-type-2#!scenarioclarification:6">admission</a>, remind the person to adhere to the following 'sick-day rules' which should have been provided by their diabetes team:</b>

	
	</li><ul><li class="level2"><b>If they are on insulin therapy, they should not stop their treatment.&nbsp;</b>

		
		</li><ul><li class="level3">The dose of insulin may need to be altered during periods of illness; they should seek advice from their diabetes team if they are unsure of how to adjust their insulin doses.</li></ul><li class="level2"><b>If self-monitoring of blood glucose levels is&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:1">indicated</a>&nbsp;(for example in people on insulin therapy), it should be done carefully and frequently.</b>
		
		</li><ul><li class="level3">It should be checked at least every 3–4&nbsp;hours including through the night, and sometimes every 1–2&nbsp;hours.&nbsp;Remind the person to record the results.</li></ul><li class="level2"><b>Consider ketone monitoring (blood or urine).</b>
		
		</li><ul><li class="level3">This should be checked regularly, for example every 3–4&nbsp;hours including through the night, and sometimes every 1–2&nbsp;hours depending on results.</li><li class="level3">If the urine ketone level is greater than 2+, or blood ketone levels are greater than 3 mmol/L, the person should contact the GP or diabetes specialist team immediately.</li></ul><li class="level2"><b>Maintain their normal meal pattern (where possible) if appetite is reduced.</b>
		
		</li><ul><li class="level3">Their normal meals could be replaced with carbohydrate-containing drinks (such as milk, milkshakes, fruit juices, and sugary drinks).</li></ul><li class="level2"><b>Aim to drink at least 3 L of fluid a day to prevent dehydration.</b> They should seek urgent medical advice if:
		
		</li><ul><li class="level3">They are sick, drowsy, or unable to keep fluids down.</li><li class="level3">They have persistent&nbsp;vomiting or diarrhoea.</li></ul><li class="level2"><b>When feeling better, they should continue to monitor their blood glucose levels carefully (if indicated) until it returns to normal.</b>
		
		</li><ul><li class="level3">This may take some time.</li><li class="level3">The person should seek medical advice if their blood glucose remains uncontrolled.</li></ul></ul><li class="level1">Further information on <a href="https://www.diabetes.org.uk/Guide-to-diabetes/Living_with_diabetes/Illness/">dealing with illness</a> is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/">www.diabetes.org.uk</a>).</li></ul></section><section class="scenariobasis" id="1312542"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p><b>Managing a period of illness</b></p><ul><li class="level1">The National Institute for Health and Care (NICE) guideline&nbsp;<i>Type 2 diabetes in adults: management</i> does not make specific recommendations on how to manage an adult with type 2 diabetes during a period of illness, but states that in people with type 2 diabetes and acute intercurrent illnesses, treatment should be reviewed and the person should be reminded on what action to take when they are unwell&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].&nbsp;</li><li class="level1">CKS did not identify any UK consensus document on how to manage an adult with type 2 diabetes during a period of illness. Consequently, these recommendations have been extrapolated from expert opinion in the US guideline&nbsp;<i>ISPAD clinical practice consensus guidelines 2014 compendium: sick day management in children and adolescents with diabetes</i>&nbsp;published by the International Society for Pediatric and Adolescent Diabetes (ISPAD)&nbsp;[<a rel="citation" resource="1090203#A79871" href="/diabetes-type-2#!references/1090203">Brink et al, 2014</a>], the&nbsp;<i>National Service Framework for Children, Young People and Maternity Services – Diabetes Type 1 in childhood and adolescence&nbsp;</i>produced by the Department of Health and Diabetes UK&nbsp;[<a rel="citation" resource="1090203#A64866" href="/diabetes-type-2#!references/1090203">DH, 2010</a>], expert opinion in textbooks on the management of diabetes&nbsp;[<a rel="citation" resource="1090203#A64127" href="/diabetes-type-2#!references/1090203">Cameron and Allgrove, 2007</a>; <a rel="citation" resource="1090203#A64085" href="/diabetes-type-2#!references/1090203">Holt and Kumar, 2010b</a>],&nbsp;and information on the&nbsp;Diabetes UK website (<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Living_with_diabetes/Illness/">www.diabetes.org.uk</a>).</li><li class="level1">NICE does not recommend routine self-monitoring of blood glucose levels in adults with type 2 diabetes but states that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].&nbsp;Based on this, CKS recommends that blood glucose levels should be checked frequently during a period of illness.&nbsp;</li></ul><p><b>'Sick-day rules'</b></p><ul><li class="level1">The recommended 'sick-day rules' are largely based on information on the Diabetes UK website (<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Living_with_diabetes/Illness/">www.diabetes.org.uk</a>).&nbsp;</li><li class="level1">The&nbsp;frequency of blood glucose monitoring (if indicated) has been extrapolated from the ISPAD paediatric guideline&nbsp;[<a rel="citation" resource="1090203#A79871" href="/diabetes-type-2#!references/1090203">Brink et al, 2014</a>].</li><li class="level1">The recommendation that ketone monitoring (blood or urine) should be considered as part of 'sick-day rules' is extrapolated from the NICE guideline&nbsp;<i>Type 1 diabetes in adults: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>], which recommends ketone monitoring for&nbsp;adults with type 1 diabetes to&nbsp;facilitate self-management of an episode of hyperglycaemia.&nbsp;</li><li class="level1">NICE does not specify how often the monitoring should be done. The&nbsp;recommended monitoring frequency is based on what CKS considers to be good clinical practice.</li></ul></section></section><section class="scenariorecommendation" id="1308718"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Screening for complications of type 2 diabetes</h3></header><p><b>People with type 2 diabetes should have regular surveillance for&nbsp;<a href="/diabetes-type-2#!backgroundsub:5">complications</a>&nbsp;of diabetes.&nbsp;</b></p><ul><li class="level1"><b>At every review appointment (if clinically indicated):</b>

	
	</li><ul><li class="level2">Measure the person's height, weight, and waist circumference, and calculate their body mass index (BMI). Manage people who are overweight or obese. See the CKS topic on&nbsp;<a href="/obesity">Obesity</a>&nbsp;for more information.</li><li class="level2">Assess for depression and anxiety.&nbsp;See the CKS topics on&nbsp;<a href="/depression">Depression</a>&nbsp;and&nbsp;<a href="/generalized-anxiety-disorder">Generalized anxiety disorder</a>&nbsp;for more information.</li><li class="level2">Check smoking status. If applicable, offer advice on smoking cessation. See the CKS topic on&nbsp;<a href="/smoking-cessation">Smoking cessation</a>&nbsp;for more information.</li><li class="level2">Assess for neuropathy and its associated complications, including erectile dysfunction, neuropathic pain, autonomic neuropathy, and gastroparesis (delayed emptying of the stomach).&nbsp;See the section on&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:8">Managing neuropathic complications</a>&nbsp;if any neuropathic complications are identified.</li></ul><li class="level1"><b>Every 6 months:</b>
	
	</li><ul><li class="level2">Measure&nbsp;HbA1c levels to ensure adequate blood glucose control.
		
		</li><ul><li class="level3">HbA1c should be measures at 3–6-monthly intervals initially, until it is stable on unchanging antidiabetic treatment. See the section on&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:1">Treatment targets</a>&nbsp;for more information.</li></ul></ul><li class="level1"><b>Once a year:</b>
	
	</li><ul><li class="level2">Ensure the person is screened for:
		
		</li><ul><li class="level3"><a href="/diabetes-type-2#!scenarioclarification:8">Retinopathy</a>&nbsp;(starting at diagnosis).</li><li class="level3"><a href="/diabetes-type-2#!scenarioclarification:9">Diabetic foot problems</a>&nbsp;(starting at diagnosis).</li><li class="level3"><a href="/diabetes-type-2#!scenarioclarification:10">Nephropathy</a>.</li><li class="level3"><a href="/diabetes-type-2#!scenarioclarification:11">Cardiovascular risk factors</a>.</li></ul><li class="level2">For people on insulin therapy, check injection sites&nbsp;and address any injection site problems. See the section on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes#!scenariorecommendation:3">Managing injection site problems</a>&nbsp;in the CKS topic on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>&nbsp;for more information.</li></ul></ul><section class="scenarioclarification" id="1308724"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Retinopathy</h4></header><p><b>Adults with type 2 diabetes should receive retinal examination (at the time of diagnosis and annually thereafter) as part of the NHS retinopathy screening programme.&nbsp;The programme aims to reduce the risk of sight loss among people with diabetes by the early detection and treatment, if needed, of sight-threatening retinopathy.&nbsp;</b></p><ul><li class="level1"><b>Arrange an emergency review by an ophthalmologist for a person with type 2 diabetes if there is:&nbsp;</b>

	
	</li><ul><li class="level2">Sudden loss of vision.&nbsp;</li><li class="level2">Rubeosis iridis (formation of abnormal blood vessels on the anterior iris).&nbsp;</li><li class="level2">Pre-retinal or vitreous haemorrhage.&nbsp;</li><li class="level2">Retinal detachment — see the CKS topic on&nbsp;<a href="/retinal-detachment">Retinal detachment</a>.&nbsp;</li></ul><li class="level1"><b>Ensure that urgent review by an ophthalmologist is arranged if there is </b>formation of new abnormal vessels on the retina.&nbsp;</li><li class="level1">Detailed information on the <a href="https://www.gov.uk/government/publications/diabetic-eye-screening-description-in-brief">NHS retinopathy screening programme</a>&nbsp;published by&nbsp;Public Health England is available at <a href="https://www.gov.uk/">www.gov.uk</a>.</li></ul></section><section class="scenarioclarification" id="1308731"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Foot problems</h4></header><p><b>People with type 2 diabetes should have their feet checked by a primary healthcare professional at diagnosis and at least once a year thereafter, or sooner if any foot problems arise.&nbsp;They should also be advised to check their own feet on a daily basis.</b></p><ul><li class="level1"><b>Appropriate information on&nbsp;the risk of developing a diabetic foot problem should be provided to all people with type 2 diabetes.</b>&nbsp;This information should be provided at diagnosis, during assessments, and if foot problems arise, and should include the following:

	
	</li><ul><li class="level2">Basic&nbsp;foot care advice and the importance of foot care.</li><li class="level2">Foot emergencies and who to contact.</li><li class="level2">Footwear advice.</li><li class="level2">The person's current individual risk of developing a foot problem.</li><li class="level2">Information on diabetes and the importance of blood glucose control.</li></ul><li class="level1"><b>To examine the feet of a person with diabetes, their shoes, socks, bandages, and dressings (as appropriate) should be removed and both feet examined for evidence of the following risk factors:</b>
	
	</li><ul><li class="level2">Neuropathy&nbsp;— a&nbsp;10 g monofilament should be used as part of a foot sensory examination.</li><li class="level2">Limb ischaemia&nbsp;— ankle brachial pressure index (ABPI) should be used, and results should be interpreted carefully because calcified arteries may falsely elevate ABPI results.&nbsp;See the section on diagnosing chronic limb ischaemia in the&nbsp;CKS topic on&nbsp;<a href="/peripheral-arterial-disease">Peripheral arterial disease</a>&nbsp;for more information.</li><li class="level2">Ulceration.</li><li class="level2">Callus formation.</li><li class="level2">Infection and/or inflammation.</li><li class="level2">Deformity.</li><li class="level2">Gangrene.</li><li class="level2">Charcot arthropathy (an acute, localized inflammatory condition&nbsp;that may lead to varying degrees and patterns of bone destruction, subluxation, dislocation, and deformity).</li></ul><li class="level1"><b>Based on the findings from the foot examination, foot ulceration risk should be categorized as:</b>
	
	</li><ul><li class="level2">Low risk — no risk factors present.</li><li class="level2">Moderate risk — one risk factor present.&nbsp;</li><li class="level2">High risk — previous ulceration or amputation, on renal replacement therapy, or more than one risk factor present.&nbsp;</li><li class="level2">Active diabetic foot problem — ulceration, spreading infection, critical ischaemia, gangrene, suspicion of an acute Charcot arthropathy, or an unexplained hot, red, swollen foot with or without pain.&nbsp;</li></ul><li class="level1"><b>Management should be based on the person's foot ulceration risk category.&nbsp;</b>
	
	</li><ul><li class="level2"><b>For people who are at low risk,</b> annual foot assessments should be continued, the importance of foot care should be continually emphasized, and they should be advised that they could progress to moderate or high risk without appropriate foot care.&nbsp;</li><li class="level2"><b>For people at moderate or high risk,</b> referral to the foot protection service should be arranged, where they should be seen within 2–4 weeks if at high risk or within 6–8 weeks if at moderate risk.&nbsp;</li></ul><li class="level1"><b>Depending on the person's risk of developing a diabetic foot problem, reassessments should be carried out at the following intervals:&nbsp;</b>
	
	</li><ul><li class="level2">Annually — for people who are at low risk.&nbsp;</li><li class="level2">Frequently (for example every 3–6 months) — for people who are at moderate risk.&nbsp;</li><li class="level2">More frequently (for example every 1–2 months) — for people who are at high risk, if there is no immediate concern.&nbsp;</li><li class="level2">Very frequently (for example every 1–2 weeks) — for people who are at high risk, if there is immediate concern.&nbsp;
		
		</li><ul><li class="level3">More frequent reassessments should be considered for people who are unable to check their own feet.</li></ul></ul></ul></section><section class="scenarioclarification" id="1308727"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Nephropathy</h4></header><p><b>All adults with&nbsp;type 2 diabetes (with or without detected nephropathy) should receive annual screening for diabetic nephropathy.&nbsp;</b></p><ul><li class="level1"><b>To assess for nephropathy:</b>

	
	</li><ul><li class="level2">Send a first-pass early morning urine specimen for estimation of the albumin:creatinine ratio (ACR).&nbsp;</li><li class="level2">Measure serum creatinine at the same time to calculate estimated&nbsp;glomerular filtration rate (eGFR).</li></ul><li class="level1"><b>Chronic kidney disease (CKD) is diagnosed</b>&nbsp;when tests have persistently (for at least three months or more) shown a reduction in kidney function or the presence of proteinuria.
	
	</li><ul><li class="level2">Diagnose CKD&nbsp;if the person's&nbsp;eGFR is persistently less than 60 mL/min/1.73 m<sup>2</sup>, and/or ACR is persistently greater than&nbsp;3 mg/mmol.</li></ul></ul></section><section class="scenarioclarification" id="1308734"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Cardiovascular risk factors</h4></header><p><b>People with type 2 diabetes should have their cardiovascular risk factors assessed annually.&nbsp;</b></p><ul><li class="level1"><b>Assess the person's:</b>

	
	</li><ul><li class="level2">Age.</li><li class="level2">Albuminuria.</li><li class="level2">Smoking status.</li><li class="level2">Blood glucose control.</li><li class="level2">Blood pressure.</li><li class="level2">Full lipid profile&nbsp;(high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, and triglycerides).</li><li class="level2">Family history of cardiovascular disease (CVD).</li><li class="level2">Waist circumference.</li></ul><li class="level1">People with CVD risks factors should be&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:7">managed</a>&nbsp;appropriately.</li></ul></section><section class="scenariobasis" id="1308719"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <i>Type 2&nbsp;diabetes in adults: management&nbsp;</i>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>]. The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng28/evidence">full NICE guideline</a>.</p><p><b>Regular monitoring for complications&nbsp;</b></p><ul><li class="level1">'Type 2 diabetes can result in a wide range of complications with repercussions for both the person and the NHS'&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].&nbsp;</li><li class="level1">The NICE guideline development group (GDG) recommends that people with type 2 diabetes are carefully monitored for signs of complications so that prompt&nbsp;interventions and/or referral can be arranged in order to reduce the progression of late complications into adverse health outcomes.</li></ul><p><b>Screening for retinopathy</b></p><ul><li class="level1">'Diabetic&nbsp;eye damage is the single largest cause of blindness before old age with a progressive incidence in people with type 2 diabetes'&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].</li><li class="level1">CKS has not outlined the individual NICE recommendations regarding screening for retinopathy in people with type 2 diabetes because this is usually done as part of the annual NHS retinopathy screening programme. However, information on the need for an emergency review or urgent review by an ophthalmologist has been highlighted as these people may be seen in primary care.</li><li class="level1">The GDG of the NICE type 2 diabetes guideline agreed that&nbsp;recommendations for people with type 2 diabetes should closely follow those for type 1 diabetes. See the CKS topic on&nbsp;<a href="/diabetes-type-1">Diabetes - type 1</a>&nbsp;for more information.</li></ul><p><b>Screening for diabetic foot problems</b></p><ul><li class="level1">The recommendations on foot care are based on the NICE guideline <i>Diabetic foot problems: prevention and management&nbsp;</i>[<a rel="citation" resource="1090203#A1299588" href="/diabetes-type-2#!references/1090203">NICE, 2015c</a>]. For detailed information on the evidence NICE used to make these recommendations, see the&nbsp;<a href="https://www.nice.org.uk/guidance/ng19">full NICE guideline</a>.&nbsp;</li><li class="level1">The definition of Charcot arthropathy is based on expert opinion in the review article <i>The Charcot Foot in Diabetes</i> published by the American Diabetes Association&nbsp;[<a rel="citation" resource="1090203#A1301999" href="/diabetes-type-2#!references/1090203">Rogers et al, 2011</a>].</li></ul><p><b>Screening for nephropathy</b></p><ul><li class="level1">The NICE guideline on type 2 diabetes in adults does not make specific recommendations on screening for nephropathy but notes that prolonged&nbsp;hyperglycaemia can lead to irreversible microvascular complications, including nephropathy&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].</li><li class="level1">CKS has extrapolated the recommendations on screening for nephropathy from recommendations in the NICE guideline&nbsp;<i>Type 1 diabetes in adults: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>].</li></ul><p><b>Screening for cardiovascular disease (CVD) risk</b></p><ul><li class="level1">The NICE guideline does not make specific recommendations on screening for CVD risk but states that type 2 diabetes is notable for the increased cardiovascular risk that it carries.&nbsp;</li><li class="level1">CKS has extrapolated the recommendations on screening for CVD risk from&nbsp;recommendations in the NICE guideline&nbsp;<i>Type 1 diabetes in adults: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>].</li></ul></section></section><section class="scenariorecommendation" id="1307682"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Managing cardiovascular risk</h3></header><section class="scenarioclarification" id="1312507"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Smoking, diet, exercise and physical activity</h4></header><ul><li class="level1"><b>For advice on smoking, diet, and exercise and physical activity, </b>see the section on&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:3">Lifestyle advice</a>.</li></ul></section><section class="scenarioclarification" id="1307688"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Antihypertensive treatment</h4></header><p><b>For adults with type 2 diabetes on </b> <b>antihypertensive drug treatment when diabetes is diagnosed:</b></p><ul><li class="level1">Review blood pressure control and treatments used.&nbsp;Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.</li><li class="level1">Monitor blood pressure every 1–2 months, and intensify treatment until the blood pressure is consistently below 140/80 mmHg (or below 130/80 mmHg if there is nephropathy, retinopathy, or cerebrovascular damage).</li><li class="level1">When the person has attained and consistently maintained their blood pressure target, monitor their blood pressure every&nbsp;4–6 months, and check for possible adverse effects of antihypertensive drug treatment (including hypotension).</li></ul><p><b>For adults without&nbsp;previously&nbsp;diagnosed hypertension or nephropathy:</b></p><ul><li class="level1">Measure&nbsp;blood pressure at least annually, and offer and reinforce&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:3">preventive lifestyle advice</a>.

	
	</li><ul><li class="level2">Repeat blood pressure measurements (and reinforce lifestyle advice) within:

		
		</li><ul><li class="level3">1 month if blood pressure is higher than 150/90mmHg.</li><li class="level3">2 months if blood pressure is higher than 140/80mmHg.</li><li class="level3">2 months if blood pressure is higher than&nbsp;130/80mmHg in a person with&nbsp;nephropathy, retinopathy, or cerebrovascular damage.</li></ul><li class="level2">Provide lifestyle advice if blood pressure is confirmed as being consistently above&nbsp;140/80 mmHg (or above 130/80mmHg if there is&nbsp;nephropathy, retinopathy, or cerebrovascular damage).&nbsp;</li></ul><li class="level1">If lifestyle advice does not reduce blood pressure to below these targets, add drug treatment:
	
	</li><ul><li class="level2"><b>For most people, </b>prescribe a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor first line. Exceptions to this are people of&nbsp;African or Caribbean family origin and women for whom there is a possibility of becoming pregnant.</li><li class="level2">If there is continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin-II receptor antagonist (AIIRA), if appropriate. Do not combine an ACE inhibitor with an AIIRA.</li><li class="level2">If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).</li><li class="level2">If the target is not reached with dual therapy, add the other drug (that is, the calcium-channel blocker or diuretic).</li><li class="level2">If the person's blood pressure is not reduced to the individually agreed target with triple therapy,&nbsp;add an alpha-blocker, a beta-blocker, or a potassium-sparing&nbsp;diuretic (with caution).
		
		</li><li class="level2"><b>For people of African or Caribbean family origin, </b>prescribe&nbsp;an ACE inhibitor plus either a diuretic or a calcium-channel blocker first line.&nbsp;</li><li class="level2">If an ACE inhibitor is not tolerated, substitute an AIIRA, if appropriate. Do not combine an ACE inhibitor with an AIIRA.</li><li class="level2">If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (depending on the first-line combination treatment).</li><li class="level2">If the person's blood pressure is not reduced to the individually agreed target,&nbsp;add an alpha-blocker, a beta-blocker, or a potassium-sparing&nbsp;diuretic (with caution).</li></ul><li class="level1"><b>For women for whom there is a possibility of becoming pregnant,</b> see the National Institute for Health and Care Excellence (NICE) guideline&nbsp;<a href="/hypertension-in-pregnancy">Hypertension in pregnancy</a>&nbsp;for more information.</li><li class="level1">When the person has attained&nbsp;and consistently maintained their blood pressure target, monitor their blood pressure every&nbsp;4–6 months,&nbsp;and check for possible adverse effects of antihypertensive drug treatment (including hypotension).</li></ul></section><section class="scenarioclarification" id="1308429"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Antiplatelet treatment</h4></header><ul><li class="level1"><b>Do not offer antiplatelet treatment (aspirin or clopidogrel) for the primary prevention of cardiovascular disease (CVD) in adults with type 2 diabetes.</b></li><li class="level1">For information on the primary and secondary prevention of CVD in adults with type 2 diabetes, see the CKS topic on&nbsp;<a href="/antiplatelet-treatment">Antiplatelet treatment</a>.</li></ul></section><section class="scenarioclarification" id="1308739"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Lipid modification</h4></header><ul><li class="level1"><b>For people with type 2 diabetes who&nbsp;<i>do not</i>&nbsp;have established cardiovascular disease</b>&nbsp;<b>(CVD):&nbsp;</b>

	
	</li><ul><li class="level2">Offer&nbsp;statin treatment with atorvastatin 20 mg for the primary prevention of CVD if the person is&nbsp;aged 84 years and younger and their estimated 10-year risk of developing CVD using the&nbsp;<a href="http://qrisk.org/">QRISK®2</a>&nbsp;assessment tool is 10% or more.</li><li class="level2">Consider offering&nbsp;statin treatment with atorvastatin 20 mg for the primary prevention of CVD&nbsp;to people who are 85&nbsp;years of age or older, taking into account the benefits and risks of treatment and any comorbidities that make treatment inappropriate. A formal risk assessment is not needed.</li></ul><li class="level1"><b>For people with type 2 diabetes who&nbsp;have&nbsp;established CVD,</b>&nbsp;advise statin treatment with atorvastatin 80 mg for the secondary prevention of CVD.&nbsp;A formal risk assessment is not needed.</li><li class="level1"><b>Before initiating treatment with a statin:</b>
	
	</li><ul><li class="level2">Implement measures to reduce the risk of CVD. These are discussed in detail in the CKS topic on <a href="/cvd-risk-assessment-and-management">CVD risk assessment and management</a>,&nbsp;and include:&nbsp;
		
		</li><ul><li class="level3">Addressing other modifiable CVD risk factors, such as smoking.&nbsp;</li><li class="level3">Identifying and managing secondary causes of hyperlipidaemia, such as excess alcohol consumption, hypothyroidism, liver disease, and nephrotic syndrome.&nbsp;</li></ul><li class="level2">Have an informed discussion with the person and/or their family/carers about the risks and benefits of statin treatment, taking into account additional factors such as potential benefits from lifestyle modifications, the person's preference, comorbidities, polypharmacy, general frailty, and life expectancy. Advise that:&nbsp;
		
		</li><ul><li class="level3">Statin treatment reduces CVD risk compared with no treatment.&nbsp;</li><li class="level3">The adverse effects of statins are generally mild, reversible, and not medically serious, although some people may find them distressing.</li><li class="level3">Myopathy and rhabdomyolysis are the most serious adverse effects of statins. However, they are rare, with estimated incidences of 5 cases per 100,000 person years and 1.6 cases per 100,000 person years, respectively.&nbsp;</li></ul><li class="level2">Perform baseline blood tests to ensure that statin treatment is suitable. This should include:&nbsp;
		
		</li><ul><li class="level3">A non-fasting lipid profile, liver function tests, and renal function.&nbsp;</li><li class="level3">Thyroid stimulating hormone — if hyperlipidaemia is present.&nbsp;</li><li class="level3">Creatine kinase — if the person has persistent generalized unexplained muscle pain.&nbsp;</li></ul><li class="level2">For detailed information on the baseline tests, how to initiate statin treatment, and how to monitor a person taking a statin, see the CKS topic on <a href="/lipid-modification-cvd-prevention">Lipid modification - CVD prevention</a>.</li></ul></ul></section><section class="scenariobasis" id="1307683"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline&nbsp;T<i>ype 2 diabetes in adults: management&nbsp;</i>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].&nbsp;The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the&nbsp;<a href="https://www.nice.org.uk/guidance/ng28/evidence">full NICE guideline</a>.</p><p><b>Antihypertensive treatment</b></p><ul><li class="level1"><b>Treatment targets</b>

	
	</li><ul><li class="level2">Evidence identified by NICE&nbsp;showed that overall, there was an association between low blood pressure values and a lower incidence of cardiovascular events and renal disease. However, no clear blood pressure threshold was identified as a potential therapeutic target.</li><li class="level2">The NICE guideline development group (GDG) noted the problems in assigning blood pressure lowering targets, including the difficulties with setting a cut-off (where the evidence suggests the lower the blood pressure the better, without adverse effects).&nbsp;</li><li class="level2">Based on these, the GDG decided to take a simple risk approach centred on a target level of lower than 140/80 mmHg for most people with type 2 diabetes, and lower than 130/80 mmHg for those at higher risk of cardiovascular events.&nbsp;</li><li class="level2">A systematic review of 49 trials (n = 73738) found that antihypertensive treatment reduces the risk of&nbsp;mortality and cardiovascular morbidity in people with diabetes mellitus&nbsp;and a systolic blood pressure more than 140 mm Hg. However, if systolic blood pressure is less than 140 mm Hg,&nbsp;further treatment is associated with an increased risk of cardiovascular death, with no observed benefit [<a rel="citation" resource="1090203#A1404546" href="/diabetes-type-2#!references/1090203">BMJ, 2016</a>].&nbsp;</li></ul><li class="level1"><b>Choice of antihypertensive treatment</b>
	
	</li><ul><li class="level2">The GDG of the NICE type 2 diabetes guideline considered the recommendations in the NICE guideline&nbsp;<i>Hypertension in adults: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A68249" href="/diabetes-type-2#!references/1090203">NICE, 2011b</a>]:&nbsp;
		
		</li><ul><li class="level3">For people younger than 55 years of age&nbsp;who are not of black African or Caribbean ethnic origin, a&nbsp;renin angiotensin system (RAS) blocker (angiotensin-converting enzyme [ACE] inhibitor or an angiotensin-II receptor antagonist [AIIRA]) is recommended first line.</li><li class="level3">For&nbsp;people aged 55 years of age or older and those who are of black African or Caribbean ethnic origin (of any age), a&nbsp;calcium-channel blocker or a thiazide diuretic is recommended first line.&nbsp;</li></ul><li class="level2">These recommendations were based on good-quality evidence that showed the efficacy of these drugs in reducing cardiovascular outcomes.&nbsp;However, the evidence was for people without diabetes and did not include&nbsp;renal or retinopathy outcomes, both of particular importance when considering choice of treatments for use in people with type 2 diabetes.&nbsp;</li><li class="level2">For this reason, the GDG reviewed the available evidence&nbsp;to determine the effects of different classes of antihypertensive drugs on microvascular and cardiovascular outcomes in people with type 2 diabetes.
		
		</li><ul><li class="level3">Overall, it was felt that the best evidence for preventing renal disease and reducing metabolic worsening related to the RAS blockers.&nbsp;Given the benefits of RAS blockade in terms of reno-protection and retinopathy, the GDG felt it was appropriate to recommend a RAS blocker first line for the treatment of hypertension in most adults with type 2 diabetes.</li><li class="level3">An exception was highlighted in the NICE hypertension guideline, where people of African or Caribbean descent are noted to respond less well to RAS blockers. For these group of people, the GDG of the NICE type 2 diabetes guideline recommends an ACE inhibitor plus a diuretic or calcium-channel blocker as first-line treatments. Little specific information was available for other ethnic groups.</li></ul><li class="level2">&nbsp;After three classes of drugs had been used, the NICE GDG felt that reasons for distinguishing between other drug classes were poor, so any alpha-blocker, beta-blocker, or potassium-sparing diuretic could be added at this stage.&nbsp;</li></ul></ul><p><b>Lipid modification</b></p><p>These recommendations are based on the NICE guideline&nbsp;<i>Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease&nbsp;</i>[<a rel="citation" resource="1090203#A78878" href="/diabetes-type-2#!references/1090203">NICE, 2014</a>].&nbsp;For detailed information on the evidence NICE used to make these recommendations, see the&nbsp;<a href="https://www.nice.org.uk/guidance/cg181/evidence">full NICE guideline</a>.</p><ul><li class="level1"><b>The&nbsp;QRISK®2&nbsp;assessment tool</b>

	
	</li><ul><li class="level2">The NICE guideline on lipid modification recommends the QRISK®2 tool for assessing cardiovascular risk in people with type 2 diabetes, except if they are aged 85 years or older and/or have established cardiovascular disease (CVD).
		
		</li><ul><li class="level3">For people aged 85 years and older, the GDG considered that they are at high risk of CVD by virtue of age alone and therefore have a greater likelihood of clinical benefit from lipid-modification treatment without the need for a formal assessment.&nbsp;In addition, the&nbsp;QRISK®2 tool has an upper limit of 84 years and is therefore not applicable to people aged 85 years and older.</li><li class="level3">For people with established CVD, the GDG&nbsp;recommends lipid-modification therapy without the need for a formal risk assessment because they are at increased risk of recurrence of CVD.</li></ul></ul><li class="level1"><b>Statins for primary and secondary prevention of CVD&nbsp;</b>
	
	</li><ul><li class="level2">NICE reviewed the evidence from 34 randomized studies comparing UK licensed statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin) with placebo for the prevention of CVD in adults; three studies were in people with type 2 diabetes.</li><li class="level2">Good-quality evidence showed that compared with placebo, statins have a beneficial effect on non-fatal myocardial infarction. The evidence also showed that statins have a beneficial effect on all-cause mortality and cardiovascular mortality, but the effect sizes were too small to be clinically important. There was no clinical difference between statins and placebo for stroke prevention.</li><li class="level2">The evidence also showed that&nbsp;high-intensity statin treatment is the most clinically- and cost-effective option for the primary and secondary prevention of CVD in people with type 2 diabetes.&nbsp;</li></ul><li class="level1"><b>Choice of statin</b>

	
	</li><ul><li class="level2">NICE did not identify any head-to-head trials on the effectiveness of the high-intensity statins (in terms of reducing clinical end points) in people with or without type 2 diabetes.&nbsp;</li><li class="level2">The GDG therefore assumed equivalent effectiveness between all high-intensity&nbsp;statins, but atorvastatin was preferred to simvastatin 80&nbsp;mg and all strengths of rosuvastatin because:
		
		</li><ul><li class="level3">Simvastatin 80&nbsp;mg is associated with an increased risk of myopathy&nbsp;[<a rel="citation" resource="1090203#A62450" href="/diabetes-type-2#!references/1090203">MHRA, 2010</a>]. In addition, a meta-analysis found simvastatin 80 mg to have a lesser effect in reducing low-density lipoprotein (LDL) cholesterol levels compared with atorvastatin 20 mg, 40 mg, and 80 mg&nbsp;[<a rel="citation" resource="1090203#A10706" href="/diabetes-type-2#!references/1090203">Law et al, 2003</a>].</li><li class="level3">Rosuvastatin is only available as a branded product (Crestor®) and is significantly more expensive than atorvastatin&nbsp;[<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>].&nbsp;</li></ul><li class="level2">NICE did not make specific recommendations on the choice and dose of statin for the secondary prevention of CVD in people with type 2 diabetes. CKS has therefore extrapolated this recommendation from the NICE recommendations for the secondary prevention of CVD in the general population. See the CKS topic on&nbsp;<a href="/lipid-modification-cvd-prevention">Lipid modification - CVD prevention</a>&nbsp;for more information.</li></ul><li class="level1"><b>Measures to take before initiating treatment with a statin</b>
	
	</li><ul><li class="level2">NICE recommends implementing measures to reduce the risk of CVD, discussing risks and benefits of statin treatment, and performing baseline tests before starting lipid-modification treatment.</li><li class="level2">The information on the adverse effects of statins is based on advice in&nbsp;<i>Statins benefits and risks</i>&nbsp;issued by the&nbsp;Medicines and Healthcare products&nbsp;Regulatory Agency (MHRA)&nbsp;[<a rel="citation" resource="1090203#A79003" href="/diabetes-type-2#!references/1090203">MHRA, 2014</a>].</li></ul></ul><p><b>Antiplatelet treatment</b></p><ul><li class="level1">Although aspirin and clopidogrel are not licensed for primary prevention of CVD, the GDG of the NICE type 2 diabetes guideline considered that an evidence review was important&nbsp;to determine if they could be&nbsp;used for the primary prevention of CVD in people with type 2 diabetes&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].

	
	</li><ul><li class="level2">Low- to very-low quality&nbsp;evidence suggested an increased risk of harm (including bleeding events) associated with the use of aspirin, and there was uncertainty around whether aspirin reduced the incidence of cardiovascular events&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].&nbsp;</li></ul><li class="level1">Based on the evidence identified, the GDG was confident that antiplatelets would not be of sufficient benefit for the primary prevention of CVD in the majority of people with type 2 diabetes.&nbsp;It was felt that although&nbsp;reducing the risk of CVD and mortality are important in improving life expectancy and quality of life, the relative impact of adverse events associated with the off-label use of aspirin and clopidogrel (such as bleeding) for primary prevention was also important in determining the safety and acceptability of the treatment to the person with type 2 diabetes.&nbsp;</li></ul></section></section><section class="scenariorecommendation" id="1308743"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Managing diabetic neuropathy</h3></header><section class="scenarioclarification" id="1308748"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Chronic painful neuropathy</h4></header><ul><li class="level1"><b>For information on managing adults with chronic painful neuropathy,</b>&nbsp;see the CKS topic on&nbsp;<a href="/neuropathic-pain-drug-treatment">Neuropathic pain - drug treatment</a>.</li></ul></section><section class="scenarioclarification" id="1308754"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Erectile dysfunction</h4></header><ul><li class="level1"><b>Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their regular review.&nbsp;</b></li><li class="level1"><b>Assess, educate, and support the person with erectile dysfunction,</b> addressing contributory factors (such as cardiovascular disease) as well as possible treatment options.</li><li class="level1"><b>Consider prescribing a phosphodiesterase-5 inhibitor</b> (sildenafil, vardenafil, or tadalafil), initially choosing the phosphodiesterase-5 inhibitor with the lowest acquisition cost and taking into account any contraindications.&nbsp;
	
	</li><ul><li class="level2">For detailed information on phosphodiesterase-5 inhibitors, including contraindications and cautions, see the section on Prescribing information in the CKS topic on <a href="/erectile-dysfunction">Erectile dysfunction</a>.&nbsp;</li></ul><li class="level1"><b>If phosphodiesterase-5 inhibitor treatment is unsuccessful or contraindicated,</b> refer the man to an erectile dysfunction or urology clinic.</li></ul></section><section class="scenarioclarification" id="1308751"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Autonomic neuropathy</h4></header><ul><li class="level1"><b>For adults with&nbsp;unexplained diarrhoea, particularly at night,&nbsp;</b>consider (and investigate)&nbsp;the possibility of autonomic neuropathy affecting the gut.</li><li class="level1"><b>For adults with&nbsp;bladder emptying difficulties,&nbsp;</b>consider (and investigate)&nbsp;the possibility of autonomic neuropathy affecting the&nbsp;bladder, provided alternative causes (for example lower urinary tract problems) have been excluded.&nbsp;
	
	</li><ul><li class="level2">See the CKS topics on&nbsp;<a href="/luts-in-men">LUTS in men</a>, <a href="/urinary-tract-infection-lower-men">Urinary tract infection (lower) - men</a>, and <a href="/urinary-tract-infection-lower-women">Urinary tract infection (lower) - women</a>&nbsp;for more information.</li></ul><li class="level1"><b>For adults with impaired awareness of hypoglycaemia,</b> consider the possibility of&nbsp;contributory sympathetic nervous system damage.</li><li class="level1"><b>For adults with vomiting caused by gastroparesis:</b>
	
	</li><ul><li class="level2">Advise a small-particle-size diet (mashed or pureed food) for symptomatic relief.&nbsp;</li><li class="level2">Consider referral to a gastroenterologist or the diabetes specialist team for consideration of treatment with&nbsp;a prokinetic drug, such as erythromycin (off-label use), metoclopramide, or domperidone.</li></ul><li class="level1"><b>For adults with excessive sweating,</b>&nbsp;see the CKS topic on&nbsp;<a href="/hyperhidrosis">Hyperhidrosis</a>.</li><li class="level1"><b>For adults taking a tricyclic&nbsp;antidepressant or an&nbsp;antihypertensive drug,</b>&nbsp;be aware of the increased risks of postural hypotension as a result of the combined effects of&nbsp;sympathetic autonomic neuropathy and these treatments.</li></ul></section><section class="scenariobasis" id="1308746"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <i>Type 2 diabetes in adults: management&nbsp;</i>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>]. The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href="https://www.nice.org.uk/guidance/ng28/evidence">full NICE guideline</a>.</p><p><b>Managing chronic painful neuropathy</b></p><ul><li class="level1">The NICE guideline on type 2 diabetes refers to the NICE guideline <i>Neuropathic pain - pharmacological management&nbsp;</i>[<a rel="citation" resource="1090203#A1300738" href="/diabetes-type-2#!references/1090203">NICE, 2013b</a>]&nbsp;for guidance on managing people with chronic painful neuropathy.</li></ul><p><b>Managing gastroparesis</b></p><ul><li class="level1">NICE reviewed the available evidence to determine the best management option for people with gastroparesis.</li><li class="level1">Six small randomized controlled trials (with methodological limitations) were identified, all of which involved a prokinetic drug (domperidone, metoclopramide, or erythromycin).
	
	</li><ul><li class="level2">The evidence suggested that all three drugs were effective in at least some people with gastroparesis resulting from autonomic neuropathy, although it was not possible to distinguish usefully between the drugs.&nbsp;</li></ul><li class="level1">The NICE guideline development group (GDG)&nbsp;agreed that the choice of initial treatment should be based on tolerability (including drug interactions), whilst taking into account the following&nbsp;Medicines and Healthcare products Regulatory Agency (MHRA) warnings on the use of&nbsp;domperidone or metoclopramide:
	
	</li><ul><li class="level2">Metoclopramide has well-known risks of neurological effects, such as short-term extrapyramidal disorders and tardive dyskinesia; therefore, it should be prescribed for short-term use only (up to 5 days) and at a maximum daily dose of 30 mg (usual dose of 10 mg up to three times a day)&nbsp;[<a rel="citation" resource="1090203#A79645" href="/diabetes-type-2#!references/1090203">MHRA, 2014b</a>].</li><li class="level2">Domperidone is associated with a small increased risk of serious cardiac adverse effects (such as ventricular arrhythmias, QT interval prolongation, and sudden cardiac death), especially in people older than 60 years of age, people taking daily oral domperidone doses of more than 30 mg, and people taking QT-prolonging drugs (such as erythromycin) or CYP3A4 inhibitors at the same time as domperidone.&nbsp;The maximum treatment duration should not usually exceed one week&nbsp;[<a rel="citation" resource="1090203#A79644" href="/diabetes-type-2#!references/1090203">MHRA, 2014c</a>].</li><li class="level2">The NICE GDG recommends alternating treatment with erythromycin and metoclopramide but does not provide any information on how this should be done (including information on the dose or duration of treatment).&nbsp;CKS therefore recommends seeking specialist advice if a prokinetic drug is being considered for an adult with vomiting caused by gastroparesis.</li></ul><li class="level1">The GDG discussed that the differential diagnosis of gastroparesis can be challenging, and that serious prolonged vomiting could become a medical emergency. Accordingly, specialist referral is sometimes indicated.&nbsp;
	
	</li><ul><li class="level2">Whilst the GDG gave priority to drug treatments for the management of this condition, clinical experience suggested that non-pharmacological approaches, including timing of ingestion of fluids and solids, could be useful to some people.</li></ul></ul><p><b>Managing other aspects of autonomic neuropathy</b></p><ul><li class="level1">The NICE GDG extrapolated these recommendations from the NICE&nbsp;guideline&nbsp;on type 1&nbsp;diabetes in adults&nbsp;[<a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>].</li></ul><p><b>Managing erectile dysfunction</b></p><ul><li class="level1">The NICE GDG reviewed the available evidence to determine whether&nbsp;pharmacological treatment (phosphodiesterase-5 inhibitors,&nbsp;alprostredil, and/or testosterone therapy)&nbsp;should be used to manage erectile dysfunction in men with type 2&nbsp;diabetes.</li><li class="level1">For&nbsp;phosphodiesterase-5 inhibitors:
	
	</li><ul><li class="level2">Moderate- to low-quality evidence&nbsp;showed an overall improvement in erectile function compared with placebo,&nbsp;but an increased risk of adverse effects (dyspepsia, flushing, and headache) were also reported.&nbsp;No&nbsp;phosphodiesterase-5 inhibitor was found to be more efficacious than the other.</li><li class="level2">Despite the low quality of the evidence and the fact that&nbsp;the included evidence involved a heterogeneous population that may not be representative of people with type 2 diabetes, the GDG&nbsp;was confident that&nbsp;phosphodiesterase-5 inhibitors&nbsp;will do more good than harm for most men with type 2 diabetes and are likely to be cost effective.</li><li class="level2">The GDG added the word ‘initially’ to the recommendation to reflect that in clinical practice, drugs and doses are chosen but may be altered depending on the response of the person.</li></ul><li class="level1">For testosterone therapy and alprostredil:
	
	</li><ul><li class="level2">Low-quality evidence from a single randomized controlled trial (RCT) showed that the use of long-acting intramuscular testosterone therapy was associated with improvement in erectile function in people with type 2 diabetes diagnosed with hypogonadism.&nbsp;There was limited data on the associated adverse effects of testosterone therapy.&nbsp;</li><li class="level2">No relevant studies on alprostredil were identified.</li><li class="level2">The GDG did not think that there was sufficient evidence to make any recommendations on the use of these treatments in&nbsp;managing erectile dysfunction in men with type 2&nbsp;diabetes.</li></ul></ul></section></section></section><section class="scenario hidden" id="1309446"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Scenario: Management - children and young people</h2></header><p class="age">Age from 12 months to 18 years</p><section class="scenariorecommendation" id="1309454"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Initial care and support</h3></header><ul><li class="level1"><b>Ensure that children and young people with type 2 diabetes are offered:</b>
	
	</li><ul><li class="level2"><b>An&nbsp;<a href="/diabetes-type-2#!scenarioclarification:19">ongoing integrated package of care</a></b>&nbsp;provided by a multidisciplinary paediatric diabetes team.&nbsp;
		
		</li><ul><li class="level3">Ensure that the child or young person and/or their family/carers are involved in making decisions about their care.&nbsp;</li></ul><li class="level2"><b>A continuing programme of education</b>.&nbsp;
		
		</li><ul><li class="level3">This&nbsp;should be tailored to the child/young person and include some&nbsp;<a href="/diabetes-type-2#!scenarioclarification:19">core elements</a>.</li></ul></ul><li class="level1"><b>Encourage children and young people with type 2 diabetes and/or their family/carers to:</b>
	
	</li><ul><li class="level2">Have the following immunizations recommended by the Department of Health (if applicable):
		
		</li><ul><li class="level3">Annual immunization against influenza (if over the age of 6 months). See the CKS topic on&nbsp;<a href="/immunizations-seasonal-influenza">Immunizations - seasonal influenza</a>&nbsp;for&nbsp;more&nbsp;information.</li><li class="level3">Immunization against pneumococcal infection (for children and young people with diabetes who need insulin or oral hypoglycaemic drugs).&nbsp;See the CKS topic on&nbsp;<a href="/immunizations-pneumococcal">Immunizations - pneumococcal</a>&nbsp;for&nbsp;more&nbsp;information.</li></ul><li class="level2">Always wear or carry some form of diabetes identification, for example:
		
		</li><ul><li class="level3">A MedicAlert® bracelet, necklace, or watch (available from&nbsp;<a href="http://www.medicalert.org.uk/">www.medicalert.org.uk</a>).</li><li class="level3">Diabetes ID Card (available from&nbsp;<a href="http://www.diabetes.co.uk/shop/productdetails.aspx?pid=1739">www.diabetes.co.uk</a>).</li></ul><li class="level2">Discuss any concerns or questions with their diabetes specialist team.</li></ul><li class="level1"><b>Provide information and advice on:</b>
	
	</li><ul><li class="level2">The means and frequency of communicating with the paediatric diabetes team.&nbsp;
		
		</li><ul><li class="level3">Encourage children and young people with type 2 diabetes and/or their family/carers to attend clinic 4 times a year, as regular contact is associated with optimal blood glucose control.</li><li class="level3">Ensure that the child or young person and/or their family/carers know how to contact the diabetes team during working hours and out of hours, as available.</li></ul><li class="level2">Government disability benefits, if needed —&nbsp;<a href="https://www.gov.uk/benefits-calculators">Benefits calculators</a>&nbsp;are available at www.gov.uk.</li></ul><li class="level1"><b>Manage lifestyle issues,&nbsp;</b>such as diet, exercise, smoking, and alcohol and substance misuse..&nbsp;See the section on&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:12">Lifestyle advice</a>&nbsp;for more information.</li><li class="level1"><b>Screen for complications of type 2 diabetes,</b>&nbsp;such as retinopathy and diabetic foot problems.&nbsp;See the section on&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:15">Screening for complications</a>&nbsp;for more information.</li><li class="level1"><b>Provide up-to-date information on diabetes support groups&nbsp;(local and national), </b>including information on how to contact them and the benefits of membership.&nbsp;
	
	</li><ul><li class="level2">For example,&nbsp;<a href="https://www.diabetes.org.uk/?gclid=CPqHpMedkMsCFckV0wod0qoJoQ">Diabetes UK</a>&nbsp;(a charity which provides information, support, and advocacy for people with diabetes) has&nbsp;a support helpline (0345 123 2399 or 0141 212 8710 [for Scotland])&nbsp;for people with diabetes and their family/carers.&nbsp;</li><li class="level2">Provide this information at the time of diagnosis and periodically thereafter. Written information should also be available from the diabetes team.</li></ul></ul><section class="scenarioclarification" id="1312555"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Care plan</h4></header><p><b>At the time of diagnosis, children and young people with type 2 diabetes and/or their family/carers should be offered:</b></p><ul><li class="level1"><b>An integrated package of care provided by&nbsp;a multidisciplinary paediatric diabetes team.</b>

	
	</li><ul><li class="level2">&nbsp;To optimize the effectiveness of care and reduce the risk of complications, the diabetes team should include members with appropriate training in clinical, educational, dietetic, lifestyle, mental health, and foot care aspects of diabetes for children and young people.</li><li class="level2">The child or young person may be offered&nbsp;home-based or inpatient management initially, depending on clinical need and family circumstances and wishes.&nbsp;
		
		</li><ul><li class="level3">Home-based care with support from the local paediatric diabetes team (including 24-hour telephone access) is safe and as effective as inpatient initial management.</li><li class="level3">Initial inpatient management may be offered to children younger than 2 years of age; children and young people with social or emotional factors that would make home-based management inappropriate; and children and young people that live far away from the hospital.</li></ul></ul><li class="level1"><b>A continuing programme of education.</b>&nbsp;This&nbsp;should:
	
	</li><ul><li class="level2">Include the following core elements:
		
		</li><ul><li class="level3">HbA1c monitoring and targets.</li><li class="level3">The effects of diet, physical activity, body weight, and intercurrent illness on blood glucose control.&nbsp;</li><li class="level3">The aims of metformin treatment and possible adverse effects.&nbsp;</li><li class="level3">The complications of type 2 diabetes and how to prevent them.</li></ul><li class="level2">Be tailored&nbsp;to the child/young person and/or their family/carers, taking account of issues such as:
		
		</li><ul><li class="level3">Emotional wellbeing.</li><li class="level3">Age and maturity.</li><li class="level3">Cultural considerations.</li><li class="level3">Existing knowledge.</li><li class="level3">Current and future social circumstances.</li><li class="level3">Life goals.&nbsp;</li></ul></ul></ul></section><section class="scenariobasis" id="1309457"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].&nbsp;The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the&nbsp;<a href="http://www.nice.org.uk/guidance/ng18/evidence/full-guideline-435396349">full NICE guideline</a>.</p><p><b>Ongoing package of care provided by a multidisciplinary team</b></p><ul><li class="level1">Based on their expert opinion and combined experience, the NICE guideline development group (GDG) recommends an ongoing package of care for children and young people with diabetes. The GDG justifies this recommendation by stating that type 1 diabetes can have a potentially devastating effect on a child or young person and their family/carers, and the management, education, empowerment, and support offered in the first few weeks following diagnosis can have a long-term effect on their acceptance of the condition and their skills and motivation in its ongoing management&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li><li class="level1">CKS has extrapolated this recommendation to children and young people with type 2 diabetes as the diagnosis can also&nbsp;have a potentially devastating effect on the child or young person and their family/carers.</li></ul><p><b>Continuing programme of education</b>&nbsp;</p><ul><li class="level1">The NICE GDG reviewed the available evidence to determine&nbsp;the effectiveness of structured education programmes in improving outcomes in children and young people with type 2 diabetes.</li><li class="level1">No studies were identified that met the inclusion criteria; however,&nbsp;the GDG consensus was that there was potential harm associated with not making any recommendations on education for children and young people with type 2 diabetes.&nbsp;</li><li class="level1">The GDG felt that the recommendation for children and young people with type 2 diabetes should mirror that for children and young people with type 1 diabetes, which is a continuing programme of education from diagnosis which is centred on core topics.</li><li class="level1">The GDG chose the core topics based on their consensus view of which aspects of diabetes care would be most important for obtaining health benefits and avoiding harms. The topics differed from those that were specified for children and young people with type 1 diabetes to reflect other recommendations in the guideline and differences in the relative importance of particular aspects of diabetes care (for example blood glucose monitoring is not recommended for children and young people with type 2 diabetes and so was not included as a core topic for type 2 diabetes education).</li><li class="level1">The GDG also&nbsp;felt that it was important to tailor the education programmes to each child or young person and/or their family/carers and that they should be encouraged to&nbsp;discuss any concerns and raise any questions they have with the diabetes team.</li></ul><p><b>Additional advice to the child or young person and/or their family/carers</b></p><ul><li class="level1">The NICE GDG extrapolated other recommendations from advice for children and young people with type 1 diabetes, including dental and eye examination, support groups, government disability, and immunizations&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li><li class="level1">CKS has extrapolated the recommendations on attending clinic and carrying an identification card/jewellery from the NICE&nbsp;recommendations for children and young people with type 1 diabetes as they are&nbsp;also relevant to children and young people with type 2 diabetes.</li></ul></section></section><section class="scenariorecommendation" id="1309447"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>HbA1c treatment target</h3></header><ul><li class="level1"><b>The recommended HbA1c target level for children and young people with type 2 diabetes is 48 mmol/mol (6.5%) or lower.</b>

	
	</li><ul><li class="level2">Agree an individualized lowest achievable HbA1c target with each child or young person and/or their family/carers, taking into account factors such as daily activities, individual life goals, complications, comorbidities, and the risk of hypoglycaemia (generally defined as blood glucose levels less than 3.5 mmol/L).
		
		</li><ul><li class="level3">Support them to safely achieve and maintain their individually agreed HbA1c target level.</li></ul><li class="level2">Explain that achieving and maintaining the lowest attainable HbA1c will help&nbsp;to minimize the risk of long-term&nbsp;<a href="/diabetes-type-2#!backgroundsub:5">complications</a>.
		
		</li><ul><li class="level3">If the child or young person has an HbA1c level above the ideal target, explain that any reduction in HbA1c level reduces the risk of long-term complications.</li></ul><li class="level2">Ensure that children and young people with type 2 diabetes&nbsp;are offered measurement of their HbA1c level every 3 months.</li></ul></ul><section class="scenariobasis" id="1309449"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].&nbsp;The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the&nbsp;<a href="http://www.nice.org.uk/guidance/ng18/evidence/full-guideline-435396349">full NICE guideline</a>.</p><ul><li class="level1">The NICE guideline development group (GDG)&nbsp;reviewed the available evidence to determine&nbsp;the optimal HbA1c target for children and young people with type 2 diabetes.</li><li class="level1">No studies met the inclusion criteria for this review. However, the&nbsp;GDG was aware that the NICE guideline <i>Type 2 diabetes in adults: management&nbsp;</i>recommends a target HbA1c level of 48 mmol/mol (6.5%) or lower to minimize the risk of long-term complications&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].</li><li class="level1">The GDG agreed that this was an appropriate target for&nbsp;children and young people with type 2 diabetes as it is&nbsp;safe and achievable.&nbsp;</li></ul></section></section><section class="scenariorecommendation" id="1312582"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Antidiabetic drug treatment</h3></header><ul><li class="level1"><b>Antidiabetic treatment for children and young people with type 2 diabetes should be initiated by the multidisciplinary paediatric diabetes care team.</b></li><ul><li class="level2">The National Institute for Health and Care Excellence (NICE) recommends that&nbsp;standard-release metformin should be offered from diagnosis to children and young people with type 2 diabetes.&nbsp;</li></ul></ul><section class="scenariobasis" id="1312585"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><ul><li class="level1">The National Institute for Health and Care Excellence (NICE) recommends that children and young people with diabetes are managed by a&nbsp;multidisciplinary paediatric diabetes care team&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li><li class="level1">Good evidence identified by NICE showed that&nbsp;treatment with metformin resulted in a clinically significant improvement in blood glucose control and was associated with significantly less frequent need for emergency treatment in most children and young people with type 2 diabetes.&nbsp;</li></ul></section></section><section class="scenariorecommendation" id="1312588"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Lifestyle advice</h3></header><ul><li class="level1"><b>See the sections on&nbsp;<a href="/diabetes-type-2#!scenarioclarification:20">Diet</a>,&nbsp;<a href="/diabetes-type-2#!scenarioclarification:21">Exercise</a>,&nbsp;<a href="/diabetes-type-2#!scenarioclarification:22">Alcohol intake</a>, and&nbsp;<a href="/diabetes-type-2#!scenarioclarification:23">Smoking and substance misuse</a>&nbsp;for information on managing these lifestyle issues.</b></li><li class="level1">For detailed information on managing other lifestyle and cultural issues, such as driving, fasting, holiday and travel, and shift work, see the section on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes#!scenariorecommendation:7">Additional information and advice</a>&nbsp;in the CKS topic on <a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>.</li></ul><section class="scenarioclarification" id="1312594"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Diet</h4></header><ul><li class="level1"><b>At each contact with a child or young person with type 2 diabetes:</b></li><ul><li class="level2">Explain to them and/or their family/carers how healthy eating can help to:&nbsp;</li><ul><li class="level3">Reduce hyperglycaemia.</li><li class="level3">Reduce cardiovascular risk.</li><li class="level3">Promote weight loss.</li></ul><li class="level2">Encourage children and young people with type 2 diabetes to eat at least 5 portions of fruit and vegetables each day.&nbsp;</li></ul><li class="level1"><b>Offer children and young people with type 2 diabetes dietetic support to</b> <b>help optimize body weight and blood glucose control. &nbsp;</b></li><ul><li class="level2">At each contact with a child or young person with type 2 diabetes who is overweight or obese, advise them and/or their family/carers on the benefits of physical activity and weight loss, and provide support towards achieving this.&nbsp;</li></ul></ul></section><section class="scenarioclarification" id="1312597"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Exercise and physical activity</h4></header><ul><li class="level1"><b>Advise children and young people with type 2 diabetes and/or their family/carers that:</b>

	
	</li><ul><li class="level2">Regular exercise may lower blood glucose levels&nbsp;(as exercise increases the amount of glucose used by the muscles for energy).

		
		</li><ul><li class="level3">Explain that they can take part in all forms of exercise, provided appropriate attention is given to diet.&nbsp;</li><li class="level3">Offer advice on the effects of exercise on blood glucose levels, and consider referring the person to the diabetes team for advice on strategies for avoiding hypo- or hyperglycaemia during or after physical activity.&nbsp;</li></ul><li class="level2">Regular exercise can reduce the risk of cardiovascular disease in the long term, and help with weight management (when combined with a healthy diet). The current <a href="https://www.gov.uk/government/publications/uk-physical-activity-guidelines">UK physical activity guidelines</a> state that:
		
		</li><ul><li class="level3">For children younger than 5 years of age, 180 minutes (three hours) each day is recommended once a child is able to walk.&nbsp;</li><li class="level3">For children 5 years and over and young people, 60 minutes and up to several hours of moderate- to vigorous-intensity physical activity daily is recommended (such as swimming, running, cycling, or playground activities).&nbsp;</li><li class="level3">Three days a week should include vigorous-intensity activities that strengthen muscles and bones.&nbsp;</li><li class="level3">All forms of physical activity count, and activity can be spread out through the day.</li><li class="level3">All children and young people should minimize the amount of time spent being sedentary for extended periods.</li></ul><li class="level2">They should seek advice from their diabetes team if they wish to&nbsp;participate in a sport that may have particular risks for people with diabetes.&nbsp;
		
		</li><ul><li class="level3">Additional information may be available from local and/or national support groups and organizations, such as&nbsp;Diabetes UK (<a href="http://authoringtool-jsclient.clarity.co.uk/Detailed%20information%20on%20exercise%20and%20physical%20activity%20for%20people%20with%20type%201%20diabetes%20is%20available%20on%20the%20Diabetes%20UK%20website%20(www.diabetes.org.uk).">www.diabetes.org.uk</a>).</li></ul></ul></ul></section><section class="scenarioclarification" id="1312600"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Alcohol intake</h4></header><ul><li class="level1"><b>Remind young people and/or their family/carers that the legal drinking age in the UK is 18 years.</b>
	
	</li><ul><li class="level2"><b>Offer information on the risks associated with alcohol intake in children and young people. </b>Useful publications include:
		
		</li><ul><li class="level3"><a href="http://enjoyresponsibly.co.uk/alcohol-and-young-people/">Alcohol and young people</a>&nbsp;available on <a href="http://enjoyresponsibly.co.uk/">www.enjoyresponsibly.co.uk</a>.</li><li class="level3"><a href="https://www.drinkaware.co.uk/alcohol-facts/alcohol-and-the-law/the-law-on-alcohol-and-under-18s/">The law on alcohol and under 18s</a>&nbsp;available on&nbsp;<a href="https://www.drinkaware.co.uk/">www.drinkaware.co.uk</a>.</li><li class="level3"><a href="https://www.nidirect.gov.uk/articles/young-people-and-alcohol-what-are-risks">Young people and alcohol – what are the risks?</a>&nbsp;available on&nbsp;<a href="http://www.nidirect.gov.uk/">www.nidirect.gov.uk</a>.</li></ul></ul><li class="level1"><b>For young people who chose to drink (or continue drinking), advise that:</b>
	
	</li><ul><li class="level2">They should avoid drinking alcohol on an empty stomach (as the alcohol will be absorbed faster).&nbsp;</li><li class="level2">They should eat a snack that contains carbohydrate (such as a sandwich) before and after drinking alcohol.&nbsp;</li><li class="level2">Alcohol may exacerbate or prolong the hypoglycaemic effect of antidiabetic drugs.&nbsp;
		
		</li><ul><li class="level3">The signs of&nbsp;<a href="/insulin-therapy-in-type-2-diabetes#!scenariorecommendation:8">hypoglycaemia</a>&nbsp;may become less clear, and delayed hypoglycaemia may occur up to several hours after alcohol consumption.</li><li class="level3">See the section on&nbsp;Hypoglycaemia in the CKS topic on <a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>&nbsp;for more information.&nbsp;</li></ul><li class="level2">They should&nbsp;always wear some form of diabetes identification (as the reduced awareness of&nbsp;hypoglycemia&nbsp;may be confused with alcohol intoxication).&nbsp;Examples of diabetes identification include:
		
		</li><ul><li class="level3">A MedicAlert®&nbsp;bracelet, necklace, or watch (available from&nbsp;<a href="http://www.medicalert.org.uk/">www.medicalert.org.uk</a>).</li><li class="level3">Diabetes ID Card (available from <a href="http://www.diabetes.co.uk/shop/productdetails.aspx?pid=1739">www.diabetes.co.uk</a>).</li></ul></ul></ul></section><section class="scenarioclarification" id="1312604"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Smoking and substance misuse</h4></header><ul><li class="level1"><b>Explain about general health problems associated with smoking, particularly the risks of developing vascular complications.</b>&nbsp;
	
	</li><ul><li class="level2">Encourage children and young people with type 2 diabetes not to start smoking.&nbsp;</li><li class="level2">Offer smoking cessation programmes to those who smoke. See the CKS topic on&nbsp;<a href="/smoking-cessation">Smoking cessation</a>&nbsp;for more information.&nbsp;</li></ul><li class="level1"><b>Explain about the general dangers of substance misuse and the possible effects on blood glucose control.</b>
	
	</li><ul><li class="level2">Information, advice, and support on substance misuse are available on the Talk to Frank website (<a href="http://www.talktofrank.com/">www.talktofrank.com</a>).</li></ul></ul></section><section class="scenariobasis" id="1312590"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].&nbsp;The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the&nbsp;<a href="http://www.nice.org.uk/guidance/ng18/evidence/full-guideline-435396349">full NICE guideline</a>.</p><p><b>Advice on diet</b></p><ul><li class="level1">The NICE guideline development group (GDG) reviewed the available evidence to determine&nbsp;the effectiveness of dietetic advice to optimize blood glucose control in children and young people with type 2 diabetes.</li><li class="level1">Due to a lack of good-quality evidence,&nbsp;the recommendation to give appropriate dietary advice to children and young people with type 2 diabetes and/or their family/carers was based on the clinical experience and&nbsp;consensus of the NICE GDG.&nbsp;</li><li class="level1">The GDG also extrapolated some recommendations from those for children and young people with type 1 diabetes, such as&nbsp;encouraging the consumption of at least 5 portions of fruit and vegetables daily.</li></ul><p><b>Advice on exercise and physical activity</b></p><ul><li class="level1">NICE does not make specific recommendations on exercise and physical activity for children and young people with type 2 diabetes but states that at each contact with a child or young person with type 2 diabetes who is overweight or obese, the healthcare professional should offer advice on the benefits of physical activity and weight loss, and support them towards achieving this&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li><li class="level1">In addition to information taken from the&nbsp;<a href="https://www.gov.uk/government/publications/uk-physical-activity-guidelines">UK physical activity guidelines</a>&nbsp;(available on <a href="http://www.gov.uk/">www.gov.uk</a>), CKS has extrapolated recommendations from the NICE recommendations for children and young people with type 1 diabetes.</li></ul><p><b>Advice on alcohol intake</b></p><ul><li class="level1">NICE does not make specific recommendations&nbsp;on alcohol intake for children and young people with type 2 diabetes.</li><li class="level1">The recommendation to offer information on the risk of alcohol intake in children and young people is based on what CKS considers to be good clinical practice.</li><li class="level1">The recommendations for young people who chose to drink or continue drinking have been extrapolated from the NICE recommendations on alcohol intake for&nbsp;children and young people with type 1 diabetes&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li></ul><p><b>Smoking and substance misuse</b></p><ul><li class="level1">NICE does not make specific recommendations&nbsp;on smoking and substance misuse for children and young people with type 2 diabetes.</li><li class="level1">This recommendation has been extrapolated from the NICE recommendations on&nbsp;smoking and recreational drug use&nbsp;for&nbsp;children and young people with type 1 diabetes&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li></ul></section></section><section class="scenariorecommendation" id="1312576"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Managing suspected diabetic ketoacidosis</h3></header><p><b>Diabetic ketoacidosis (DKA) is more common&nbsp;in type 1 diabetes but can occur in people with type 2 diabetes.</b></p><ul><li class="level1"><b>If DKA is&nbsp;<a href="/diabetes-type-2#!diagnosissub:2">suspected</a>&nbsp;in a child or young person,</b>&nbsp;arrange immediate admission to a hospital with acute paediatric facilities,&nbsp;for confirmation of the diagnosis and emergency treatment with intravenous insulin and fluids.&nbsp;</li><li class="level1"><b>After a child or young person with known diabetes has recovered from an episode of DKA:</b>
	
	</li><ul><li class="level2">Discuss with them and/or their family/carers the factors that may have led to the episode.</li><li class="level2">Consider the possibility of non-adherence to treatment, especially if the DKA is recurrent.&nbsp;</li><li class="level2">Give advice on how to reduce the risk of future episodes. In particular, advise them of the importance of managing&nbsp;<a href="/diabetes-type-2#!scenarioclarification:25">intercurrent illnesses</a>.</li></ul><li class="level1"><a href="https://www.diabetes.org.uk/Guide-to-diabetes/Complications/Diabetic_Ketoacidosis/">Information on DKA</a> for people with diabetes and/or their family/carers is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/">www.diabetes.org.uk</a>).</li></ul><section class="scenariobasis" id="1312579"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</p></section></section><section class="scenariorecommendation" id="1312570"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Managing intercurrent illness</h3></header><ul><li class="level1"><b>Consider the need for&nbsp;<a href="/diabetes-type-2#!scenarioclarification:24">hospital admission or seeking specialist advice</a>.</b>
	
	</li><ul><li class="level2">Use clinical judgement, taking into account the person's age, any underlying comorbidities and complications, and the presence of&nbsp;hyperglycaemia and ketosis.</li></ul><li class="level1"><b>If the child or young person can be managed in primary care:</b>
	
	</li><ul><li class="level2">Assess and manage the intercurrent illness(es).</li><li class="level2">Assess how well blood glucose has been managed with diet and antidiabetic treatment (if relevant).
		
		</li><ul><li class="level3">Consider&nbsp;referring the child or young person to the diabetes specialist team for a review of their diet and/or antidiabetic treatment.</li></ul><li class="level2">Warn the person and/or their family/carers that illness may affect blood glucose control:
		
		</li><ul><li class="level3">Some illnesses (especially if associated with fever) can raise blood glucose levels.</li><li class="level3">In contrast, illnesses associated with vomiting and diarrhoea (such as gastroenteritis) can lower blood glucose levels, possibly leading to hypoglycaemia (generally defined as blood glucose levels less than 3.5 mmol/L).</li></ul><li class="level2">Provide clear individualized oral and written advice (<a href="/diabetes-type-2#!scenarioclarification:25">'sick-day rules'</a>)&nbsp;on managing type 2 diabetes during intercurrent illness or episodes of hyperglycaemia.
		
		</li><ul><li class="level3">Reiterate the advice with the child or young person and/or their family/carers at least annually.</li></ul><li class="level2">Ensure that the person has written contact details of their diabetes specialist team.</li><li class="level2">Ensure that the person has sick-day foods and hydration supplies readily accessible at home, including:
		
		</li><ul><li class="level3">Easily digestible food and sugary drinks (to provide energy and to prevent further ketosis).</li><li class="level3">Oral rehydration salt sachets (to prevent dehydration).</li><li class="level3">Glucose tablets or oral gel (to prevent hypoglycaemia).</li><li class="level3">Equipment for ketone monitoring.&nbsp;</li><li class="level3">A glucagon kit (if appropriate).</li></ul><li class="level2">See the section on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes#!scenariorecommendation:2">Accessories for insulin therapy</a>&nbsp;in the CKS topic on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>&nbsp;for information on blood glucose and ketone monitoring meters, glucose oral gels, and other accessories.</li></ul></ul><section class="scenarioclarification" id="1312670"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Admission or specialist advice</h4></header><p><b>The decision to admit a person or seek specialist advice will depend on clinical judgement, taking into account the person's age, underlying&nbsp;comorbidities&nbsp;and complications, and the presence of hyperglycaemia and ketosis.</b></p><ul><li class="level1"><b>Arrange immediate hospital admission if:&nbsp;</b>

	
	</li><ul><li class="level2">There is an immediate risk of&nbsp;<a href="/diabetes-type-2#!diagnosissub:2">diabetic ketoacidosis</a>&nbsp;(DKA).&nbsp;</li><li class="level2">There is moderate ketonaemia (1.5–2.9 mmol/L) with or without hyperglycaemia and the person cannot eat or drink, as there is a risk of DKA.&nbsp;</li></ul><li class="level1"><b>Consider arranging hospital admission or seeking urgent specialist advice (depending on clinical judgement) if:&nbsp;</b>
	
	</li><ul><li class="level2">The underlying condition is unclear.&nbsp;</li><li class="level2">The person is dehydrated or at risk of dehydration.&nbsp;</li><li class="level2">Vomiting persists beyond 2 hours&nbsp;(particularly in young children).&nbsp;</li><li class="level2">The child is:&nbsp;
		
		</li><ul><li class="level3">Becoming exhausted, confused, or dehydrated; is hyperventilating; or has severe abdominal pain.&nbsp;</li><li class="level3">Younger than 3 years of age or has a co-existing medical condition.</li></ul><li class="level2">The person and/or their family/carers are exhausted, for example due to repeated night-time waking.&nbsp;</li></ul></ul></section><section class="scenarioclarification" id="1312674"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>'Sick-day rules'</h4></header><ul><li class="level1"><b>During a period of illness that does not require&nbsp;<a href="/diabetes-type-2#!scenarioclarification:24">admission</a>, remind the child or young person and/or their family/carers to adhere to the 'sick-day rules' which should have been&nbsp;provided by their diabetes specialist team. </b>This should include information on how to:
	
	</li><ul><li class="level2">Monitor their blood glucose and blood ketone levels.</li><li class="level2">Manage their diet and antidiabetic treatment.</li><li class="level2">Maintain adequate fluid intake to prevent dehydration.&nbsp;They should seek urgent medical advice if:
		
		</li><ul><li class="level3">They are sick, drowsy, or unable to keep fluids down.</li><li class="level3">They have persistent&nbsp;vomiting or diarrhoea.</li></ul></ul></ul></section><section class="scenariobasis" id="1312572"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p><b>Managing a period of illness</b></p><ul><li class="level1">The National Institute for Health and Care (NICE) guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>]&nbsp;does not make specific recommendations on how to manage a child or young person with type 2 diabetes during a period of illness.</li><li class="level1">These recommendations are based on (and in some cases extrapolated from) the US guideline&nbsp;<i>ISPAD clinical practice consensus guidelines 2014 compendium: sick day management in children and adolescents with diabetes&nbsp;</i>published by the International Society for Pediatric and Adolescent Diabetes (ISPAD)&nbsp;[<a rel="citation" resource="1090203#A79871" href="/diabetes-type-2#!references/1090203">Brink et al, 2014</a>], the&nbsp;<i>National Service Framework for Children, Young People and Maternity Services – Diabetes Type 1 in childhood and adolescence</i>&nbsp;produced by the Department of Health and Diabetes UK&nbsp;[<a rel="citation" resource="1090203#A64866" href="/diabetes-type-2#!references/1090203">DH, 2010</a>], textbooks on the management of diabetes&nbsp;[<a rel="citation" resource="1090203#A64127" href="/diabetes-type-2#!references/1090203">Cameron and Allgrove, 2007</a>; <a rel="citation" resource="1090203#A64085" href="/diabetes-type-2#!references/1090203">Holt and Kumar, 2010b</a>],&nbsp;and information on the&nbsp;Diabetes UK website&nbsp;(<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Living_with_diabetes/Illness/">www.diabetes.org.uk</a>).</li></ul><p><b>'Sick-days rules'</b></p><ul><li class="level1">The NICE guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>]&nbsp;states that&nbsp;clear and individualized oral and written&nbsp;information on managing intercurrent illness ('sick-day rules') should be offered to children and young people with type 1 diabetes and/or their family/carers.&nbsp;CKS has extrapolated this recommendation to children and young people with type 2 diabetes.</li><li class="level1">NICE recommends that children and young people with diabetes are managed by a&nbsp;multidisciplinary paediatric diabetes care team. It is expected that they will provide the child or young person with&nbsp;individualized oral and written 'sick-day rules'.</li></ul></section></section><section class="scenariorecommendation" id="1312565"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Screening for complications of type 2 diabetes</h3></header><p><b>Children and young people with type 2&nbsp;diabetes should have regular surveillance for the complications of diabetes.&nbsp;</b></p><ul><li class="level1"><b>Most children and young people with type 2 diabetes are managed in secondary care.&nbsp;</b></li><li class="level1"><b>For a child or young person being managed&nbsp;in primary care,&nbsp;</b>address the following at every review&nbsp;appointment:&nbsp;
	
	</li><ul><li class="level2">Measure height and weight&nbsp;and plot on an appropriate growth chart. Calculate body mass index (BMI).
		
		</li><ul><li class="level3">Check for normal growth and/or significant changes in weight because these may reflect changes in blood glucose control.&nbsp;</li><li class="level3">Manage children and young people who are overweight or obese.&nbsp;</li></ul><li class="level2">Check the smoking status of the child or young person. If applicable, offer smoking cessation advice. See the CKS topic on&nbsp;<a href="/smoking-cessation">Smoking cessation</a>.</li><li class="level2">Assess for psychological problems (such as depression, anxiety, and conduct disorders), and social problems (such as alcohol and substance misuse, and relationship problems).&nbsp;
		
		</li><ul><li class="level3">Alerting signs include difficulty with self-care and poor blood glucose control.</li><li class="level3">See the CKS topics on&nbsp;<a href="/depression-in-children">Depression in children</a>&nbsp;and&nbsp;<a href="/conduct-disorders-in-children-and-young-people">Conduct disorders in children and young people</a>&nbsp;for more information.</li></ul></ul><li class="level1"><b>Advise children and young people with type 2 diabetes and/or their family/carers to get:</b>
	
	</li><ul><li class="level2">Their HbA1c levels checked every 3 months to ensure adequate&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:10">blood glucose control</a>.</li><li class="level2">Regular dental examinations, for example every 3–6 months.&nbsp;</li><li class="level2">An eye examination by an optometrist every 2 years until the age of 12 years when they will be eligible for&nbsp;<a href="/diabetes-type-2#!scenarioclarification:29">annual retinopathy screening</a>.</li><li class="level2">Their feet assessed for&nbsp;<a href="/diabetes-type-2#!scenarioclarification:30">diabetic foot problems</a>.</li></ul><li class="level1"><b>Once a year, offer screening for:</b>
	
	</li><ul><li class="level2"><a href="/diabetes-type-2#!scenarioclarification:26">Hypertension</a>&nbsp;(starting at diagnosis).</li><li class="level2"><a href="/diabetes-type-2#!scenarioclarification:27">Dyslipidaemia</a>&nbsp;(starting at diagnosis).</li><li class="level2"><a href="/diabetes-type-2#!scenarioclarification:28">Diabetic nephropathy</a>&nbsp;(starting at diagnosis).</li><li class="level2"><a href="/diabetes-type-2#!scenarioclarification:29">Diabetic retinopathy</a>&nbsp;(in children aged 12 years and older).</li></ul></ul><section class="scenarioclarification" id="1312680"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Hypertension</h4></header><ul><li class="level1"><b>Explain to children and young people with type 2 diabetes and/or their family members/carers that</b> monitoring is important because if hypertension is found, early treatment will reduce the risk of complications.&nbsp;</li><li class="level1"><b>When measuring blood pressure in a child or young person with type 2 diabetes:</b></li><ul><li class="level2">Use a cuff of the correct size for the person.</li><li class="level2">If repeated resting measurements are greater than the 95th percentile for age and sex, confirm hypertension using 24-hour ambulatory blood pressure monitoring before starting antihypertensive treatment.</li></ul></ul></section><section class="scenarioclarification" id="1312682"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Dyslipidaemia</h4></header><ul><li class="level1"><b>Explain to children and young people with type 2 diabetes and/or their family/carers that </b>monitoring is important because if dyslipidaemia is found, early treatment will reduce the risk of complications.&nbsp;</li><li class="level1"><b>When screening for dyslipidaemia in children and young people with type 2 diabetes:</b></li><ul><li class="level2">Measure total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, and triglyceride concentrations.</li><li class="level2">Confirm dyslipidaemia using a repeat sample (fasting or non-fasting) before deciding on further management strategies.&nbsp;</li></ul></ul></section><section class="scenarioclarification" id="1312688"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Diabetic nephropathy</h4></header><p><b>Children and young people with type 2 diabetes should receive&nbsp;annual screening for diabetic nephropathy from diagnosis.</b></p><ul><li class="level1"><b>Use the first-pass urine sample of the day to measure the albumin:creatinine ratio (ACR).&nbsp;</b>If the first urine sample of the day is not available, use a random sample, but be aware that this is associated with an increased risk of false positive results.

	
	</li><ul><li class="level2">If the initial ACR is above 3 mg/mmol but below 30 mg/mmol, confirm the result by repeating the test on 2 further occasions using first-pass urine samples of the day before starting further investigations and treatment.</li><li class="level2">Investigate further if there is proteinuria (ACR of 30 mg/mmol or more).</li></ul><li class="level1"><b>Explain to children and young people with type 2 diabetes and/or their family /carers that:&nbsp;</b>
	
	</li><ul><li class="level2">Using the first-void urine sample of the day to screen for moderately increased albuminuria (ACR 3–30 mg/mmol; microalbuminuria) is important as it reduces the risk of false positive results.</li><li class="level2">If moderately increased albuminuria is detected, improving blood glucose control will reduce the risk of this progressing to significant diabetic nephropathy.</li><li class="level2">Annual monitoring is important because, if diabetic nephropathy is found, early treatment will improve the outcome.</li></ul></ul></section><section class="scenarioclarification" id="1312685"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Diabetic retinopathy</h4></header><p><b>From the age of 12 years, people with type 2 diabetes should receive a retinal examination (at the time of diagnosis and annually thereafter) as part of the NHS retinopathy screening programme. The programme aims to reduce the risk of sight loss among people with diabetes by the early detection and treatment, if needed, of sight-threatening retinopathy.</b></p><ul><li class="level1">Explain to children and young people with type 2 diabetes and/or their family/carers that:&nbsp;
	
	</li><ul><li class="level2">Background retinopathy is often found through monitoring, and improving blood glucose control will reduce the risk of this progressing to significant diabetic retinopathy.</li><li class="level2">Annual monitoring from 12 years is important because if significant diabetic retinopathy is found, early treatment will improve the outcome.</li></ul><li class="level1">Children should be referred to the local diabetic screening programme prior to their twelfth birthday to ensure that they are seen from 12 years of age.</li><li class="level1">Consider referring children and young people with type 2 diabetes who are younger than 12 years to an ophthalmologist for retinal examination if blood glucose control is suboptimal.&nbsp;</li></ul></section><section class="scenarioclarification" id="1312691"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Diabetic foot problems</h4></header><ul><li class="level1"><b>For children with diabetes who are younger than 12&nbsp;years of age,&nbsp;</b>give them and/or their family/carers basic foot care advice.</li><li class="level1"><b>For young people with diabetes aged between 12–17&nbsp;years,&nbsp;</b>ensure that the paediatric care team or the transitional care team assesses their feet as part of their annual assessment, and provide information on foot care.&nbsp;
	
	</li><ul><li class="level2">If a diabetic foot problem is found or suspected, refer the person to an appropriate specialist.</li></ul></ul></section><section class="scenariobasis" id="1312567"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].&nbsp;The basis for the NICE recommendations has been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the&nbsp;<a href="http://www.nice.org.uk/guidance/ng18/evidence/full-guideline-435396349">full NICE guideline</a>.</p><p><b>Measuring height, weight, and body mass index (BMI)</b></p><ul><li class="level1">In the expert opinion of the NICE guideline development group (GDG), measurement of height and weight is an integral part of diabetes care&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li><li class="level1">The NICE GDG extrapolated the recommendation to measure height, weight, and BMI at every clinic visit from the recommendations for managing children and young people with type 1 diabetes&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li></ul><p><b>Checking smoking status</b></p><ul><li class="level1">This recommendation is based on the fact that smoking is a risk factor for macrovascular disease&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li></ul><p><b>Checking for psychological and social problems</b></p><ul><li class="level1">In the absence of evidence, the NICE GDG agreed that it was not appropriate to make recommendations on specific psychological interventions for children and young people with type 2 diabetes. However, the group highlighted the need for the diabetes team to be aware of the higher risk of emotional and behavioural difficulties in children and young people with type 2 diabetes&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li></ul><p><b>Dental and eye screening</b></p><ul><li class="level1">NICE did not review the evidence for these recommendations in children and young people with type 2 diabetes but mirrored recommendations for children and young people with type 1 diabetes[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].

	
	</li><ul><li class="level2">In children and young people with type 1 diabetes,&nbsp;NICE found evidence showing a higher prevalence of periodontitis compared with children and young people without diabetes, and an association between poor blood glucose control and increased incidence of dental caries.</li></ul></ul><p><b>Screening for diabetic foot problems</b></p><ul><li class="level1"><b>The recommendations on foot care are based on recommendations in the NICE guideline&nbsp;<i>Diabetic foot problems: prevention and management&nbsp;</i></b>[<a rel="citation" resource="1090203#A1299588" href="/diabetes-type-2#!references/1090203">NICE, 2015c</a>]<b>.</b></li></ul><p><b>Screening for hypertension</b></p><ul><li class="level1">The NICE guideline states that hypertension is associated with a higher risk of morbidity and mortality in the long term, and there is evidence that it&nbsp;is more likely to impact on adverse long-term outcomes than poor blood glucose control in people with diabetes&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</li><li class="level1">The NICE GDG discussed the risk of potential misdiagnosis and ensuing unnecessary treatment, but it was felt that this risk was relatively small overall and was outweighed by the benefits of accurate identification as early as possible.</li><li class="level1">However, the GDG felt that based on their clinical experience, it was appropriate to provide guidance on how to carry out monitoring to reduce the likelihood of misdiagnosis, for example by using a large enough cuff for the child or young person.&nbsp;</li></ul><p><b>Screening for dyslipidaemia</b></p><ul><li class="level1">The NICE guideline states that dyslipidaemia is a risk factor for cardiovascular disease&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].&nbsp;</li><li class="level1">The NICE GDG discussed the risk of potential misdiagnosis and ensuing unnecessary treatment, but it was felt that this risk was relatively small overall and was outweighed by the benefits of accurate identification as early as possible.</li><li class="level1">However, the GDG felt that based on their clinical experience, it was appropriate to provide guidance&nbsp;on how to&nbsp;reduce the likelihood of incorrect measurements being used to determine treatment, for example by&nbsp;taking repeat samples (fasting or non-fasting) before starting treatment.</li></ul><p><b>Screening for diabetic nephropathy</b></p><ul><li class="level1">The NICE GDG agreed that the early identification of low-level albuminuria (a risk factor for nephropathy) presented an important clinical benefit because it can prompt early intervention which may alter disease progression and&nbsp;reduce the risk of chronic kidney disease (CKD) and ultimately mortality&nbsp;[<a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>].</li><li class="level1">This is particularly important for children and young people with type 2 diabetes as they are at risk of rapid progression to CKD (possibly because of associated morbidities such as obesity and hypertension).</li><li class="level1">Evidence identified by NICE showed a high prevalence of&nbsp;low-level albuminuria&nbsp;(more than 29%)&nbsp;in children and young people with type 2 diabetes, and supports&nbsp;monitoring for low-level albuminuria from diagnosis.</li></ul><p><b>Screening for diabetic retinopathy</b></p><ul><li class="level1">Evidence identified by NICE and the clinical experience of the GDG suggest that retinopathy requiring treatment is rare in children and young people with type 2 diabetes. However, the&nbsp;GDG agreed that&nbsp;the early identification of retinopathy is of major importance in reducing the risk of sight loss due to diabetes.</li><li class="level1">The GDG felt that there was no need to deviate from the current national screening recommendations (that is, screening from the age of 12 years). However,&nbsp;the GDG highlighted that it is at the clinician’s discretion to refer any child or young person whom they feel may be at higher risk of retinopathy (for example due to suboptimal blood glucose control or long duration of disease).</li></ul></section></section><section class="scenariorecommendation" id="1312558"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Transition to adult care services</h3></header><ul><li class="level1"><b>Explain to young people with type 2 diabetes who are preparing for transition to adult services that&nbsp;some aspects of diabetes care will change at transition,</b>&nbsp;for example clinic time and location, and their diabetes specialist team.</li><li class="level1">Detailed information on the <a href="https://www.diabetes.org.uk/Guide-to-diabetes/Teens/Me-and-my-diabetes/Transition-to-adult-clinics/">transition to adult clinics</a> for young people with diabetes and their family/carers is available on the Diabetes UK website (<a href="https://www.diabetes.org.uk/">www.diabetes.org.uk</a>).</li></ul><section class="scenariobasis" id="1312560"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h4>Basis for recommendation</h4></header><p>This recommendation is based on the&nbsp;National Institute for Health and Care Excellence (NICE) guideline <i>Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>]&nbsp;and on information on the Diabetes UK website (<a href="https://www.diabetes.org.uk/Guide-to-diabetes/Teens/Me-and-my-diabetes/Transition-to-adult-clinics/">www.diabetes.org.uk</a>).</p><ul><li class="level1">NICE states that in young people with diabetes who are preparing for transition to adult services, clinic attendance rates may be improved by:

	
	</li><ul><li class="level2">Allowing&nbsp;sufficient time for the young person to familiarize themselves with the practicalities of the transition.</li><li class="level2">Giving&nbsp;appropriate information and advice on what to expect following the transition.</li></ul></ul></section></section></section><section class="prescribinginfosub hidden" id="1313529"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Metformin</h2></header><section class="prescribinginfosub" id="1313658"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Mode of action</h3></header><ul><li class="level1">
            <b>Metformin </b>acts mainly by decreasing gluconeogenesis and increasing peripheral utilization of glucose. It is only effective if there are some residual functioning pancreatic islet cells.</li><li class="level1">Metformin is currently the only available biguanide.</li></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313880"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Recommended doses</h3></header><ul><li class="level1">
            <b>For standard-release metformin tablets&nbsp;</b>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
            <b>&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314616" href="/diabetes-type-2#!references/1090203">ABPI, 2016d</a>]
            <b>:</b>
	
	</li><ul><li class="level2">The British National Formulary (BNF) recommends the following regimen for the treatment of type 2 diabetes in adults:
		
		</li><ul><li class="level3">500&nbsp;mg with breakfast for at least 1 week, <i>then&nbsp;</i>500&nbsp;mg with breakfast and evening meal for at least 1 week, <i>then </i>500&nbsp;mg with breakfast, lunch, and evening meal thereafter; the&nbsp;usual maximum dose is 2&nbsp;g daily (in divided doses).</li></ul><li class="level2">This differs from the&nbsp;manufacturer's&nbsp;recommended regimen, which is:
		
		</li><ul><li class="level3">500 mg two or three times daily given during or after meals. After 10 to 15 days, the dose should be adjusted on the basis of blood glucose measurements; the maximum dose is 3 g daily (in three divided doses).</li></ul></ul><li class="level1">
            <b>For modified-release metformin tablets&nbsp;</b>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
            <b>&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314627" href="/diabetes-type-2#!references/1090203">ABPI Medicines Compendium, 2015</a>]
            <b>:</b>
	
	</li><ul><li class="level2">The recommended regimen is&nbsp;500&nbsp;mg once daily, increased every 10–15 days on the basis of blood glucose measurements;&nbsp;the maximum recommended dose is 2&nbsp;g once daily with the evening meal.</li><li class="level2">If control is not achieved, 1&nbsp;g twice daily with meals should be tried.</li></ul><li class="level1">
            <b>Dose reductions of metformin may need to be adjusted:</b>
	
	</li><ul><li class="level2">Based on&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:3">renal function</a>.</li><li class="level2">During concurrent treatment with&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:6">certain drugs</a>.</li></ul></ul></section><section class="prescribinginfosub" id="1313660"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Initiating and monitoring metformin treatment</h3></header><ul><li class="level1">
            <b>Before starting treatment with metformin, </b>check renal function.

	
	</li><ul><li class="level2">Do not start metformin treatment if&nbsp;estimated glomerular filtration rate (eGFR)&nbsp;is less than 30 mL/min/1.73 m<sup>2</sup>.</li></ul><li class="level1">
            <b>During treatment with metformin:</b>
	
	</li><ul><li class="level2">Monitor renal function:
		
		</li><ul><li class="level3">At least once a year in people with normal renal function.</li><li class="level3">At least twice a year in people&nbsp;with&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:4">additional risk factors</a>&nbsp;for renal impairment (such as in elderly people) or if deterioration suspected.</li></ul><li class="level2">Review the dose of metformin if eGFR is less than 45 mL/min/1.73 m<sup>2</sup>.</li><li class="level2">Stop treatment with&nbsp;metformin:
		
		</li><ul><li class="level3">If eGFR is less than 30 mL/min/1.73 m<sup>2</sup>.</li><li class="level3">In&nbsp;people&nbsp;at risk of tissue hypoxia or sudden deterioration in renal function. See the section on&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:4">Contraindications and cautions</a>&nbsp;for more information.</li></ul></ul></ul><p>
            [<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>; <a rel="citation" resource="1090203#A1314616" href="/diabetes-type-2#!references/1090203">ABPI, 2016d</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313553"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Contraindications and cautions</h3></header><ul><li class="level1">
            <b>Do not prescribe metformin to:</b>
	
	</li><ul><li class="level2">People at risk of&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:5">lactic acidosis</a>, including people with:
		
		</li><ul><li class="level3">Diabetic ketoacidosis (or diabetic pre-coma).</li><li class="level3">Estimated glomerular filtration rate (eGFR) less than 30 mL/minute/1.73 m<sup>2</sup> (for standard-release metformin)&nbsp;or less than&nbsp;45 mL/minute/1.73 m<sup>2</sup> (for&nbsp;modified-release metformin tablets).</li><li class="level3">Acute conditions with the potential to alter renal function, such as dehydration, prolonged fasting, severe infection, or shock.</li><li class="level3">Acute or chronic disease which may cause tissue hypoxia, such as cardiac or respiratory failure, recent myocardial infarction, or shock.</li><li class="level3">Hepatic insufficiency, acute alcohol intoxication, or alcohol addiction.</li></ul><li class="level2">People about to undergo elective surgery.
		
		</li><ul><li class="level3">Metformin should be discontinued 48 hours before elective surgery under general, spinal, or peridural anaesthesia. Treatment may be restarted no earlier than&nbsp;48 hours following surgery or resumption of oral nutrition and only if normal renal function has been established.</li></ul></ul><li class="level1">
            <b>Prescribe metformin with caution to people with:</b>
	
	</li><ul><li class="level2">Mild to moderate CKD, and in situations where renal function may become impaired, for example when initiating certain&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:6">drug treatments</a>&nbsp;or in elderly people (due to the increased risk of lactic acidosis).</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>; <a rel="citation" resource="1090203#A1314627" href="/diabetes-type-2#!references/1090203">ABPI Medicines Compendium, 2015</a>; <a rel="citation" resource="1090203#A1314616" href="/diabetes-type-2#!references/1090203">ABPI, 2016d</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313613"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Adverse effects</h3></header><ul><li class="level1">
            <b>Adverse effects of metformin include:</b>

	
	</li><ul><li class="level2">
            <b>Gastrointestinal adverse effects,</b> such as nausea, vomiting, diarrhoea, abdominal pain, and loss of appetite — these are common, occur most frequently during initiation of treatment, and resolve spontaneously in most cases.&nbsp;

		
		</li><ul><li class="level3">The National Institute for Health and Care Excellence (NICE) recommends that&nbsp;the dose of metformin is stepped up gradually over several weeks to minimize the risk of gastrointestinal adverse effects&nbsp;[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>].</li></ul><li class="level2">
            <b>Lactic acidosis —</b> this is a rare but potentially fatal adverse effect&nbsp;that can occur due to metformin accumulation.&nbsp;
		
		</li><ul><li class="level3">It has an insidious onset with non-specific signs and symptoms, such as abdominal pain, anorexia, hypothermia, lethargy, nausea, respiratory distress, and vomiting.</li><li class="level3">Stop metformin treatment&nbsp;if estimated glomerular filtration rate (eGFR) is less than 30 mL/min/1.73 m&nbsp;<sup>2</sup>, or when tissue hypoxia is suspected.</li></ul><li class="level2">
            <b>Vitamin B12 deficiency&nbsp;—</b> a decrease in vitamin B12 absorption (and hence decreased serum levels) has been reported during long-term use of metformin. This should be considered if a person taking metformin&nbsp;presents with megaloblastic anaemia.</li><li class="level2">
            <b>Hypoglycaemia — </b>metformin alone does not cause hypoglycaemia, but caution is advised when it is used in combination with&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:6">certain drugs</a>.</li><li class="level2">
            <b>Taste disturbance</b>&nbsp;(common).</li><li class="level2">
            <b>Skin reactions</b> (rare),&nbsp;including erythema, pruritus, and urticaria.&nbsp;</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1314616" href="/diabetes-type-2#!references/1090203">ABPI, 2016d</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313622"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Drug interactions</h3></header><ul><li class="level1">
            <b>Drug interactions associated with metformin include:</b>
	
	</li><ul><li class="level2">
            <b>Alcohol —&nbsp;</b>increased risk of&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:5">lactic acidosis</a>&nbsp;when alcohol is taken by a person on metformin treatment. In addition, the&nbsp;hypoglycaemic effect of metformin may be enhanced by alcohol.&nbsp;Concurrent use is not recommended.</li><li class="level2">
            <b>Beta-blockers —</b>&nbsp;the&nbsp;warning signs of hypoglycaemia (such as tremor) may be masked during concurrent treatment with a beta-blocker.</li><li class="level2">
            <b>Ketotifen —</b>&nbsp;platelet&nbsp;count may be depressed when metformin is given with ketotifen. Avoid concurrent use.&nbsp;</li><li class="level2">
            <b>Topiramate —</b>&nbsp;plasma concentration of metformin may be increased by topiramate.</li><li class="level2">
            <b>Octreotide and lanreotide —</b>&nbsp;the&nbsp;requirements for metformin may be reduced by these drugs.</li><li class="level2">
            <b>Other antidiabetic drugs&nbsp;—</b> caution is&nbsp;advised when metformin is used in combination with a sulfonylurea (due to the risk of hypoglycaemia).</li></ul><li class="level1">
            <b>In addition:</b>
	
	</li><ul><li class="level2">
            <b>The blood glucose-lowering effects of metformin may be enhanced by:</b>
		
		</li><ul><li class="level3">Angiotensin-converting enzyme (ACE) inhibitors.</li><li class="level3">Anabolic steroids.</li><li class="level3">Disopyramide.</li><li class="level3">Monoamine oxidase inhibitors (MAOIs).</li><li class="level3">Testosterone.</li></ul><li class="level2">
            <b>The&nbsp;blood glucose-lowering effects of metformin&nbsp;may be antagonized by:</b>
		
		</li><ul><li class="level3">Corticosteroids.</li><li class="level3">Diuretics (thiazide and related, and loop).&nbsp;</li><li class="level3">Oestrogens and progestogens.</li></ul><li class="level2">
            <b>Metformin is a substrate of both organic cation transporters, OCT1 and OCT2. Co-administration of metformin with:</b>
		
		</li><ul><li class="level3">Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.</li><li class="level3">Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.</li><li class="level3">Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprime, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.</li><li class="level3">Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of metformin.</li></ul><li class="level2">Caution is therefore advised, especially in patients with renal impairment, when these drugs are co-administered with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>; <a rel="citation" resource="1090203#A1314616" href="/diabetes-type-2#!references/1090203">ABPI, 2016d</a>; <a rel="citation" resource="1090203#A1406496" href="/diabetes-type-2#!references/1090203">ABPI, 2017</a>]
          </p></section></section><section class="prescribinginfosub hidden" id="1313642"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Gliptins</h2></header><section class="prescribinginfosub" id="1313654"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Mode of action</h3></header><ul><li class="level1">
            <b>Gliptins </b>are inhibitors of the enzyme dipeptidyl peptidase 4 (DPP-4).
	
	</li><ul><li class="level2">DPP-4 plays a major role in glucose metabolism by rapidly degrading the incretins (glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide 1 [GLP-1]) which stimulate postprandial insulin secretion and suppress glucagon secretion.&nbsp;</li><li class="level2">Inhibition of DPP-4 therefore results in increased circulating levels of GIP and GLP-1 following the ingestion of food, and to increased insulin secretion and reduced glucagon secretion.</li></ul><li class="level1">
            <b>There are currently five gliptins available in the UK: </b>sitagliptin, saxagliptin, vildagliptin, linagliptin, and alogliptin.&nbsp;</li></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313882"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Recommended doses</h3></header><ul><li class="level1">
            <b>For the treatment of diabetes in adults over 18 years of age, the recommended doses are:</b>

	
	</li><ul><li class="level2">
            <b>Alogliptin:</b>&nbsp;25 mg once daily.</li><li class="level2">
            <b>Linagliptin:&nbsp;</b>5 mg once daily.</li><li class="level2">
            <b>Sitagliptin:</b> 100 mg once daily.</li><li class="level2">
            <b>Saxagliptin:</b> 5 mg once daily.</li><li class="level2">
            <b>Vildagliptin:</b> 50 mg twice daily.</li></ul><li class="level1">
            <b>When a gliptin is used in combination with sulfonylurea,</b>&nbsp;a lower dose of the sulfonylurea&nbsp;may be needed to reduce the risk of hypoglycaemia.
	
	</li><ul><li class="level2">
            <b>For vildagliptin, </b>when used in combination with a sulfonylurea,&nbsp;the recommended dose is 50 mg once daily, in the morning.</li></ul><li class="level1">
            <b>In people with renal impairment, the recommended&nbsp;doses&nbsp;are:</b>
	
	</li><ul><li class="level2">
            <b>For alogliptin:&nbsp;</b>
		
		</li><ul><li class="level3">12.5 mg once daily if&nbsp;estimated glomerular filteration rate (eGFR)&nbsp;is 30–50 mL/minute/1.73m<sup>2</sup>.</li><li class="level3">6.25 mg once daily if eGFR is less than 30 mL/minute/1.73m<sup>2</sup>.</li></ul><li class="level2">
            <b>For linagliptin,</b>&nbsp;no dose adjustment is required.</li><li class="level2">
            <b>For saxagliptin:&nbsp;</b>2.5 mg once daily in people with moderate to severe renal impairment.&nbsp;No dose adjustment is recommended for people with mild renal impairment.</li><li class="level2">
            <b>For&nbsp;sitagliptin:&nbsp;</b>
		
		</li><ul><li class="level3">50 mg once daily if eGFR is 30–50 mL/minute/1.73 m<sup>2</sup>.</li><li class="level3">25 mg once daily if eGFR is less than 30 mL/minute/1.73m<sup>2</sup>.</li></ul><li class="level2">
            <b>For&nbsp;vildagliptin:</b> 50 mg once daily if eGFR is less than 50 mL/minute/1.73m<sup>2</sup>.</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1314671" href="/diabetes-type-2#!references/1090203">ABPI, 2016e</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313672"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Initiating and monitoring treatment with a gliptin</h3></header><ul><li class="level1">
            <b>Before starting treatment with saxagliptin, vildagliptin, or alogliptin:</b>

	
	</li><ul><li class="level2">Check liver and kidney function.&nbsp;</li><li class="level2">See the section on&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:11">Contraindications and cautions</a>&nbsp;for more information.</li></ul><li class="level1">
            <b>During treatment with:</b>
	
	</li><ul><li class="level2">
            <b>Vildagliptin:&nbsp;</b>monitor liver function<b>&nbsp;</b>at three-monthly intervals during the first year, and periodically thereafter.
		
		</li><ul><li class="level3">If the person develops increased transaminase levels, arrange a second liver function test (LFT) to confirm the finding. Arrange frequent LFTs until the abnormality(ies) return(s) to normal.&nbsp;</li><li class="level3">If the increased transaminase levels persist, stop vildagliptin treatment. Do not restart vildagliptin when LFTs return to normal.</li><li class="level3">If the person develops&nbsp;jaundice or other signs suggestive of liver dysfunction (such as&nbsp;nausea, vomiting, abdominal pain, fatigue, and dark urine), stop vildagliptin treatment.&nbsp;</li></ul><li class="level2">
            <b>Saxagliptin:&nbsp;</b>monitor renal function&nbsp;periodically (for example annually).</li><li class="level2">
            <b>Alogliptin:</b>
		
		</li><ul><li class="level3">Monitor renal function periodically (for example annually).</li><li class="level3">Check liver function promptly in people with symptoms suggestive of liver injury. If an abnormality is found and an alternative cause is not established, consider discontinuation of alogliptin treatment.</li></ul></ul><li class="level1">
            <b>The manufacturers and the British National Formulary (BNF) do not recommend any specific monitoring requirements for sitagliptin and linagliptin.</b>
          </li></ul><p>
            [<a rel="citation" resource="1090203#A1314682" href="/diabetes-type-2#!references/1090203">ABPI, 2015</a>; <a rel="citation" resource="1090203#A1314671" href="/diabetes-type-2#!references/1090203">ABPI, 2016e</a>; <a rel="citation" resource="1090203#A1314649" href="/diabetes-type-2#!references/1090203">ABPI, 2016f</a>; <a rel="citation" resource="1090203#A1314638" href="/diabetes-type-2#!references/1090203">ABPI, 2016g</a>; <a rel="citation" resource="1090203#A1314660" href="/diabetes-type-2#!references/1090203">ABPI, 2016h</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313651"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Contraindications and cautions</h3></header><ul><li class="level1">
            <b>Do not prescribe a gliptin to people with:</b>
	
	</li><ul><li class="level2">Ketoacidosis.</li><li class="level2">Renal impairment:
		
		</li><ul><li class="level3">Avoid saxagliptin in people with end stage renal disease requiring haemodialysis.&nbsp;</li></ul><li class="level2">Hepatic impairment:
		
		</li><ul><li class="level3">Avoid vildagliptin in people with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than three times the upper limit of normal.&nbsp;</li><li class="level3">Avoid saxagliptin and alogliptin in people with severe hepatic impairment (Child-Pugh score greater than 9).</li></ul><li class="level2">Heart failure:
		
		</li><ul><li class="level3">Avoid vildaglitpin in people with severe heart failure.</li><li class="level3">Avoid alogliptin in people with&nbsp;moderate to severe heart failure.</li></ul></ul><li class="level1">
            <b>Prescribe gliptins with caution to:</b>
	
	</li><ul><li class="level2">People with renal impairment&nbsp;— it may be necessary to reduce the&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:9">dose</a>&nbsp;of the gliptin.</li><li class="level2">People with hepatic impairment:
		
		</li><ul><li class="level3">Use saxagliptin with caution in people with moderate hepatic impairment.&nbsp;</li><li class="level3">No dose adjustment is required for people with mild or moderate hepatic impairment.</li></ul><li class="level2">Elderly people:
		
		</li><ul><li class="level3">Use saxagliptin with caution in elderly people.</li><li class="level3">Use linagliptin with caution in people aged over 80 years.</li></ul><li class="level2">People with a history of pancreatitis. See the section on&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:12">Adverse effects</a>&nbsp;for more information.</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1314682" href="/diabetes-type-2#!references/1090203">ABPI, 2015</a>; <a rel="citation" resource="1090203#A1314671" href="/diabetes-type-2#!references/1090203">ABPI, 2016e</a>; <a rel="citation" resource="1090203#A1314638" href="/diabetes-type-2#!references/1090203">ABPI, 2016g</a>; <a rel="citation" resource="1090203#A1314649" href="/diabetes-type-2#!references/1090203">ABPI, 2016f</a>; <a rel="citation" resource="1090203#A1314660" href="/diabetes-type-2#!references/1090203">ABPI, 2016h</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313674"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Adverse effects</h3></header><ul><li class="level1">
            <b>Gastrointestinal&nbsp;disturbances</b>&nbsp;(including constipation,&nbsp;vomiting, nausea, diarrhoea, dyspepsia, gastritis, and&nbsp;gastro-oesophageal reflux) are common with gliptins.&nbsp;</li><li class="level1">
            <b>Acute pancreatitis is an uncommon but serious adverse effect of gliptins.&nbsp;</b>
	
	</li><ul><li class="level2">Advise the person and/or their family/carers to&nbsp;seek prompt&nbsp;medical attention if they experience severe, persistent abdominal pain.&nbsp;</li><li class="level2">Discontinue treatment if pancreatits is suspected.</li></ul><li class="level1">
            <b>Bullous pemphigoid, </b>the manufacturers summary of product characteristics states that there have been reports of bullous pemphigoid in patients taking DPP-4 inhibitors including sitagliptin. If bullous pemphigoid is suspected, sitagliptin treatment should be discontinued. See&nbsp;<a href="http://www.medicines.org.uk/emc/medicine/19609">http://www.medicines.org.uk/emc/medicine/19609</a>.</li><li class="level1">
            <b>Hypoglycaemia </b>may occur when gliptins are used in combination with certain drugs.</li><li class="level1">
            <b>Nervous system disorders </b>(such as headache, dizziness, and tremor) are common with sitagliptin, saxagliptin, vildagliptin, and alogliptin.</li><li class="level1">
            <b>Skin and subcutaneous tissue disorders</b> (such as pruritus, angioedema, rash, urticaria,&nbsp;cutaneous vasculitis, and Stevens-Johnson syndrome) may occur with sitagliptin, linaglitpin, saxagliptin, vildagliptin&nbsp;and alogliptin.</li><li class="level1">
            <b>Musculoskeletal and connective tissue disorders</b> (including back pain, arthralgia, myalgia, and arthropathy) may occur with sitagliptin and saxagliptin.</li><li class="level1">
            <b>Infections</b> (including&nbsp;upper respiratory tract infection, urinary tract infection, gastroenteritis, sinusitis, and nasopharyngitis) are common with saxagliptin and alogliptin.</li><li class="level1">
            <b>Hepatic dysfunction,</b> including hepatitis and hepatic failure, has rarely been reported with vildaglitpin and alogliptin.</li><li class="level1">
            <b>Hypersensitivity reactions</b>&nbsp;(including anaphylactic responses)&nbsp;have been reported with sitagliptin, saxagliptin, linagliptin, and alogliptin.</li><li class="level1">
            <b>Other adverse effects include:</b>
	

	
	</li><ul><li class="level2">
            <b>For linagliptin: </b>nasopharyngitis, cough, and increased amylase levels.</li><li class="level2">
            <b>For&nbsp;sitagliptin:</b>&nbsp;interstitial lung disease, impaired renal function, thrombocytopaenia and acute renal failure.</li><li class="level2">
            <b>For saxagliptin: </b>erectile dysfunction, peripheral oedema, dyslipidaemia, and hypertriglyceridaemia.</li></ul><li class="level1">
            <b>Linagliptin and alogliptin are black triangle drugs</b> and are monitored intensively by the Medicines and Healthcare products Regulatory Agency (MHRA). All suspected adverse reactions associated with these drugs (and other drugs) should be reported.</li></ul><p>
            [<a rel="citation" resource="1090203#A1314649" href="/diabetes-type-2#!references/1090203">ABPI, 2016f</a>; <a rel="citation" resource="1090203#A1314682" href="/diabetes-type-2#!references/1090203">ABPI, 2015</a>; <a rel="citation" resource="1090203#A1314671" href="/diabetes-type-2#!references/1090203">ABPI, 2016e</a>; <a rel="citation" resource="1090203#A1314638" href="/diabetes-type-2#!references/1090203">ABPI, 2016g</a>; <a rel="citation" resource="1090203#A1314660" href="/diabetes-type-2#!references/1090203">ABPI, 2016h</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313677"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Drug interactions</h3></header><ul><li class="level1">
            <b>Drug interactions associated with gliptins include:&nbsp;</b>

	
	</li><ul><li class="level2">
            <b>Beta-blockers —</b> the&nbsp;warning signs of hypoglycaemia (such as tremor) may be masked during concurrent treatment with a beta-blocker.</li><li class="level2">
            <b>Angiotensin-converting enzyme (ACE) inhibitors</b> — there may be an increased risk of angioedema in people taking&nbsp;vildagliptin and&nbsp;ACE-inhibitors concomitantly.</li><li class="level2">
            <b>Digoxin —</b>&nbsp;sitagliptin increases plasma concentration of digoxin.&nbsp;No dose adjustment of digoxin is recommended. However, monitor people at risk of digoxin toxicity.</li><li class="level2">
            <b>Ketoconazole —</b>&nbsp;plasma concentration of saxagliptin may be increased by ketoconazole.</li><li class="level2">
            <b>Lancreotide and octreotide —</b>&nbsp;the&nbsp;requirements for gliptins may be reduced by these drugs.</li><li class="level2">
            <b>Rifampicin —</b>&nbsp;effects of linagliptin are possibly reduced by rifampicin.</li><li class="level2">
            <b>Other antidiabetic drugs —</b>&nbsp;the dose of concomitant sulfonylurea may need to be reduced due to an increased risk of hypoglycaemia.</li></ul><li class="level1">
            <b>In addition:</b>
	
	</li><ul><li class="level2">
            <b>The blood glucose-lowering effects of&nbsp;gliptins may be enhanced by:&nbsp;</b>
		
		</li><ul><li class="level3">Alcohol.</li><li class="level3">Anabolic steroids.</li><li class="level3">Monoamine oxidase inhibitors (MAOIs).</li><li class="level3">Testosterone.&nbsp;</li></ul><li class="level2">
            <b>The blood glucose-lowering effects of&nbsp;gliptins may be antagonized by:&nbsp;</b>
		
		</li><ul><li class="level3">Corticosteroids.&nbsp;</li><li class="level3">Diuretics (thiazide and related, and loop).&nbsp;</li><li class="level3">Oestrogens and progestogens.</li></ul></ul></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section></section><section class="prescribinginfosub hidden" id="1313536"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Pioglitazone</h2></header><section class="prescribinginfosub" id="1313665"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Mode of action</h3></header><ul><li class="level1">
            <b>Pioglitazone </b>acts by reducing&nbsp;peripheral insulin resistance, thereby leading to a reduction in blood glucose concentration. It&nbsp;does not directly stimulate insulin secretion.</li><li class="level1">
            <b>Pioglitazone is the only glitazone currently available in the UK.</b>
          </li></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313669"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Initiating and monitoring pioglitazone treatment</h3></header><ul><li class="level1">
            <b>&nbsp;Before starting treatment with pioglitazone:</b>
	
	</li><ul><li class="level2">
            <b>Check the person's liver function.</b>
		
		</li><ul><li class="level3">If alanine aminotransferase (ALT) is more than 2.5&nbsp;times the upper limit of normal, or there is any other evidence of liver disease, do not start treatment.</li></ul><li class="level2">
            <b>Measure the full blood count.</b>
		
		</li><ul><li class="level3">Risk of anaemia is increased if haemoglobin is low before starting treatment.</li></ul><li class="level2">
            <b>Record the person's weight.</b>
          </li><li class="level2">
            <b>Check whether the person has a history of bladder cancer or visible blood in the urine which has not been investigated.</b>
		
		</li><ul><li class="level3">If any of the above apply, do not prescribe pioglitazone.</li></ul><li class="level2">
            <b>Pioglitazone should not be used in patients with active bladder cancer. </b>The&nbsp;benefits and risks of use in patients with history of bladder cancer should be considered.<b>&nbsp;</b></li><li class="level2">
            <b>Assess the following known risk factors for bladder cancer:</b>
		
		</li><ul><li class="level3">Age — the use of pioglitazone in elderly people should be considered carefully before and during treatment because the risk of bladder cancer increases with age.</li><li class="level3">Current or past history of smoking.</li><li class="level3">Exposure to some occupational or chemotherapy drugs, such as cyclophosphamide.</li><li class="level3">Previous radiation therapy to the pelvic region.</li></ul></ul><li class="level1">
            <b>Following initiation of treatment with pioglitazone:</b>
	
	</li><ul><li class="level2">
            <b>Monitor liver enzymes periodically, based on clinical judgement.&nbsp;</b>
		
		</li><ul><li class="level3">If ALT levels are increased to three times the upper limit of normal during pioglitazone treatment, promptly reassess liver enzyme levels.&nbsp;</li><li class="level3">If ALT levels remain more than three times the upper limit of normal, discontinue treatment with pioglitazone.&nbsp;</li><li class="level3">If the person develops symptoms suggesting hepatic dysfunction (such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and/or dark urine), check liver enzymes. Use clinical judgement to decide whether to continue treatment with pioglitazone,&nbsp;pending laboratory evaluations.&nbsp;</li><li class="level3">If jaundice is observed, discontinue treatment with pioglitazone.</li></ul><li class="level2">
            <b>Monitor for signs and symptoms of fluid retention (including weight&nbsp;gain or oedema).&nbsp;</b>
		
		</li><ul><li class="level3">Stop pioglitazone if any deterioration in cardiac function is seen.</li></ul><li class="level2">
            <b>Assess the safety and efficacy of pioglitazone 3</b>–<b>6 months after treatment is initiated, and regularly afterwards.</b>&nbsp;
		
		</li><ul><li class="level3">People who are already receiving pioglitazone should also commence a similar programme of monitoring. This is to ensure that only people who are deriving benefit continue to be treated.</li><li class="level3">Stop pioglitazone in people who do not respond adequately to treatment.</li></ul></ul></ul><p>
            [<a rel="citation" resource="1090203#A68225" href="/diabetes-type-2#!references/1090203">EMA, 2011</a>; <a rel="citation" resource="1090203#A68224" href="/diabetes-type-2#!references/1090203">MHRA, 2011</a>; <a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>; <a rel="citation" resource="1090203#A1404805" href="/diabetes-type-2#!references/1090203">FDA, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313885"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Recommended dose</h3></header><ul><li class="level1">
            <b>The recommended dose of pioglitazone for the treatment of diabetes mellitus in adults aged over 18 years is&nbsp;</b>15–30&nbsp;mg once daily, increased to 45&nbsp;mg once daily according to response.</li></ul><p>
            [<a rel="citation" resource="1090203#A1314693" href="/diabetes-type-2#!references/1090203">ABPI, 2016a</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313624"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Contraindications and cautions</h3></header><ul><li class="level1">
            <b>Do not prescribe pioglitazone to people with:</b>
	
	</li><ul><li class="level2">Heart failure or a history of heart failure (New York Heart Association stages I to IV).</li><li class="level2">Diabetic ketoacidosis.</li><li class="level2">Uninvestigated macroscopic haematuria.</li><li class="level2">Previous or active bladder cancer.</li><li class="level2">Hepatic impairment.</li></ul><li class="level1">
            <b>Prescribe pioglitazone with caution to people:</b>
	
	</li><ul><li class="level2">With<b>&nbsp;</b>at least one risk factor for developing congestive heart failure (such as prior myocardial infarction, symptomatic coronary artery disease, or advancing age).
		
		</li><ul><li class="level3">Start with the lowest available&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:17">dose</a>&nbsp;and increase the dose gradually.&nbsp;</li><li class="level3">
            
              <a href="/diabetes-type-2#!prescribinginfosub:16">Monitor</a>
            &nbsp;for signs and symptoms of heart failure, weight gain, or oedema.</li></ul></ul></ul></section><section class="prescribinginfosub" id="1313627"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Adverse effects</h3></header><ul><li class="level1">
            <b>Fluid retention</b> may occur and can exacerbate or precipitate heart failure.&nbsp;If cardiac function deteriorates, stop treatment with pioglitazone.&nbsp;Ensure the person knows how to recognize the signs and symptoms of heart failure and when to seek medical advice.</li><li class="level1">
            <b>Bladder cancer </b>has been associated with pioglitazone use.&nbsp;However, with careful&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:16">patient selection</a>, the benefits of pioglitazone continue to outweigh the risks&nbsp;[<a rel="citation" resource="1090203#A68225" href="/diabetes-type-2#!references/1090203">EMA, 2011</a>; <a rel="citation" resource="1090203#A68224" href="/diabetes-type-2#!references/1090203">MHRA, 2011</a>].</li><li class="level1">
            <b>An increased incidence of bone fractures </b>(bone, hand, or arm) has been observed in both men and women taking pioglitazone.</li><li class="level1">
            <b>Weight gain</b>, due to fat&nbsp;accumulation&nbsp;and/or fluid retention, has been associated with pioglitazone use.&nbsp;Use pioglitazone with caution in people taking&nbsp;other drugs that may cause weight gain, such as sulfonylureas.&nbsp;Give lifestyle advice to reduce the risk of weight gain. See the sections on lifestyle advice for&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:3">adults</a>&nbsp;and&nbsp;<a href="/diabetes-type-2#!scenariorecommendation:12">chilldren</a>&nbsp;for more information.</li><li class="level1">
            <b>Decreased visual acuity</b> due to worsening or new-onset macular oedema has been associated with the use of pioglitazone.&nbsp;Consider ophthalmological referral for anyone reporting disturbances in visual acuity.&nbsp;</li><li class="level1">
            <b>Hypoglycaemia risk is&nbsp;increased in</b>&nbsp;people taking pioglitazone with&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:20">other drugs</a>.</li><li class="level1">
            <b>Liver toxicity </b>has rarely been reported.&nbsp;<a href="/diabetes-type-2#!prescribinginfosub:16">Monitor</a>&nbsp;the person appropriately.</li><li class="level1">
            <b>Others adverse&nbsp;effects&nbsp;include</b>&nbsp;gastro-intestinal disturbances, anaemia, headache, dizziness, arthralgia, hypoaesthesia, haematuria, and impotence.</li></ul><p>
            [<a rel="citation" resource="1090203#A1314693" href="/diabetes-type-2#!references/1090203">ABPI, 2016a</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313630"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Drug interactions</h3></header><ul><li class="level1">
            <b>Drug interactions associated with pioglitazone include:</b>
	
	</li><ul><li class="level2">
            <b>Beta-blockers —</b>&nbsp;the&nbsp;warning signs of hypoglycaemia (such as tremor) may be masked when pioglitazone is given with a beta-blocker.</li><li class="level2">
            <b>Gemfibrozil —</b> can significantly increase the plasma concentration of pioglitazone. To counteract the potential for dose-related adverse effects, consider reducing the dose of pioglitazone.</li><li class="level2">
            <b>Ketoconazole — </b>the&nbsp;plasma concentration of pioglitazone may be increased by ketoconazole.</li><li class="level2">
            <b>Lancreotide and octreotide —</b>&nbsp;the&nbsp;requirements for pioglitazone may be reduced by these drugs.</li><li class="level2">
            <b>Nonsteroidal anti-inflammatory drugs (NSAIDs) — </b>post marketing cases of peripheral oedema and cardiac failure have been reported with concomitant use of pioglitazone and NSAIDs, including selective COX-2 inhibitors. Discontinue pioglitazone if any deterioration in cardiac status occurs.</li><li class="level2">
            <b>Liver enzyme inducing drugs —</b>&nbsp;rifampicin can significantly reduce the plasma concentration of pioglitazone (and the pioglitazone dose may need to be increased). Closely monitor blood glucose control during concurrent use of pioglitazone and other liver enzyme inducers, such as phenytoin, carbamazepine, and St John's wort, as these may also affect the plasma concentration of pioglitazone.</li><li class="level2">
            <b>Other antidiabetic drugs&nbsp;—</b>&nbsp;people taking pioglitazone in dual or triple oral therapy with a sulfonylurea may be at increased risk of hypoglycaemia. It may be necessary to reduce the dose of the sulfonylurea.</li></ul><li class="level1">
            <b>In addition:&nbsp;</b>
	
	</li><ul><li class="level2">
            <b>The blood glucose-lowering effects of pioglitazone may be enhanced by:&nbsp;</b>
		
		</li><ul><li class="level3">Alcohol.</li><li class="level3">Anabolic steroids.&nbsp;</li><li class="level3">Monoamine oxidase inhibitors (MAOIs).</li><li class="level3">Testosterone.&nbsp;</li></ul><li class="level2">
            <b>The&nbsp;blood glucose-lowering effects of&nbsp;pioglitazone may be antagonized by:&nbsp;</b>
		
		</li><ul><li class="level3">Corticosteroids.&nbsp;</li><li class="level3">Diuretics (thiazide and related, and loop).&nbsp;</li><li class="level3">Oestrogens and progestogens.</li></ul></ul></ul><p>
            [<a rel="citation" resource="1090203#A67307" href="/diabetes-type-2#!references/1090203">MHRA, 2011b</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section></section><section class="prescribinginfosub hidden" id="1313538"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Sulfonylureas</h2></header><section class="prescribinginfosub" id="1313705"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Mode of action</h3></header><ul><li class="level1">
            <b>Sulfonylureas&nbsp;</b>are insulin secretagogues. They&nbsp;act mainly&nbsp;by augmenting insulin secretion and consequently are effective only when some residual pancreatic beta-cell activity is present.</li><li class="level1">
            <b>There are currently five sulfonylureas available in the UK: </b>glibenclamide, gliclazide, glimepiride, glipizide, and tolbutamide.</li></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313888"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Recommended doses</h3></header><ul><li class="level1">
            <b>For the treatment of diabetes in adults over 18 years of age, the recommended doses are:</b>
	
	</li><ul><li class="level2">
            <b>For glibenclamide </b>
            [<a rel="citation" resource="1090203#A1314704" href="/diabetes-type-2#!references/1090203">ABPI, 2015b</a>]
            <b>:</b>&nbsp;
		
		</li><ul><li class="level3">5&nbsp;mg daily (with, or immediately after, breakfast), dose adjusted according to response. The maximum dose is 15&nbsp;mg daily.&nbsp;</li></ul><li class="level2">
            <b>For gliclazide&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314726" href="/diabetes-type-2#!references/1090203">ABPI, 2016i</a>]
            <b>&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314715" href="/diabetes-type-2#!references/1090203">ABPI, 2016j</a>]
            <b>:&nbsp;</b>
		
		</li><ul><li class="level3">Standard release tablets: 40–80&nbsp;mg daily, adjusted according to response; up to 160&nbsp;mg as a single dose with breakfast (higher doses should be divided). The maximum dose is 320&nbsp;mg daily.</li><li class="level3">Modified release tablets:&nbsp;30&nbsp;mg daily with breakfast, adjusted according to response every 4 weeks&nbsp;except in people whose blood glucose has not reduced after two weeks of treatment. In such cases, the dose may be increased at the end of the second week of treatment. The maximum dose is 120 mg daily.</li></ul><li class="level2">
            <b>Glimepiride&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314737" href="/diabetes-type-2#!references/1090203">ABPI, 2014</a>]
            <b>:&nbsp;</b>
		
		</li><ul><li class="level3">1&nbsp;mg daily&nbsp;taken shortly before or with first main meal, adjusted according to response in 1 mg steps at 1–2 week intervals. The usual maximum dose is 4&nbsp;mg daily (exceptionally, up to 6&nbsp;mg daily may be used).</li></ul><li class="level2">
            <b>Glipizide&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314748" href="/diabetes-type-2#!references/1090203">ABPI, 2014b</a>]
            <b>:</b>&nbsp;
		
		</li><ul><li class="level3">2.5–5&nbsp;mg daily shortly before breakfast or lunch, adjusted according to response. The&nbsp;maximum&nbsp;dose is 20&nbsp;mg daily. Doses of up to 15&nbsp;mg may be given as a single dose; higher&nbsp;doses should be divided.</li></ul><li class="level2">
            <b>Tolbutamide&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314759" href="/diabetes-type-2#!references/1090203">ABPI, 2016k</a>]
            <b>:&nbsp;</b>
		
		</li><ul><li class="level3">0.5–1.5&nbsp;g daily in divided doses (with, or immediately after, meals) or as a single dose (with, or immediately after, breakfast). The maximum dose is 2 g daily in divided doses.</li></ul></ul></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313633"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Contraindications and cautions</h3></header><ul><li class="level1">
            <b>Do not prescribe a sulfonylurea to people with:</b>

	
	</li><ul><li class="level2">Acute porphyria, although glipizide and glimepiride are thought to be safe and can be considered if absolutely necessary.</li><li class="level2">Ketoacidosis.</li><li class="level2">Severe renal impairment:
		
		</li><ul><li class="level3">Do not prescribe glipizide if the person has both renal and hepatic impairment.</li><li class="level3">If necessary, tolbutamide (which is short acting) and gliclazide (which is principally metabolized in the liver) can be used in renal impairment, but careful monitoring of blood-glucose concentration is essential and the lowest dose that adequately controls blood glucose should be used.</li></ul></ul><li class="level1">
            <b>Prescribe sulfonylureas with caution in:</b>
	
	</li><ul><li class="level2">People with severe hepatic impairment&nbsp;(due to the increased risk of hypoglycaemia)&nbsp;— reduce the dose of the sulfonylurea if treatment is absolutely necessary.</li><li class="level2">People with mild to moderate renal impairment (due to the risk of hypoglycaemia).</li><li class="level2">People who are obese — sulfonylureas can encourage weight gain and should be prescribed only if poor control and symptoms persist despite adequate attempts at dieting.</li><li class="level2">Elderly people — glibenclamide (a long-acting sulfonylurea) is associated with a greater risk of hypoglycaemia and should be avoided in elderly people; shorter-acting alternatives (such as gliclazide or tolbutamide) should be used instead.</li><li class="level2">People with G6PD deficiency.</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313636"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Adverse effects</h3></header><ul><li class="level1">
            <b>Adverse effects of sulfonylureas&nbsp;are generally mild and infrequent.</b>
          </li><li class="level1">
            <b>Gastro-intestinal disturbances,</b> such as nausea, vomiting, diarrhoea, and constipation, have been reported.&nbsp;</li><li class="level1">
            <b>Disturbance in liver function</b>&nbsp;can occasionally occur and may rarely lead to cholestatic jaundice, hepatitis, and hepatic failure.&nbsp;</li><li class="level1">
            <b>Hypersensitivity reactions</b> occur usually in the first 6–8 weeks of treatment and consist mainly of allergic skin reactions which progress rarely to erythema multiforme and exfoliative dermatitis, fever, and jaundice. Photosensitivity has rarely been reported with glipizide.&nbsp;</li><li class="level1">
            <b>Skin and subcutaneous tissue disorders</b> rarely occur, but may include rash, pruritus, urticaria, angioedema, erythema, maculopapular rashes, bullous reactions (such as Stevens-Johnson syndrome and toxic epidermal necrolysis).
	
	</li><ul><li class="level2">Exceptionally, drug rash with eosinophilia and systemic symptoms (DRESS).</li></ul><li class="level1">
            <b>Blood disorders</b> can rarely occur and&nbsp;may include leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, haemolytic anaemia, and aplastic anaemia.</li><li class="level1">
            <b>Hyponatraemia&nbsp;</b>has been reported with glimepiride and glipizide.</li><li class="level1">
            <b>Dizziness and drowsiness</b> may occur with glipizide.</li><li class="level1">
            <b>Headache and tinnitus</b> may occur with tolbutamide.</li></ul><p>
            [<a rel="citation" resource="1090203#A1314748" href="/diabetes-type-2#!references/1090203">ABPI, 2014b</a>; <a rel="citation" resource="1090203#A1314704" href="/diabetes-type-2#!references/1090203">ABPI, 2015b</a>; <a rel="citation" resource="1090203#A1314726" href="/diabetes-type-2#!references/1090203">ABPI, 2016i</a>; <a rel="citation" resource="1090203#A1403667" href="/diabetes-type-2#!references/1090203">ABPI, 2016c</a>; <a rel="citation" resource="1090203#A1314759" href="/diabetes-type-2#!references/1090203">ABPI, 2016k</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313640"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Drug interactions</h3></header><ul><li class="level1">
            <b>Drug interactions associated with&nbsp;sulfonylureas include:&nbsp;</b>
	
	</li><ul><li class="level2">
            <b>Aprepitant and fosaprepitant —</b>&nbsp;plasma concentration of tolbutamide may be reduced by these drugs.</li><li class="level2">
            <b>Beta-blockers —</b>&nbsp;the warning signs of hypoglycaemia (such as tremor) may be masked when a sulfonylurea is given with a beta-blocker.</li><li class="level2">
            <b>Bosentan —</b>&nbsp;increased risk of hepatotoxicity when glibenclamide is given with bosentan. Avoid concomitant use.</li><li class="level2">
            <b>Colesevelam —</b>&nbsp;the&nbsp;absorption of glibenclamide, glimepiride, and glipizide may be&nbsp;reduced by colesevelam.
		
		</li><ul><li class="level3">The manufacturer of glimepiride advises that it is taken at least 4 hours before colesevelam.&nbsp;</li><li class="level3">Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption</li></ul><li class="level2">
            <b>Fibrates —</b>&nbsp;there may be improved glucose tolerance and an additive effect when a sulfonylurea is given with a fibrate.</li><li class="level2">
            <b>Fluconazole —</b>&nbsp;the&nbsp;plasma concentration of sulfonylureas may be increased by fluconazole.</li><li class="level2">
            <b>Fluvastatin — </b>the&nbsp;plasma concentration of glibenclamide may be increased by fluvastatin.</li><li class="level2">
            <b>Lancreotide and octreotide —</b>&nbsp;the requirements for antidiabetic drugs may be reduced by these drugs.</li><li class="level2">
            <b>Norfloxacin —</b>&nbsp;the&nbsp;effects of glibenclamide may be enhanced by norfloxacin.</li><li class="level2">
            <b>Phenytoin and fosphenytoin&nbsp;—</b>&nbsp;tolbutamide transiently increases plasma concentration of these drugs (possibility of toxicity).</li><li class="level2">
            <b>Rifamycins — </b>the<b>&nbsp;</b>metabolism of sulfonylureas may be accelerated by rifamycins (reduced effect).</li><li class="level2">
            <b>Ritonavir&nbsp;—</b>&nbsp;the&nbsp;plasma concentration of tolbutamide may be increased by ritonavir.</li><li class="level2">
            <b>St John’s wort (<i>Hypericum perforatum</i>) </b>can cause poor blood glucose control when taken in combination with gliclazide. The manufacturer's Summary of Product Characteristics advises that in some cases, it may be necessary to administer insulin.</li><li class="level2">
            <b>Sulfinpyrazone&nbsp;—</b>&nbsp;the effects of sulfonylureas may be enhanced by sulfinpyrazone.</li><li class="level2">
            <b>Topiramate —</b>&nbsp;the&nbsp;plasma concentration of glibenclamide may be reduced by topiramate.</li><li class="level2">
            <b>Trimethoprim —</b>&nbsp;the&nbsp;effects of sulfonylureas may be enhanced by trimethoprim.</li><li class="level2">
            <b>Voriconazole and ketoconazole —</b>&nbsp;the&nbsp;plasma concentration of sulfonylureas may be increased by voriconazole, and plasma concentration of tolbutamide may be increased by ketoconazole.</li><li class="level2">
            <b>Other antidiabetic drugs —</b>&nbsp;the dose of the sufonylurea (and in some cases the concomitant antidiabetic drug) may need to be reduced to reduce the risk of hypoglycaemia.</li></ul><li class="level1">
            <b>In addition:</b>
	
	</li><ul><li class="level2">
            <b>The blood glucose-lowering effects of sulfonylureas may be enhanced by:&nbsp;</b>
		
		</li><ul><li class="level3">Alcohol.</li><li class="level3">Anabolic steroids.</li><li class="level3">Angiotensin-converting enzyme (ACE) inhibitors.</li><li class="level3">Chloramphenicol.</li><li class="level3">Cimetidine.</li><li class="level3">Coumarins.</li><li class="level3">Disopyramide (enhances hypoglycaemic effect of gliclazide).</li><li class="level3">Leflunomide (enhances hypoglycaemic effect of tolbutamide).</li><li class="level3">Monoamine oxidase inhibitors (MAOIs).</li><li class="level3">Miconazole (avoid&nbsp;concurrent&nbsp;use with gliclazide and glipizide).</li><li class="level3">Nonsteroidal anti-inflammatory drugs.</li><li class="level3">Posaconazole (enhances hypoglycaemic effect of glipizide).</li><li class="level3">Testosterone.&nbsp;</li><li class="level3">Tetracyclines.</li><li class="level3">Trimethoprim (rare).</li></ul><li class="level2">
            <b>The&nbsp;blood glucose-lowering effects&nbsp;of sulfonylureas may be antagonized by:&nbsp;</b>
		
		</li><ul><li class="level3">Corticosteroids.&nbsp;</li><li class="level3">Diuretics (thiazide and related, and loop).&nbsp;</li><li class="level3">Oestrogens and progestogens.</li><li class="level3">Phenothiazines.</li></ul></ul></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>; <a rel="citation" resource="1090203#A1403667" href="/diabetes-type-2#!references/1090203">ABPI, 2016c</a>]&nbsp;&nbsp;</p></section></section><section class="prescribinginfosub hidden" id="1313541"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Insulin</h2></header><ul><li class="level1">
          <b>For detailed information on prescribing insulin,&nbsp;</b>see the CKS topic on&nbsp;<a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>.</li></ul></section><section class="prescribinginfosub hidden" id="1313544"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Glucagon-like peptide 1 (GLP-1) mimetics</h2></header><section class="prescribinginfosub" id="1313891"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Mode of action</h3></header><ul><li class="level1">
            <b>Glucagon-like peptide 1 (GLP-1) mimetics&nbsp;</b>bind to, and activate, the GLP-1 receptor to increase insulin secretion, suppress glucagon secretion, and slow gastric emptying.&nbsp;</li><li class="level1">
            <b>There are currently three GLP-1 mimetics available in the UK: </b>exenatide, liraglutide, and lixisenatide.</li></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313894"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Recommended doses</h3></header><ul><li class="level1">
            <b>Glucagon-like peptide 1 (GLP-1) mimetics are self-administered by subcutaneous injection&nbsp;in the thigh, abdomen, or upper arm.</b>
          </li><li class="level1">
            <b>The recommended doses for treating diabetes in adults aged&nbsp;over&nbsp;18 years are:</b>
	
	</li><ul><li class="level2">
            <b>For exenatide&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314770" href="/diabetes-type-2#!references/1090203">ABPI, 2016l</a>]
            <b>&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314781" href="/diabetes-type-2#!references/1090203">ABPI, 2016m</a>]
            <b>:</b>
		
		</li><ul><li class="level3">
            <b>Standard-release formulation:</b> 5&nbsp;micrograms twice daily, increased if necessary after at least 1 month to a maximum dose of 10&nbsp;micrograms twice daily. It should be administered within 1 hour before 2 main meals (a least 6 hours apart). It should not be&nbsp;administered&nbsp;after a meal.</li><li class="level3">
            <b>Modified-release formulation:</b>&nbsp;2&nbsp;mg once weekly on the same day each week (at any time, with or without meals).&nbsp;The day of weekly administration can be changed if necessary as long as the next dose is administered at least one day (24 hours) later.&nbsp;</li></ul><li class="level2">
            <b>For liraglutide&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314792" href="/diabetes-type-2#!references/1090203">ABPI, 2016n</a>]
            <b>:&nbsp;</b>
		
		</li><ul><li class="level3">0.6&nbsp;mg once daily, increased after at least 1 week to 1.2&nbsp;mg once daily. This can be further increased if necessary after an interval of at least 1 week to a maximum dose of 1.8&nbsp;mg once daily.</li></ul><li class="level2">
            <b>For lixisenatide&nbsp;</b>
            [<a rel="citation" resource="1090203#A1314803" href="/diabetes-type-2#!references/1090203">ABPI, 2016o</a>]
            <b>:&nbsp;</b>
		
		</li><ul><li class="level3">10&nbsp;micrograms once daily within 1 hour before the first meal of the day or the evening meal for 14 days, increased to 20&nbsp;micrograms once daily thereafter.</li></ul></ul></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313898"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Initiating and monitoring treatment with glucagon-like peptide 1 mimetics</h3></header><ul><li class="level1">
            <b>The National Institute for Health and Care Excellence (NICE) recommends that combination treatment with&nbsp;metformin, a sulfonylurea, and a glucagon-like peptide 1 (GLP-1) mimetic&nbsp;should only be considered if</b>triple therapy with metformin and two other oral antidiabetic drugs is not effective, not tolerated, or contraindicated in adults with type&nbsp;2 diabetes who:
	
	</li><ul><li class="level2">Have a body mass index (BMI) of 35&nbsp;kg/m<sup>2</sup>&nbsp;or higher (adjust accordingly for people from black, Asian, and other minority ethnic groups) and specific psychological or other medical problems associated with obesity, <i>or</i></li><li class="level2">Have a BMI lower than 35&nbsp;kg/m<sup>2</sup>&nbsp;and:&nbsp;
		
		</li><ul><li class="level3">For whom insulin therapy would have significant occupational implications, <i>or</i></li><li class="level3">Weight loss would benefit other significant obesity-related comorbidities.&nbsp;</li></ul></ul><li class="level1">
            <b>After 6 months of treatment with a GLP-1 mimetic, </b>check the person's body weight and HbA1c level.
	
	</li><ul><li class="level2">Only continue treatment if the person has had a beneficial metabolic response (a reduction of at least 11&nbsp;mmol/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight).</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>]
          </p></section><section class="prescribinginfosub" id="1313900"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Contraindications and cautions</h3></header><ul><li class="level1">
            <b>Do not prescribe a&nbsp;glucagon-like peptide 1 (GLP-1) mimetic to people with:</b>
	
	</li><ul><li class="level2">Ketoacidosis.</li><li class="level2">Renal impairment:
		
		</li><ul><li class="level3">Avoid&nbsp;liraglutide, lixisenatide, or&nbsp;exenatide standard-release injection if estimated glomerular filtration rate (eGFR) is less than&nbsp;30&nbsp;mL/minute/1.73m<sup>2</sup> .</li><li class="level3">Avoid exenatide modified-release injection if eGFR is less than&nbsp;50&nbsp;mL/minute/1.73&nbsp;m<sup>2</sup>.</li></ul><li class="level2">Severe gastro-intestinal disease&nbsp;— avoid exenatide or lixisenatide.</li><li class="level2">Moderate to severe&nbsp;congestive heart failure&nbsp;— avoid&nbsp;liraglutide.</li><li class="level2">Hepatic impairment&nbsp;— avoid liraglutide.</li><li class="level2">Inflammatory bowel disease&nbsp;— avoid liraglutide.</li><li class="level2">Diabetic gastroparesis&nbsp;— avoid liraglutide.</li></ul><li class="level1">
            <b>Prescribe GLP-1 mimetics with caution in:</b>
	
	</li><ul><li class="level2">People with a history of pancreatitis&nbsp;—&nbsp;discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain) occur. See the section on<a href="/diabetes-type-2#!prescribinginfosub:33">adverse effects</a>for more information.</li><li class="level2">People with eGFR of 30–50&nbsp;mL/minute/1.73&nbsp;m<sup>2</sup>&nbsp;— use exenatide with caution.</li><li class="level2">Elderly people&nbsp;— use exenatide with caution.</li><li class="level2">Women of childbearing potential&nbsp;— advise that&nbsp;effective contraception should be used:
		
		</li><ul><li class="level3">During treatment with exenatide, or lixisenatide.</li><li class="level3">During&nbsp;treatment with&nbsp;modified-release exenatide injection,&nbsp;and continued for 12 weeks after discontinuation of treatment.</li></ul><li class="level2">People with mild congestive heart failure&nbsp;— use liraglutide with caution.</li><li class="level2">People with thyroid disease&nbsp;— use liraglutide with caution.</li><li class="level2">People with eGFR of 30–50&nbsp;mL/minute/1.73&nbsp;m<sup>2</sup>&nbsp;— use&nbsp;lixisenatide with caution.</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1314781" href="/diabetes-type-2#!references/1090203">ABPI, 2016m</a>; <a rel="citation" resource="1090203#A1314770" href="/diabetes-type-2#!references/1090203">ABPI, 2016l</a>; <a rel="citation" resource="1090203#A1314803" href="/diabetes-type-2#!references/1090203">ABPI, 2016o</a>; <a rel="citation" resource="1090203#A1314792" href="/diabetes-type-2#!references/1090203">ABPI, 2016n</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313917"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Adverse effects</h3></header><ul><li class="level1">
            <b>Acute pancreatitis is a rare but serious adverse effect of&nbsp;glucagon-like peptide 1 (GLP-1) mimetics.</b>
	
	</li><ul><li class="level2">Advise the person and/or their family/carers to seek prompt medical attention if symptoms such as persistent, severe abdominal pain; nausea; and/or vomiting develop.</li><li class="level2">Discontinue treatment if pancreatitis is suspected.</li></ul><li class="level1">
            <b>Gastrointestinal adverse effects</b> are common and include&nbsp;nausea, vomiting, dyspepsia, constipation, and&nbsp;gastro-oesophageal reflux disease (GORD).</li><li class="level1">
            <b>Hypoglycaemia</b> is common with certain drugs, such as other antidiabetic treatments.&nbsp;</li><li class="level1">
            <b>Headache, dizziness, drowsiness, and injection-site reactions,&nbsp;and skin reactions</b> (such as alopecia, rash, angioedema, urticaria, and pruritus) may occur.</li><li class="level1">
            <b>Dehydration</b>&nbsp;may occur with exenatide and liraglutide.</li><li class="level1">
            <b>Altered renal function </b>(including acute renal failure, worsened chronic renal failure, renal impairment, and increased serum creatinine) may occur with exenatide and liraglutide.</li><li class="level1">
            <b>Increased lipase and increased amylase </b>are&nbsp;common in people taking liraglutide.</li><li class="level1">
            <b>Increased heart rate</b> may occur with liraglutide and lixisenatide.</li><li class="level1">
            <b>Anaphylactic reactions</b> are rare and may occur with liraglutide and lixisenatide.</li><li class="level1">
            <b>Other adverse effects include:</b>
	
	</li><ul><li class="level2">
            <b>In addition for exenatide: </b>decreased appetite, weight loss, feeling jittery, asthenia, and anaphylactic reactions (rare).</li><li class="level2">
            <b>In addition for liraglutide: </b>bronchitis and nasopharyngitis, toothache, fatigue, and intestinal obstruction (rare).</li><li class="level2">
            <b>In addition for lixisenatide: </b>influenza, upper respiratory tract infection, cystitis, viral infection, back pain, and palpitations.</li><li class="level2">
            <b>Exenatide (Byetta®) and lixisenatide (Lyxumia®) are black triangle drugs </b>and&nbsp;are monitored intensively by the Medicines and Healthcare products Regulatory Agency (MHRA). All suspected adverse reactions associated with these (and other) drugs should be reported.</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1314792" href="/diabetes-type-2#!references/1090203">ABPI, 2016n</a>; <a rel="citation" resource="1090203#A1314770" href="/diabetes-type-2#!references/1090203">ABPI, 2016l</a>; <a rel="citation" resource="1090203#A1314803" href="/diabetes-type-2#!references/1090203">ABPI, 2016o</a>; <a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section><section class="prescribinginfosub" id="1313922"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Drug interactions</h3></header><ul><li class="level1">
            <b>Drug interactions associated with&nbsp;glucagon-like peptide 1 (GLP-1) mimetics&nbsp;include:</b>
	
	</li><ul><li class="level2">
            <b>Beta-blockers —</b>&nbsp;the warning signs of hypoglycaemia (such as tremor) may be masked during concurrent treatment with a beta-blocker.</li><li class="level2">
            <b>Lanreotide and octreotide — </b>the<b>&nbsp;</b>requirements for antidiabetic drugs may be reduced by these drugs.</li><li class="level2">
            <b>Paracetamol —</b>&nbsp;lixisenatide possibly reduces the absorption of paracetamol when given 1 to 4 hours before paracetamol.</li><li class="level2">
            <b>Warfarin&nbsp;—&nbsp;</b>exenatide and liraglutide possibly enhance the anticoagulant effect of warfarin. Monitor&nbsp;International Normalised Ratio (INR) during concurrent treatment with warfarin. Also consider monitoring INR&nbsp;at the time of initiation or stopping of lixisenatide treatment.</li><li class="level2">
            <b>Other orally&nbsp;administered&nbsp;drugs&nbsp;—</b> other orally administered drugs may need to be taken at least 1 hour before or 4 hours after lixisenatide<b>&nbsp;</b>or exenatide injection, or taken with a meal when lixisenatide is not administered, to minimize possible interference with absorption.</li><li class="level2">
            <b>Other antidiabetic drugs&nbsp;— </b>due to the increased risk of hypoglycaemia, the dose of&nbsp;concomitant sulfonylurea may need to be reduced during treatment with a GLP-1 mimetic.</li></ul><li class="level1">
            <b>In addition:</b>
	
	</li><ul><li class="level2">
            <b>The blood glucose-lowering effects of GLP-1 mimetics may be enhanced by:</b>
		
		</li><ul><li class="level3">Alcohol.</li><li class="level3">Anabolic steroids.</li><li class="level3">Disopyramide.</li><li class="level3">Monoamine oxidase inhibitors (MAOIs).</li><li class="level3">Testosterone.</li></ul><li class="level2">
            <b>The&nbsp;blood glucose-lowering effects&nbsp;of&nbsp;GLP-1 mimetics may be&nbsp;antagonized by:</b>
		
		</li><ul><li class="level3">Corticosteroids.</li><li class="level3">Diuretics (thiazide and related, and loop).</li><li class="level3">Oestrogens and progestogens.</li></ul></ul></ul><p>
            [<a rel="citation" resource="1090203#A1307230" href="/diabetes-type-2#!references/1090203">BNF 71, 2016</a>]
          </p></section></section><section class="prescribinginfosub hidden" id="1422721"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) </h2></header><section class="prescribinginfosub" id="1422724"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Mode of action</h3></header><p>The three Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are canagliflozin, dapagliflozin, and empagliflozin. These medications reversibly inhibit sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.</p><p>
            [<a rel="citation" resource="1090203#A1422767" href="/diabetes-type-2#!references/1090203">ABPI, 2017b</a>; <a rel="citation" resource="1090203#A1422756" href="/diabetes-type-2#!references/1090203">ABPI, 2017c</a>; <a rel="citation" resource="1090203#A1422746" href="/diabetes-type-2#!references/1090203">ABPI, 2017d</a>; <a rel="citation" resource="1090203#A1415960" href="/diabetes-type-2#!references/1090203">BNF 73, 2017</a>]
          </p></section><section class="prescribinginfosub" id="1422728"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Recommended doses</h3></header><p>Canagliflozin, dapagliflozin, and empagliflozin are licensed for use in type 2 diabetes as monotherapy (if metformin inappropriate), or in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control). Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea.</p><ul><li class="level1">
            <b>Canagliflozin</b>

	
	</li><ul><li class="level2">The recommended starting dose of canagliflozin is 100 mg once daily. In patients tolerating canagliflozin 100 mg once daily who have an eGFR ≥ 60 mL/min/1.73 m2 or CrCl ≥ 60 mL/min and need tighter glycaemic control, the dose can be increased to 300 mg once daily orally.</li></ul><li class="level1">
            <b>Dapagliflozin</b>
	
	</li><ul><li class="level2">The recommended dose is 10 mg dapagliflozin once daily for monotherapy and add-on combination therapy with other glucose-lowering medicinal products including insulin. When dapagliflozin is used in combination with insulin or an insulin secretagogue, such as a sulfonylurea, a lower dose of insulin or insulin secretagogue may be considered to reduce the risk of hypoglycaemia.</li></ul><li class="level1">
            <b>Empagliflozin</b>
	
	</li><ul><li class="level2">The recommended starting dose is 10 mg empagliflozin once daily for monotherapy and add-on combination therapy with other medicinal products for the treatment of diabetes. In patients tolerating empagliflozin 10 mg once daily who have an eGFR ≥60 ml/min/1.73 m2 and need tighter glycaemic control, the dose can be increased to 25 mg once daily. The maximum daily dose is 25 mg.&nbsp;</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1422767" href="/diabetes-type-2#!references/1090203">ABPI, 2017b</a>; <a rel="citation" resource="1090203#A1422756" href="/diabetes-type-2#!references/1090203">ABPI, 2017c</a>; <a rel="citation" resource="1090203#A1422746" href="/diabetes-type-2#!references/1090203">ABPI, 2017d</a>; <a rel="citation" resource="1090203#A1415960" href="/diabetes-type-2#!references/1090203">BNF 73, 2017</a>]
          </p></section><section class="prescribinginfosub" id="1422730"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Contraindications and cautions</h3></header><ul><li class="level1">Serious and potentially life-threatening cases of diabetic ketoacidosis (DKA) have been reported in patients taking SGLT2 inhibitors canagliflozin, dapagliflozin or empagliflozin for type 2 diabetes. The European Medicines Agency has issued the following advice to minimise the risk of such effects when treating patients with a SGLT2 inhibitor:
	
	</li><ul><li class="level2">Test for raised ketones in patients presenting with symptoms of DKA, even if plasma glucose levels are near-normal; omitting this test could delay a diagnosis of DKA.</li><li class="level2">Discontinue treatment if DKA is suspected.</li><li class="level2">If DKA is confirmed, take appropriate measures to correct the DKA and monitor glucose levels.</li><li class="level2">Patients should be advised on how to recognise the signs and symptoms of DKA such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness, and to seek prompt medical attention if symptoms of DKA develop.</li></ul></ul><p>
            <b>Renal impairment</b>
          </p><ul><li class="level1">SGLT2i are not recommended for use in patients with moderate to severe renal impairment (patients with creatinine clearance [CrCl] &lt; 60 ml/min or estimated glomerular filtration rate [eGFR] &lt; 60 ml/min/1.73 m2.</li><li class="level1">No dosage adjustment is indicated in patients with mild renal impairment.</li></ul><p>
            <b>Hepatic impairment</b>
          </p><ul><li class="level1">No dosage adjustment is necessary for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, a smaller starting dose is recommended. If well tolerated, the dose may be increased.</li><li class="level1">Elderly (≥ 65 years)</li><li class="level1">In general, no dosage adjustment is recommended based on age. Renal function and risk of volume depletion should be taken into account. Due to the limited therapeutic experience in patients 75 years and older, initiation of SGLT-2i therapy is not recommended.</li></ul><p>
            <b>Increased risk of volume depletion</b>
          </p><ul><li class="level1">Based on the mode of action of SGLT-2 inhibitors, osmotic diuresis accompanying therapeutic glycosuria may lead to a modest decrease in blood pressure. Therefore, caution should be exercised in patients for whom a drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients on anti-hypertensive therapy with a history of hypotension or patients aged 75 years and older.</li><li class="level1">In case of conditions that may lead to fluid loss (e.g. gastrointestinal illness), careful monitoring of volume status (e.g. physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended for patients receiving SGLT-2i medication. Temporary interruption of treatment should be considered until the fluid loss is corrected.</li></ul><p>
            <b>Lactose intolerance</b>
          </p><ul><li class="level1">The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.</li></ul><p>
            <b>Canagliflozin:</b>
          </p><ul><li class="level1">A signal of increased lower limb amputation (mostly affecting toes) has been reported in patients taking canagliflozin in an ongoing clinical trial in high cardiovascular risk patients. The MHRA has issued the following advice while this report is under investigation:
	
	</li><ul><li class="level2">Consider stopping canagliflozin if a patient develops a significant lower limb complication (e.g. skin ulcer, osteomyelitis, or gangrene), at least until the condition has resolved, and continue to monitor the patient closely;</li><li class="level2">Carefully monitor patients who have risk factors for amputation (e.g. previous amputations, existing peripheral vascular disease, or neuropathy);</li><li class="level2">Monitor all patients for signs and symptoms of water or salt loss; ensure patients stay sufficiently hydrated to prevent volume depletion in line with the manufacturer's recommendations;</li><li class="level2">Advise patients to stay well hydrated, carry out routine preventive foot care, and seek medical advice promptly if they develop skin ulceration, discolouration, or new pain or tenderness;</li><li class="level2">Start treatment for foot problems (e.g. ulceration, infection, or new pain or tenderness) as early as possible;</li><li class="level2">Continue to follow standard treatment guidelines for routine preventive foot care for people with diabetes.</li></ul></ul><p>
            [<a rel="citation" resource="1090203#A1422767" href="/diabetes-type-2#!references/1090203">ABPI, 2017b</a>; <a rel="citation" resource="1090203#A1422756" href="/diabetes-type-2#!references/1090203">ABPI, 2017c</a>; <a rel="citation" resource="1090203#A1422746" href="/diabetes-type-2#!references/1090203">ABPI, 2017d</a>; <a rel="citation" resource="1090203#A1415960" href="/diabetes-type-2#!references/1090203">BNF 73, 2017</a>]
          </p></section><section class="prescribinginfosub" id="1422733"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Adverse effects</h3></header><ul><li class="level1">Vulvovaginitis, balanitis, urinary tract infection</li><li class="level1">Hypoglycaemia</li><li class="level1">Pruritus</li><li class="level1">Frequency of micturition</li><li class="level1">Raised serum lipids</li><li class="level1">Haematocrit raised</li><li class="level1">Fournier’s gangrene. Patients should seek immediate medical attention if they have symptoms of tenderness/redness/swelling of genitals or area from genitals back to rectum, and fever &gt;100.4 F</li></ul><p>
            [<a rel="citation" resource="1090203#A1422767" href="/diabetes-type-2#!references/1090203">ABPI, 2017b</a>; <a rel="citation" resource="1090203#A1422756" href="/diabetes-type-2#!references/1090203">ABPI, 2017c</a>; <a rel="citation" resource="1090203#A1422746" href="/diabetes-type-2#!references/1090203">ABPI, 2017d</a>; <a rel="citation" resource="1090203#A1415960" href="/diabetes-type-2#!references/1090203">BNF 73, 2017</a>]
          </p></section><section class="prescribinginfosub" id="1422739"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h3>Drug interactions</h3></header><p>
            <b>Thiazide and loop diuretics </b>
          </p><ul><li class="level1">Add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension.</li></ul><p>
            <b>Insulin and insulin secretagogues</b>
          </p><ul><li class="level1">Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with dapagliflozin. NICE recommend that dapagliflozin is not prescribed in combination with pioglitazone.</li></ul><p>
            <b>Enzyme inducers</b>
          </p><ul><li class="level1">Enzyme inducers (such as St. John's wort [Hypericum perforatum], rifampicin, barbiturates, phenytoin, carbamazepine, ritonavir, efavirenz) may decrease the efficacy of canagliflozin.</li></ul><p>
            <b>Digoxin</b>
          </p><ul><li class="level1">Patients taking digoxin or other cardiac glycosides (e.g., digitoxin) should be monitored appropriately as a increases in digoxin toxicity are possible. &nbsp;</li></ul><p>
            <b>Dabigatran</b>
          </p><ul><li class="level1">As dabigatran concentrations may be increased in the presence of canagliflozin, monitoring (looking for signs of bleeding or anaemia) should be exercised when dabigatran is combined with canagliflozin.</li></ul><p>
            <b>Cholestyramine</b>
          </p><ul><li class="level1">Cholestyramine may potentially reduce canagliflozin exposure. Dosing of canagliflozin should occur at least 1 hour before or 4-6 hours after administration of a bile acid sequestrant to minimize possible interference with their absorption.</li></ul><p>
            [<a rel="citation" resource="1090203#A1422767" href="/diabetes-type-2#!references/1090203">ABPI, 2017b</a>; <a rel="citation" resource="1090203#A1422756" href="/diabetes-type-2#!references/1090203">ABPI, 2017c</a>; <a rel="citation" resource="1090203#A1422746" href="/diabetes-type-2#!references/1090203">ABPI, 2017d</a>; <a rel="citation" resource="1090203#A1415960" href="/diabetes-type-2#!references/1090203">BNF 73, 2017</a>]
          </p></section></section><section class="prescribinginfosub hidden" id="1313547"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Antihypertensive drugs</h2></header><ul><li class="level1">
          <b>For detailed information on prescribing angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists, calcium-channel blockers, diuretics, beta-blockers, and alpha-blockers, </b>see the section on 'Prescribing information' in the CKS topic on&nbsp;<a href="/hypertension-not-diabetic">Hypertension - not diabetic</a>.</li></ul></section><section class="prescribinginfosub hidden" id="1313550"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Atorvastatin</h2></header><ul><li class="level1">
          <b>For detailed information on prescribing atorvastatin, </b>see the section on 'Prescribing information' in the CKS topic on&nbsp;<a href="/lipid-modification-cvd-prevention">Lipid modification - CVD prevention</a>.</li></ul></section><section class="searchstrategyforpublication hidden" id="1453633"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Search strategy</h2></header><h5>Scope of search</h5><p>A literature search was conducted for guidelines, systematic reviews and randomized controlled trials on primary care management of diabetes - type 2.</p><h5>Search dates</h5><p>June 2009 - May 2016</p><h5>Key search terms</h5><p>Various combinations of searches were carried out. The terms listed below are the core search terms that were used for Medline.</p><ul><li class="level1">diabetes type 2".ti,ab exp DIABETES MELLITUS TYPE 2/</li><li class="level1">(diabetes adj2 "type 2").ti,ab Diabetes AND "type 2"&nbsp;</li><li class="level1">(MH "Diabetes Mellitus, Type 2+")&nbsp;</li></ul><h5>Sources of guidelines</h5><ul><li class="level1"><a href="http://www.nice.org.uk/">National Institute for Health and Care Excellence (NICE)</a></li><li class="level1"><a href="http://www.sign.ac.uk/">Scottish Intercollegiate Guidelines Network (SIGN)</a></li><li class="level1"><a href="http://www.rcplondon.ac.uk/">Royal College of Physicians</a></li><li class="level1"><a href="http://www.rcgp.org.uk/">Royal College of General Practitioners</a></li><li class="level1"><a href="http://www.rcn.org.uk/development/practice/clinicalguidelines">Royal College of Nursing</a></li><li class="level1"><a href="https://www.evidence.nhs.uk/topics/">NICE Evidence</a></li><li class="level1"><a href="http://www.hpa.org.uk/">Health Protection Agency</a></li><li class="level1"><a href="http://www.who.int/">World Health Organization</a></li><li class="level1"><a href="http://www.guideline.gov/">National Guidelines Clearinghouse</a></li><li class="level1"><a href="http://www.g-i-n.net/">Guidelines International Network</a></li><li class="level1"><a href="http://www.tripdatabase.com/">TRIP database</a></li><li class="level1"><a href="http://www.gain-ni.org/index.php/audits/guidelines">GAIN</a></li><li class="level1"><a href="http://www.pathways.scot.nhs.uk/">NHS Scotland National Patient Pathways</a></li><li class="level1"><a href="http://www.nzgg.org.nz/">New Zealand Guidelines Group</a></li><li class="level1"><a href="http://www.ahrq.gov/">Agency for Healthcare Research and Quality</a></li><li class="level1"><a href="http://www.icsi.org/">Institute for Clinical Systems Improvement</a></li><li class="level1"><a href="http://www.nhmrc.gov.au/publications/index.htm">National Health and Medical Research Council (Australia)</a></li><li class="level1"><a href="http://www.racgp.org.au/your-practice/guidelines/">Royal Australian College of General Practitioners</a></li><li class="level1"><a href="http://www.health.gov.bc.ca/gpac/index.html">British Columbia Medical Association</a></li><li class="level1"><a href="http://www.cma.ca/index.php/ci_id/54316/la_id/1.htm">Canadian Medical Association</a></li><li class="level1"><a href="http://www.topalbertadoctors.org/cpgs.php">Alberta Medical Association</a></li><li class="level1"><a href="http://ocpd.med.umich.edu/cme/self-study/">University of Michigan Medical School</a></li><li class="level1"><a href="http://mqic.org/guidelines.htm">Michigan Quality Improvement Consortium</a></li><li class="level1"><a href="http://www.moh.gov.sg/content/moh_web/home/Publications/guidelines/cpg.html">Singapore Ministry of Health</a></li><li class="level1"><a href="http://www.nric.org.uk/">National Resource for Infection Control</a></li><li class="level1"><a href="http://www.patient.co.uk/guidelines.asp">Patient UK Guideline links</a></li><li class="level1"><a href="http://www2.warwick.ac.uk/fac/med/research/hsri/emergencycare/jrcalc_2006/guidelines/">UK Ambulance Service Clinical Practice Guidelines</a></li><li class="level1"><a href="http://www.refhelp.scot.nhs.uk/index.php?option=com_content&amp;task=view&amp;id=490&amp;Itemid=104">RefHELP NHS Lothian Referral Guidelines</a></li><li class="level1">Medline (with guideline filter)</li><li class="level1"><a href="http://www.dft.gov.uk/dvla/medical/ataglance.aspx">Driver and Vehicle Licensing Agency</a></li><li class="level1"><a href="http://www.nhshealthatwork.co.uk/oh-guidelines.asp">NHS Health at Work</a>(occupational health practice)</li></ul><h5>Sources of systematic reviews and meta-analyses</h5><ul><li class="level1"><a href="http://www.thecochranelibrary.com/">The Cochrane Library</a>:

    

    </li><ul><li class="level2">Systematic reviews</li><li class="level2">Protocols</li><li class="level2">Database of Abstracts of Reviews of Effects</li></ul><li class="level1">Medline (with systematic review filter)</li><li class="level1">EMBASE (with systematic review filter)</li></ul><h5>Sources of health technology assessments and economic appraisals</h5><ul><li class="level1"><a href="http://www.hta.ac.uk/">NIHR Health Technology Assessment programme</a></li><li class="level1"><a href="http://www.thecochranelibrary.com/">The Cochrane Library</a>:

    

    </li><ul><li class="level2">NHS Economic Evaluations</li><li class="level2">Health Technology Assessments</li></ul><li class="level1"><a href="http://www.cadth.ca/">Canadian Agency for Drugs and Technologies in Health</a></li><li class="level1"><a href="http://www.inahta.org/">International Network of Agencies for Health Technology Assessment</a></li></ul><h5>Sources of randomized controlled trials</h5><ul><li class="level1"><a href="http://www.thecochranelibrary.com/">The Cochrane Library</a>:

    

    </li><ul><li class="level2">Central Register of Controlled Trials</li></ul><li class="level1">Medline (with randomized controlled trial filter)</li><li class="level1">EMBASE (with randomized controlled trial filter)</li></ul><h5>Sources of evidence based reviews and evidence summaries</h5><ul><li class="level1"><a href="http://www.medicine.ox.ac.uk/bandolier/">Bandolier</a></li><li class="level1"><a href="http://dtb.bmj.com/"> Drug &amp; amp; Therapeutics Bulletin</a></li><li class="level1"><a href="http://www.tripdatabase.com/"> TRIP database</a></li><li class="level1"><a href="http://www.medicinesni.com/courses/type.asp?ID=CN"> Central Services Agency COMPASS Therapeutic Notes</a></li></ul><h5>Sources of national policy</h5><ul><li class="level1"><a href="http://www.dh.gov.uk/">Department of Health</a></li><li class="level1">Health Management Information Consortium(HMIC)</li></ul><h5>Patient experiences</h5><ul><li class="level1"><a href="http://www.healthtalkonline.org/">Healthtalkonline</a></li><li class="level1"><a href="http://www.bmj.com/bmj-series/patient-journeys"> BMJ - Patient Journeys</a></li><li class="level1"><a href="http://www.patient.co.uk/selfhelp.asp"> Patient.co.uk - Patient Support Groups</a></li></ul><h5>Sources of medicines information</h5><p>The following sources are used by CKS pharmacists and are not necessarily searched by CKS information specialists for all topics. Some of these resources are not freely available and require subscriptions to access content.</p><ul><li class="level1"><a href="http://www.evidence.nhs.uk/formulary/bnf/current">British National Formulary</a>(BNF)</li><li class="level1"><a href="http://www.medicines.org.uk/">electronic Medicines Compendium</a>(eMC)</li><li class="level1"><a href="http://www.ema.europa.eu/ema/">European Medicines Agency</a>(EMEA)</li><li class="level1"><a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT">LactMed</a></li><li class="level1"><a href="http://www.mhra.gov.uk/index.htm">Medicines and Healthcare products Regulatory Agency</a>(MHRA)</li><li class="level1"><a href="http://www.reprotox.org/Default.aspx">REPROTOX</a></li><li class="level1"><a href="http://www.scottishmedicines.org.uk/Home">Scottish Medicines Consortium</a></li><li class="level1"><a href="https://www.medicinescomplete.com/mc/stockley/current/login.htm?uri=http%3A%2F%2Fwww.medicinescomplete.com%2Fmc%2Fstockley%2Fcurrent%2F">Stockley's Drug Interactions</a></li><li class="level1"><a href="http://depts.washington.edu/terisweb/teris/">TERIS</a></li><li class="level1"><a href="http://www.toxbase.org/">TOXBASE</a></li><li class="level1"><a href="http://www.micromedex.com/products/hcs/">Micromedex</a></li><li class="level1"><a href="http://www.ukmi.nhs.uk/">UK Medicines Information</a></li></ul></section><section class="stakeholderengagement hidden" id="1462332"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Stakeholder engagement</h2></header><h5>Our policy</h5><p>The external review process is an essential part of CKS topic development. Consultation with a wide range of stakeholders provides quality assurance of the topic in terms of:</p><ul><li class="level1">Clinical accuracy.</li><li class="level1">Consistency with other providers of clinical knowledge for primary care.</li><li class="level1">Accuracy of implementation of national guidance (in particular NICE guidelines).</li><li class="level1">Usability.</li></ul><h5>Principles of the consultation process</h5><ul><li class="level1">The process is inclusive and any individual may participate.</li><li class="level1">To participate, an individual must declare whether they have any competing interests or not. If they do not declare whether or not they have competing interests, their comments will not be considered.</li><li class="level1">Comments received after the deadline will be considered, but they may not be acted upon before the clinical topic is issued onto the website.</li><li class="level1">Comments are accepted in any format that is convenient to the reviewer, although an electronic format is encouraged.</li><li class="level1">External reviewers are not paid for commenting on the draft topics.</li><li class="level1">Discussion with an individual or an organization about the CKS&nbsp;response to their comments is only undertaken in exceptional circumstances (at the discretion of the Clinical Editor or Editorial Steering Group).</li><li class="level1">All reviewers are thanked and offered a letter acknowledging their contribution for the purposes of appraisal/revalidation.</li><li class="level1">All reviewers are invited to be acknowledged on the website.All reviewers are given the opportunity to feedback about the external review process, enabling improvements to be made where appropriate.</li></ul><h5>Stakeholders</h5><ul><li class="level1">Key stakeholders identified by the CKS team are invited to comment on draft CKS topics. Individuals and organizations can also register an interest to feedback on a specific topic, or topics in a particular clinical area, through the <a href="http://cks.clarity.co.uk/get-involved/">Getting involved</a> section of the <a href="https://clarity.co.uk/">Clarity Informatics</a> website.</li><li class="level1">Stakeholders identified from the following groups are invited to review draft topics:
	
	</li><ul><li class="level2">Experts in the topic area.</li><li class="level2">Professional organizations and societies(for example, Royal Colleges).</li><li class="level2">Patient organizations, Clarity has established close links with groups such as Age UK and the Alzheimer’s Society specifically for their input into new topic development, review of current topic content and advice on relevant areas of expert knowledge.</li><li class="level2">Guideline development groups where the topic is an implementation of a guideline.</li><li class="level2">The British National Formulary team.</li><li class="level2">The editorial team that develop MeReC Publications.</li></ul><li class="level1">Reviewers are provided with clear instructions about what to review, what comments are particularly helpful, how to submit comments, and declaring interests.</li></ul><h5>Patient engagement</h5><p>Clarity Informatics has enlisted the support and involvement of patients and lay persons at all stages in the process of creating the content which include:</p><ul><li class="level1">Topic selection</li><li class="level1">Scoping of topic</li><li class="level1">Selection of clinical scenarios</li><li class="level1">First draft internal review</li><li class="level1">Second draft internal review</li><li class="level1">External review</li><li class="level1">Final draft and pre-publication</li></ul><p>Our lay and patient involvement includes membership on the editorial steering group, contacting expert patient groups, organizations and individuals.</p></section><section class="evidenceexclusioncriteria hidden" id="1466492"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Evidence exclusion criteria</h2></header><h5>Our policy</h5><p>Scoping a literature search, and reviewing the evidence for CKS is a methodical and systematic process that is carried out by the lead clinical author for each topic. Relevant evidence is gathered in order that the clinical author can make fully informed decisions and recommendations. It is important to note that some evidence may be excluded for a variety of reasons. These reasons may be applied across all CKS topics or may be specific to a given topic.</p><p>Studies identified during literature searches are reviewed to identify the most appropriate information to author a CKS topic, ensuring any recommendations are based on the best evidence. We use the principles of the GRADE and PICOT approaches to assess the quality of published research. We use the principles of AGREE II to assess the quality of published guidelines.</p><h5>Standard exclusions for scoping literature:</h5><ul><li class="level1">Animal studies</li><li class="level1">Original research is not written in English</li></ul><h5>Possible exclusions for reviewed literature:</h5><ul><li class="level1">Sample size too small or study underpowered</li><li class="level1">Bias evident or promotional literature</li><li class="level1">Population not relevant</li><li class="level1">Intervention/treatment not relevant</li><li class="level1">Outcomes not relevant</li><li class="level1">Outcomes have no clear evidence of clinical effectiveness</li><li class="level1">Setting not relevant</li><li class="level1">Not relevant to UK</li><li class="level1">Incorrect study type</li><li class="level1">Review article</li><li class="level1">Duplicate reference</li></ul></section><section class="organizationalbarriers hidden" id="1469484"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Organizational, behavioural and financial barriers</h2></header><h5>Our policy</h5><p>The CKS&nbsp;literature searches take into consideration the following concepts, which are discussed at the initial scoping of the topic.</p><ul><li class="level1">Feasibility
	
	</li><ul><li class="level2">Studies are selected depending on whether the intervention under investigation is available in the NHS and can be practically and safely undertaken in primary care.</li></ul><li class="level1">Organizational and Financial Impact Analysis</li><li class="level1">Studies are selected and evaluated on whether the intervention under investigations may have an impact on local clinical service provision or national impact on cost for the NHS. The principles of clinical budget impact analysis are adhered to, evaluated and recorded by the author. The following factors are considered when making this assessment and analysis.
	
	</li><ul><li class="level2">Eligible population</li><li class="level2">Current interventions</li><li class="level2">Likely uptake of new intervention or recommendation</li><li class="level2">Cost of the current or new intervention mix</li><li class="level2">Impact on other costs</li><li class="level2">Condition-related costs</li><li class="level2">In-direct costs and service impacts</li><li class="level2">Time dependencies</li></ul><li class="level1">Cost-effectiveness or cost-benefit analysis studies are identified where available.&nbsp;</li></ul><p>We also evaluate and include evidence from NICE accredited sources which provide economic evaluations of recommendations, such as NICE guidelines.&nbsp;When a recommended action may not be possible because of resource constraints, this is explicitly indicated to healthcare professionals by the wording of the CKS recommendation.</p></section><section class="declarationsofinterest hidden" id="1471820"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Declarations of interest</h2></header><h5>Our policy</h5><p>Clarity Informatics requests that all those involved in the writing and reviewing of topics, and those involved in the external review process to declare any competing interests. Signed copies are securely held by Clarity Informatics and are available on request with the permission of the individual. A copy of the declaration of interest form which participants are asked to complete annually is also available on request. A brief outline of the declarations of interest policy is described here and full details of the policy is available on the <a href="https://cks.clarity.co.uk/">Clarity Informatics website</a>. Declarations of interests of the authors are not routinely published, however competing interests of all those involved in the topic update or development are listed below. Competing interests include:</p><ul><li class="level1">Personal financial interests</li><li class="level1">Personal family interest</li><li class="level1">Personal non-financial interest</li><li class="level1">Non-personal financial gain or benefit</li></ul><p>Although particular attention is given to interests that could result in financial gains or losses for the individual, competing interests may also arise from academic competition or for political, personal, religious, and reputational reasons.An individual is not obliged to seek out knowledge of work done for, or on behalf of, the healthcare industry within the departments for which they are responsible if they would not normally expect to be informed.</p><h5>Who should declare competing interests?</h5><p>Any individual (or organization) involved in developing, reviewing, or commenting on clinical content, particularly the recommendations should declare competing interests. This includes the authoring team members, expert advisers, external reviewers of draft topics, individuals providing feedback on published topics, and Editorial Steering Group members. Declarations of interest are completed annually for authoring team and editorial steering group members, and are completed at the start of the topic update and development process for external stakeholders.</p><h5>Competing interests declared for this topic:</h5><p>None.</p></section><section class="topicsummary hidden" property="review" typeof="Review"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Summary: Diabetes - type 2</h2></header><ul><li class="level1">Diabetes mellitus is a group of metabolic disorders characterized by persistent hyperglycaemia (HbA1c more than 48 mmol/mol [6.5%] or random plasma glucose more than 11 mmol/L).</li><li class="level1">Type 2 diabetes is caused by a combination of insulin resistance (where the body is unable to respond to normal levels of insulin) and insulin deficiency (where the pancreas is unable to secrete enough insulin to compensate for this resistance).&nbsp;</li><li class="level1">Type 2 diabetes is the most common form of diabetes, accounting for about 90% of cases. It can occur in all ages and is increasingly being diagnosed in children.</li><li class="level1">Risk factors for type 2 diabetes include obesity, lack of physical activity, a history of gestational diabetes, and treatment with certain drugs (such as thiazide diuretics and corticosteroids).</li><li class="level1">Complications of type 2 diabetes include:</li><ul><li class="level2">Microvascular complications — retinopathy, nephropathy, and neuropathy.&nbsp;</li><li class="level2">Macrovascular complications — cardiovascular disease (CVD), cerebrovascular disease, and peripheral arterial disease (PAD).&nbsp;</li><li class="level2">Metabolic complications — dyslipidaemia and&nbsp;diabetic ketoacidosis (DKA, uncommon).&nbsp;</li><li class="level2">Psychological complications — including anxiety and depression.</li><li class="level2">Reduced quality of life.&nbsp;</li><li class="level2">Reduced life expectancy.</li></ul><li class="level1">Type 2 diabetes is likely in a person who presents with:</li><ul><li class="level2">Hyperglycaemia&nbsp;— the characteristic features (thirst, polyuria, blurred vision, weight loss, recurrent infections, and tiredness) are not usually severe and may be absent.</li><li class="level2">Risk factor(s) for type 2 diabetes.</li><li class="level2">Evidence of insulin resistance (for example acanthosis nigricans).</li><li class="level2">No additional features of type 1 diabetes (such as rapid onset, often in childhood, insulin dependence, or ketoacidosis).</li><li class="level2">No features of monogenic diabetes or diabetes secondary to a pathological condition or disease, drug treatment, trauma, or pancreatic surgery.</li></ul><li class="level1">In adults, the diagnosis of type 2 diabetes is usually confirmed by a serum&nbsp;HbA1c of 48 mmol/mol (6.5%) or more. Children and young people with suspected type 2 diabetes should be&nbsp;referred&nbsp;immediately (on the same day) to a multidisciplinary paediatric diabetes care team with the competencies needed to confirm the diagnosis and provide immediate care.&nbsp;</li><li class="level1">Lifestyle interventions (such as diet and physical activity) are initially used to manage type 2 diabetes. However, over time, many people will require antidiabetic drug treatments (including insulin).&nbsp;</li><li class="level1">Primary care management of people with type 2 diabetes includes:&nbsp;</li><ul><li class="level2">Providing appropriate care, education, and support for the person and/or their family/carers from diagnosis onwards.&nbsp;</li><li class="level2">Managing adverse effects of antidiabetic drug treatments, such as hypoglycaemia.&nbsp;</li><li class="level2">Managing the person during a period of illness.</li><li class="level2">Identifying and managing acute complications of diabetes, such as dyslipidaemia.&nbsp;</li><li class="level2">Minimizing the risk of, and screening for, long-term complications of type 2 diabetes, such as CVD, retinopathy, neuropathy, and nephropathy.&nbsp;</li></ul></ul><ul class="sub-sections hidden"></ul></section><section class="righttopic hidden" id="-350355"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Have I got the right topic?</h2></header><p class="age">Age from 12 months onwards</p><p>This CKS topic is largely based on the National Institute for Health and Care Excellence (NICE) guidelines&nbsp;<i>Type 2 diabetes in adults: management&nbsp;</i>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015</a>]&nbsp;and<i>&nbsp;Diabetes (type 1 and type 2) in children and young people: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].</p><p>This CKS topic covers the role of primary care in the diagnosis and management of type 2 diabetes.</p><p>This CKS topic does not cover the prescribing of insulin or the management of women with type 2 diabetes who are pregnant, planning a pregnancy, or breastfeeding.&nbsp;It also does not cover the diagnosis and management of impaired glucose regulation, or make detailed recommendations on the diagnosis and management of other types of diabetes.</p><p>There are separate CKS topics on <a href="/diabetes-type-1">Diabetes - type 1</a>&nbsp;<a href="/insulin-therapy-in-type-1-diabetes">Insulin therapy in type 1 diabetes</a>&nbsp;and&nbsp;<a href="/insulin-therapy-in-type-2-diabetes">Insulin therapy in type 2 diabetes</a>.</p><p>The target audience for this CKS topic is healthcare professionals working within the NHS in the UK, and providing first contact or primary healthcare.</p><ul class="sub-sections hidden"></ul></section><section class="uptodate hidden" id="-350353"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>How up-to-date is this topic?</h2></header><ul class="sub-sections"><li><a href="#!changes">Changes</a></li><li><a href="#!annual_know_upd">Update</a></li></ul></section><section class="goalsoutcomes hidden" id="-350389"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Goals and outcome measures</h2></header><ul class="sub-sections"><li><a href="#!goals">Goals</a></li><li><a href="#!outcomemeasures">Outcome measures</a></li><li><a href="#!cksauditcriteria">Audit criteria</a></li><li><a href="#!cksgmsquality">QOF indicators</a></li><li><a href="#!qipp">QIPP - Options for local implementation</a></li><li><a href="#!nicequalitystandards">NICE quality standards</a></li></ul></section><section class="background hidden" id="-350394"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Background information</h2></header><ul class="sub-sections"><li><a href="#!backgroundsub">Definition</a></li><li><a href="#!backgroundsub:1">Causes</a></li><li><a href="#!backgroundsub:2">Risk factors</a></li><li><a href="#!backgroundsub:3">Incidence and prevalence</a></li><li><a href="#!backgroundsub:4">Prognosis</a></li><li><a href="#!backgroundsub:5">Complications</a></li></ul></section><section class="diagnosis hidden" id="-489247"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Diagnosis</h2></header><ul class="sub-sections"><li><a href="#!diagnosissub">Diagnosis - adults</a></li><li><a href="#!diagnosissub:1">Diagnosis - children and young people</a></li><li><a href="#!diagnosissub:2">When to suspect diabetic ketoacidosis</a></li><li><a href="#!diagnosissub:3">When to suspect hypoglycaemia</a></li></ul></section><section class="management hidden" id="-350367"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Management</h2></header><ul><li class="level1"><b><a href="/diabetes-type-2#!scenario">Scenario: Management - adults</a>:&nbsp;</b>covers the primary care management of adults with type 2 diabetes.</li><li class="level1"><b><a href="/diabetes-type-2#!scenario:1">Scenario: Management - children and young people</a>:&nbsp;</b>covers the primary care management of children and young people with type 2 diabetes.</li></ul><ul class="sub-sections hidden"><li><a href="#!scenario">Scenario: Management - adults</a></li><li><a href="#!scenario:1">Scenario: Management - children and young people</a></li></ul></section><section class="prescribinginfo hidden" id="1090202"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Prescribing information</h2></header><p>Important aspects of prescribing information relevant to primary healthcare are covered in this section specifically for the drugs recommended in this CKS topic. For further information on contraindications, cautions, drug interactions, and adverse effects, see the&nbsp;<a href="http://www.medicines.org.uk/emc/">electronic Medicines Compendium</a>&nbsp;(eMC) or the&nbsp;<a href="https://bnf.nice.org.uk/">British National Formulary</a>&nbsp;(BNF).</p><ul class="sub-sections hidden"><li><a href="#!prescribinginfosub">Metformin</a></li><li><a href="#!prescribinginfosub:7">Gliptins</a></li><li><a href="#!prescribinginfosub:14">Pioglitazone</a></li><li><a href="#!prescribinginfosub:21">Sulfonylureas</a></li><li><a href="#!prescribinginfosub:27">Insulin</a></li><li><a href="#!prescribinginfosub:28">Glucagon-like peptide 1 (GLP-1) mimetics</a></li><li><a href="#!prescribinginfosub:35">Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) </a></li><li><a href="#!prescribinginfosub:41">Antihypertensive drugs</a></li><li><a href="#!prescribinginfosub:42">Atorvastatin</a></li></ul></section><section class="supportingevidence hidden" id="-489246"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>Supporting evidence</h2></header><p>This CKS topic is largely based on the National Institute for Health and Care Excellence (NICE) guidelines&nbsp;<i>Type 1 diabetes in adults: diagnosis and management&nbsp;</i>[<a rel="citation" resource="1090203#A1295090" href="/diabetes-type-2#!references/1090203">NICE, 2015d</a>], <i>Type 2 diabetes in adults - management&nbsp;</i>[<a rel="citation" resource="1090203#A1295065" href="/diabetes-type-2#!references/1090203">NICE, 2015a</a>],&nbsp;and&nbsp;<i>Diabetes (type 1 and type 2) in children and young people: diagnosis and managemen</i>t&nbsp;[<a rel="citation" resource="1090203#A1295112" href="/diabetes-type-2#!references/1090203">NICE, 2015b</a>].&nbsp;For a detailed discussion of the evidence NICE used to base their recommendations, see the full NICE guidelines (available at&nbsp;<a href="https://www.nice.org.uk/">www.nice.org.uk</a>).</p><ul class="sub-sections hidden"></ul></section><section class="howthistopicwasdeveloped hidden" id="1450216"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>How this topic was developed</h2></header><p>This section briefly describes the processes used in developing and updating this topic. Further details on the full process can be found in the <a href="http://cks.nice.org.uk/development">About Us</a> section and on the <a href="https://clarity.co.uk/">Clarity Informatics</a> website.</p><ul class="sub-sections hidden"><li><a href="#!searchstrategyforpublication">Search strategy</a></li><li><a href="#!stakeholderengagement">Stakeholder engagement</a></li><li><a href="#!evidenceexclusioncriteria">Evidence exclusion criteria</a></li><li><a href="#!organizationalbarriers">Organizational, behavioural and financial barriers</a></li><li><a href="#!declarationsofinterest">Declarations of interest</a></li></ul></section><section class="references hidden" id="1090203"><header><a href="#top" class="pull-right" data-track="back to top link">Back to top</a><h2>References</h2></header><p rel="citation bibo:article" resource="-350333#A1300251">
        <span property="author bibo:authorList">American Diabetes Association</span> (<span property="datePublished dcterms:issued">2016</span>)  <span property="name dc:title">Standards of medical care in diabetes - 2016.</span> <i property="publisher dc:publisher">Journal of Clinical and Applied Research and Education.</i> <b property="bibo:volume">39</b>(<span property="bibo:Issue">1</span>), <span property="bibo:pageStart">1</span>-<span property="bibo:pageEnd">119</span>.</p><p rel="citation bibo:article" resource="-350333#A1299764">
        <span property="author bibo:authorList">BMA and NHS Employers</span> (<span property="datePublished dcterms:issued">2015</span>)  <i><span property="name dc:title">2015/16 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF) Guidance for GMS contract 2015/16.</span></i> <i property="publisher dc:publisher">NHS England.</i>. <span><a href="http://www.nhsemployers.org">www.nhsemployers.org</a></span></p><p rel="citation bibo:article" resource="-350333#A1307230">
        <span property="author bibo:authorList">BNF 71</span> (2016)  <i><span property="name dc:title">British National Formulary.</span></i> 71st edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain.</p><p rel="citation bibo:article" resource="-350333#A1415960">
        <span property="author bibo:authorList">BNF 73</span> (2017)  <i><span property="name dc:title">British National Formulary.</span></i> 73rd edn. London: British Medical Association and Royal Pharmaceutical Society.</p><p rel="citation bibo:article" resource="-350333#A79871">
        <span property="author bibo:authorList">Brink,S., Joel,D., Laffel,L., et al.</span> (<span property="datePublished dcterms:issued">2014</span>)  <span property="name dc:title">ISPAD clinical practice consensus guidelines 2014 compendium: sick day management in children and adolescents with diabetes.</span> <i property="publisher dc:publisher">Pediatric Diabetes.</i> <b property="bibo:volume">15</b>(<span property="bibo:Issue">Suppl. 20</span>), <span property="bibo:pageStart">193</span>-<span property="bibo:pageEnd">202</span>.</p><p rel="citation bibo:article" resource="-350333#A1404546">
        <span property="author bibo:authorList">Brunstrom, M</span> (<span property="datePublished dcterms:issued">2016</span>)  <span property="name dc:title">Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses.</span> <i property="publisher dc:publisher">British Medical Journal.</i> <b property="bibo:volume"></b><span property="bibo:Issue"></span>, <span property="bibo:pageStart"></span><span property="bibo:pageEnd"></span>. [<span><a href="http://www.bmj.com/content/352/bmj.i717">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A79929">
        <span property="author bibo:authorList">BSPED</span> (<span property="datePublished dcterms:issued">2013</span>)  <i><span property="name dc:title">BSPED recommended DKA guidelines 2009 (minor review 2013).</span></i> <i property="publisher dc:publisher">British Society for Paediatric Endocrinology and Diabetes.</i>. [<span><a href="http://www.bsped.org.uk/clinical/docs/DKAGuideline.pdf">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A64127">
        <span property="author bibo:authorList">Cameron, F.J. and Allgrove, J.</span> (<span property="datePublished dcterms:issued">2007</span>)  <bookchapter>Evidence-based paediatric and adolescent diabetes.</bookchapter> In: <span property="bibo:editorList">Allgrove, J., Swift, P.G.F., Greene, S.</span> (Eds.) <i><span property="name dc:title">Management of special situations in diabetes.</span></i><span property="bibo:edition"></span> edn. : Blackwell Publishing.<span property="bibo:pageStart">93</span>, <span property="bibo:pageStart">93</span>-<span property="bibo:pageEnd">103</span>.</p><p rel="citation bibo:article" resource="-350333#A1299577">
        <span property="author bibo:authorList">Diabetes UK</span> (<span property="datePublished dcterms:issued">2015</span>)  <i><span property="name dc:title">Facts and stats.</span></i> <i property="publisher dc:publisher">Diabetes UK.</i>. [<span><a href="https://www.diabetes.org.uk/Documents/Position%20statements/Diabetes%20UK%20Facts%20and%20Stats_Dec%202015.pdf">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A68225">
        <span property="author bibo:authorList">EMA</span> (<span property="datePublished dcterms:issued">2011</span>)  <i><span property="name dc:title">European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer.</span></i> <i property="publisher dc:publisher">European Medicines Agency.</i>. [<span><a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001311.jsp&amp;murl=menus/news_and_events/news_and_events.jsp&amp;mid=WC0b01ac058004d5c1&amp;jsenabled=true">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A64085">
        <span property="author bibo:authorList">Holt, T. and Kumar, S.</span> (<span property="datePublished dcterms:issued">2010</span>)  <bookchapter>ABC of Diabetes.</bookchapter> In: <span property="bibo:editorList">Holt, T., Kumar, S.</span> (Eds.) <i><span property="name dc:title">Hyperglycaemic emergencies and the management of diabetes in hospital.</span></i><span property="bibo:edition"></span> edn. : Wiley-Blackwell Publication.<span property="bibo:pageStart">31</span>, <span property="bibo:pageStart">31</span>-<span property="bibo:pageEnd">34</span>.</p><p rel="citation bibo:article" resource="-350333#A63987">
        <span property="author bibo:authorList">Holt, T. and Kumar, S.</span> (<span property="datePublished dcterms:issued">2010</span>)  <bookchapter>ABC of Diabetes.</bookchapter> In: <span property="bibo:editorList">Holt, T., Kumar, S.</span> (Eds.) <i><span property="name dc:title">Types of Diabetes.</span></i><span property="bibo:edition"></span> edn. : Wiley-Blackwell Publication.<span property="bibo:pageStart">5</span>, <span property="bibo:pageStart">5</span>-<span property="bibo:pageEnd">8</span>.</p><p rel="citation bibo:article" resource="-350333#A1299786">
        <span property="author bibo:authorList">Joint British Diabetes Societies Inpatient Care</span> (<span property="datePublished dcterms:issued">2013</span>)  <i><span property="name dc:title">Joint British Diabetes Societies Inpatient Care Group: The management of diabetic ketoacidosis in adults.</span></i> <i property="publisher dc:publisher">Joint British Diabetes Societies Inpatient Care Group.</i>. <span><a href="http://diabetes.org.uk">diabetes.org.uk</a></span> [<span><a href="https://www.diabetes.org.uk/Documents/About%20Us/What%20we%20say/Management-of-DKA-241013.pdf">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A79928">
        <span property="author bibo:authorList">Joint British Diabetes Societies Inpatient Care Group</span> (<span property="datePublished dcterms:issued">2013</span>)  <i><span property="name dc:title">Joint British Diabetes Societies Inpatient Care Group: The management of diabetic ketoacidosis in adults.</span></i> <i property="publisher dc:publisher">Joint British Diabetes Societies Inpatient Care Group.</i>. <span><a href="http://diabetes.org.uk/">diabetes.org.uk/</a></span> [<span><a href="http://www.diabetes.org.uk/Documents/About%20Us/What%20we%20say/Management-of-DKA-241013.pdf">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1314577">
        <span property="author bibo:authorList">Kajantie, E., Osmond, C., Barker, D.J. and and Eriksson, J.G.</span> (<span property="datePublished dcterms:issued">2010</span>)  <span property="name dc:title">Preterm birth - a risk factor for type 2 diabetes? The Helsinki birth cohort study.</span> <i property="publisher dc:publisher">Diabetes care.</i> <b property="bibo:volume">33</b>(<span property="bibo:Issue">12</span>), <span property="bibo:pageStart">2623</span>-<span property="bibo:pageEnd">2625</span>. [<span><a href="http://www.ncbi.nlm.nih.gov/pubmed/20823347">Abstract</a></span>]</p><p rel="citation bibo:article" resource="-350333#A79176">
        <span property="author bibo:authorList">Kilpatrick,E. and Atkin,S.</span> (<span property="datePublished dcterms:issued">2014</span>)  <i><span property="name dc:title">Using haemoglobin A(1c) to diagnose type 2 diabetes or to identify people at high risk of diabetes (rational testing).</span></i> <span property="bibo:Collection">BMJ.</span> <i property="publisher dc:publisher">BMJ.</i>.</p><p rel="citation bibo:article" resource="-350333#A79927">
        <span property="author bibo:authorList">Kitabchi, A.E., Umpierrez, G.E., Miles,J. and Fisher,J.</span> (<span property="datePublished dcterms:issued">2009</span>)  <span property="name dc:title">Hyperglycemic crises in adult patients with diabetes.</span> <i property="publisher dc:publisher">Diabetes Care.</i> <b property="bibo:volume">32</b>(<span property="bibo:Issue">7</span>), <span property="bibo:pageStart">1335</span>-<span property="bibo:pageEnd">1343</span>.</p><p rel="citation bibo:article" resource="-350333#A10706">
        <span property="author bibo:authorList">Law,M.R., Wald,N.J. and Rudnicka,A.R.</span> (<span property="datePublished dcterms:issued">2003</span>)  <span property="name dc:title">Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.</span> <i property="publisher dc:publisher">British Medical Journal.</i> <b property="bibo:volume">326</b>(<span property="bibo:Issue">7404</span>), <span property="bibo:pageStart">1423</span>-<span property="bibo:pageEnd">1429</span>. [<span><a href="http://www.ncbi.nlm.nih.gov/pubmed/12829554">Abstract</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1403259">
        <span property="author bibo:authorList">Medicines and Healthcare products Regulatory Agency</span> (<span property="datePublished dcterms:issued">2016</span>)  <i><span property="name dc:title">SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis.</span></i> <i property="publisher dc:publisher">MHRA.</i>. <span><a href="https://www.gov.uk/drug-safety-update/sglt2-inhibitors-updated-advice-on-the-risk-of-diabetic-ketoacidosis">www.gov.uk/drug-safety-update/sglt2-inhibitors-updated-advice-on-the-risk-of-diabetic-ketoacidosis</a></span></p><p rel="citation bibo:article" resource="-350333#A23356">
        <span property="author bibo:authorList">MeReC</span> (<span property="datePublished dcterms:issued">2004</span>)  <span property="name dc:title">Drug management of type 2 diabetes: summary.</span> <i property="publisher dc:publisher">MeReC Bulletin.</i> <b property="bibo:volume">15</b>(<span property="bibo:Issue">1</span>), <span property="bibo:pageStart"></span><span property="bibo:pageEnd"></span>.</p><p rel="citation bibo:article" resource="-350333#A62450">
        <span property="author bibo:authorList">MHRA</span> (<span property="datePublished dcterms:issued">2010</span>)  <span property="name dc:title">Simvastatin: increased risk of myopathy at high dose (80 mg).</span> <i property="publisher dc:publisher">Drug Safety Update.</i> <b property="bibo:volume">3</b>(<span property="bibo:Issue">10</span>), <span property="bibo:pageStart">7</span>-<span property="bibo:pageEnd">8</span>.</p><p rel="citation bibo:article" resource="-350333#A67307">
        <span property="author bibo:authorList">MHRA</span> (<span property="datePublished dcterms:issued">2011</span>)  <span property="name dc:title">Insulin combined with pioglitazone: risk of cardiac failure.</span> <i property="publisher dc:publisher">Drug Safety Update.</i> <b property="bibo:volume">4</b>(<span property="bibo:Issue">6</span>), <span property="bibo:pageStart">A2</span><span property="bibo:pageEnd"></span>.</p><p rel="citation bibo:article" resource="-350333#A68224">
        <span property="author bibo:authorList">MHRA</span> (<span property="datePublished dcterms:issued">2011</span>)  <i><span property="name dc:title">New advice on risk of bladder cancer with the anti-diabetic drug pioglitazone (Actos [black triangle], Competact [black triangle]).</span></i> <i property="publisher dc:publisher">Medicines and Healthcare products Regulatory Agency.</i>. [<span><a href="http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON123285">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A68615">
        <span property="author bibo:authorList">MHRA</span> (<span property="datePublished dcterms:issued">2012</span>)  <span property="name dc:title">Statins: risk of hyperglycaemic and diabetes.</span> <i property="publisher dc:publisher">Drug Safety Update.</i> <b property="bibo:volume">5</b>(<span property="bibo:Issue">6</span>), <span property="bibo:pageStart">A2</span><span property="bibo:pageEnd"></span>.</p><p rel="citation bibo:article" resource="-350333#A79644">
        <span property="author bibo:authorList">MHRA</span> (<span property="datePublished dcterms:issued">2014</span>)  <span property="name dc:title">Domperidone: risks of cardiac side effects.</span> <i property="publisher dc:publisher">Drug Safety Update.</i> <b property="bibo:volume">7</b>(<span property="bibo:Issue">10</span>), <span property="bibo:pageStart">A1</span><span property="bibo:pageEnd"></span>.</p><p rel="citation bibo:article" resource="-350333#A79645">
        <span property="author bibo:authorList">MHRA</span> (<span property="datePublished dcterms:issued">2014</span>)  <span property="name dc:title">Metoclopramide: risk of neurological adverse effects.</span> <i property="publisher dc:publisher">Drug Safety Update.</i> <b property="bibo:volume">7</b>(<span property="bibo:Issue">1</span>), <span property="bibo:pageStart">S2</span><span property="bibo:pageEnd"></span>.</p><p rel="citation bibo:article" resource="-350333#A79003">
        <span property="author bibo:authorList">MHRA</span> (<span property="datePublished dcterms:issued">2014</span>)  <span property="name dc:title">Statins benefits and risks.</span> <i property="publisher dc:publisher">Drug Safety Update.</i> <b property="bibo:volume">7</b>(<span property="bibo:Issue">10</span>), <span property="bibo:pageStart">H1</span><span property="bibo:pageEnd"></span>.</p><p rel="citation bibo:article" resource="-350333#A64340">
        <span property="author bibo:authorList">Morrish, N.J., Wang, S.L., Stevens, L.K., et al.</span> (<span property="datePublished dcterms:issued">2001</span>)  <span property="name dc:title">Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.</span> <i property="publisher dc:publisher">Diabetologia.</i> <b property="bibo:volume">44</b>(<span property="bibo:Issue">Suppl 2</span>), <span property="bibo:pageStart">S14</span>-<span property="bibo:pageEnd">S21</span>. [<span><a href="http://www.ncbi.nlm.nih.gov/pubmed/11587045">Abstract</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1402667">
        <span property="author bibo:authorList">National Institute of Health and Care Excellence</span> (<span property="datePublished dcterms:issued">2016</span>)  <i><span property="name dc:title">Diabetes in children and young people.</span></i> <i property="publisher dc:publisher">NICE.</i>. <span><a href="https://www.nice.org.uk/guidance/qs125">www.nice.org.uk/guidance/qs125</a></span></p><p rel="citation bibo:article" resource="-350333#A64866">
        <span property="author bibo:authorList">NHS Diabetes, Diabetes UK, Department of Health</span> (<span property="datePublished dcterms:issued">2010</span>)  <i><span property="name dc:title">National Service Framework for Children, Young People and Maternity Services – Diabetes Type 1 in childhood and adolescence.</span></i> <i property="publisher dc:publisher">NHS Diabetes.</i>. [<span><a href="https://www.gov.uk/government/publications/diabetes-type-1-in-childhood-national-service-framework-for-children-young-people-and-maternity-services">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A68249">
        <span property="author bibo:authorList">NICE</span> (<span property="datePublished dcterms:issued">2011</span>)  <i><span property="name dc:title">Hypertension. Clinical management of primary hypertension in adults (NICE guideline).</span></i> <span property="bibo:Collection">Clinical guidance 127.</span> <i property="publisher dc:publisher">National Institute for Health and Clinical Excellence.</i>. [<span><a href="http://guidance.nice.org.uk/CG127/NICEGuidance/pdf/English">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1299775">
        <span property="author bibo:authorList">NICE</span> (<span property="datePublished dcterms:issued">2011</span>)  <i><span property="name dc:title">Quality standard on diabetes in adults.</span></i> <i property="publisher dc:publisher">National Institute for Health and Care Excellence.</i>. [<span><a href="https://www.nice.org.uk/guidance/qs6/chapter/List-of-statements">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1300738">
        <span property="author bibo:authorList">NICE</span> (<span property="datePublished dcterms:issued">2013</span>)  <i><span property="name dc:title">Neuropathic pain in adults: pharmacological management in non-specialist settings.</span></i> <i property="publisher dc:publisher">National Institute for Health and Care Excellence.</i>. [<span><a href="https://www.nice.org.uk/guidance/cg173/evidence">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1314603">
        <span property="author bibo:authorList">NICE</span> (<span property="datePublished dcterms:issued">2013</span>)  <i><span property="name dc:title">Physical activity: brief advice for adults in primary care.</span></i> <span property="bibo:Collection">NICE guidelines PH44.</span> <i property="publisher dc:publisher">National Institute for Health and Care Excellence.</i>. [<span><a href="https://www.nice.org.uk/guidance/ph44">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A78878">
        <span property="author bibo:authorList">NICE</span> (<span property="datePublished dcterms:issued">2014</span>)  <i><span property="name dc:title">Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (full guideline).</span></i> <i property="publisher dc:publisher">National Institute for Health and Care Excellence.</i>. [<span><a href="http://www.nice.org.uk/Guidance/CG181/Evidence">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1295112">
        <span property="author bibo:authorList">NICE</span> (<span property="datePublished dcterms:issued">2015</span>)  <i><span property="name dc:title">Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NICE guideline).</span></i> <span property="bibo:Collection">NICE guidelines [NG18].</span> <i property="publisher dc:publisher">National Institute for Health and Care Excellence.</i>. <span><a href="https://www.nice.org.uk/">www.nice.org.uk/</a></span> [<span><a href="https://www.nice.org.uk/guidance/ng18">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1299588">
        <span property="author bibo:authorList">NICE</span> (<span property="datePublished dcterms:issued">2015</span>)  <i><span property="name dc:title">Diabetic foot problems: prevention and management.</span></i> <i property="publisher dc:publisher">National Institute for Health and Care Excellence.</i>.</p><p rel="citation bibo:article" resource="-350333#A1295090">
        <span property="author bibo:authorList">NICE</span> (<span property="datePublished dcterms:issued">2015</span>)  <i><span property="name dc:title">Type 1 diabetes in adults: diagnosis and management (NICE guideline).</span></i> <span property="bibo:Collection">NICE guidelines [NG17].</span> <i property="publisher dc:publisher">National Institute for Health and Care Excellence.</i>. <span><a href="https://www.nice.org.uk/">www.nice.org.uk/</a></span> [<span><a href="https://www.nice.org.uk/guidance/ng17">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1295065">
        <span property="author bibo:authorList">NICE Internal Clinical Guidelines Team</span> (<span property="datePublished dcterms:issued">2015</span>)  <i><span property="name dc:title">Type 2 diabetes in adults: management (full guideline).</span></i> <span property="bibo:Collection">Clinical Guideline Update (NG28).</span> <i property="publisher dc:publisher">National Institute for Health and Care Excellence.</i>. <span><a href="https://www.nice.org.uk/">www.nice.org.uk/</a></span> [<span><a href="https://www.nice.org.uk/guidance/ng28/evidence/full-guideline-2185320349">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A79868">
        <span property="author bibo:authorList">RCN</span> (<span property="datePublished dcterms:issued">2012</span>)  <i><span property="name dc:title">Starting injectable treatment in adults with Type 2 diabetes: RCN guidance for nurses.</span></i> <i property="publisher dc:publisher">Royal College of Nursing.</i>. [<span><a href="http://www.rcn.org.uk/__data/assets/pdf_file/0009/78606/002254.pdf">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1301999">
        <span property="author bibo:authorList">Rogers, L.C., Frykberg, R.G. and Armstrong, D.G. et al.</span> (<span property="datePublished dcterms:issued">2011</span>)  <span property="name dc:title">The Charcot Foot in Diabetes.</span> <i property="publisher dc:publisher">Diabetes Care.</i> <b property="bibo:volume">34</b>(<span property="bibo:Issue">9</span>), <span property="bibo:pageStart">2123</span>-<span property="bibo:pageEnd">2129</span>.</p><p rel="citation bibo:article" resource="-350333#A1404805">
        <span property="author bibo:authorList">US Food &amp; Drug Administration</span> (<span property="datePublished dcterms:issued">2016</span>)  <i><span property="name dc:title">Drug Safety Communication: Pioglitazone-containing medicines&nbsp;- increased risk of bladder cancer.&nbsp;Updated FDA review,.</span></i> <i property="publisher dc:publisher">US Food &amp; Drug Administration.</i>. [<span><a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm532772.htm">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1314592">
        <span property="author bibo:authorList">WHO</span> (<span property="datePublished dcterms:issued">1999</span>)  <i><span property="name dc:title">Definition, diagnosis and classification of diabetes mellitus and its complications.</span></i> <i property="publisher dc:publisher">World Health Organization.</i>. [<span><a href="http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A1299518">
        <span property="author bibo:authorList">WHO</span> (<span property="datePublished dcterms:issued">2006</span>)  <i><span property="name dc:title">Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation.</span></i> <i property="publisher dc:publisher">World Health Organisation.</i>. [<span><a href="http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf">Free Full-text</a></span>]</p><p rel="citation bibo:article" resource="-350333#A79177">
        <span property="author bibo:authorList">WHO</span> (<span property="datePublished dcterms:issued">2011</span>)  <i><span property="name dc:title">Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation.</span></i> <span property="bibo:Collection">World Health Organization.</span> <i property="publisher dc:publisher"></i> [<span><a href="http://www.who.int/cardiovascular_diseases/report-hba1c_2011_edited.pdf">Free Full-text</a></span>]</p><ul class="sub-sections hidden"></ul></section></article>
        </div>
							  </div>
							  <div class="modal-footer">
							    <button type="button" class="btn btn-secondary" data-dismiss="modal">Close</button>

							  </div>
							</div><!--end modal-content-->
						      </div><!--end modal-dialog-->
						    </div><!--end modal-->
						    <div class="modal fade" id="Modal2" tabindex="-1" role="dialog" aria-labelledby="exampleModalLabel" aria-hidden="true">
						      <div class="modal-dialog" role="document">
							<div class="modal-content">
							  <div class="modal-header">
							    <h5 class="modal-title" id="exampleModalLabel">Hanna Gover</h5>
							    <button type="button" class="close" data-dismiss="modal" aria-label="Close">
							      <span aria-hidden="true">×</span>
							    </button>
							  </div>
							  <div class="modal-body">
							    <img src="/images/patient-info.png" alt="patient info">
							  </div>
							  <div class="modal-footer">
							    <button type="button" class="btn btn-secondary" data-dismiss="modal">Close</button>
							    <button type="button" class="btn btn-primary">Joshi Nirav</button>
							  </div>
							</div><!--end modal-content-->
						      </div><!--end modal-dialog-->
						    </div><!--end modal--->
						    <div class="modal fade" id="Modal3" tabindex="-1" role="dialog" aria-labelledby="exampleModalLabel" aria-hidden="true">
						      <div class="modal-dialog" role="document">
							<div class="modal-content">
							  <div class="modal-header">
							    <h5 class="modal-title" id="exampleModalLabel">Joshi Sunil</h5>
							    <button type="button" class="close" data-dismiss="modal" aria-label="Close">
							      <span aria-hidden="true">×</span>
							    </button>
							  </div>
							  <div class="modal-body">
							    <img src="/images/patient-info.png" alt="patient info">
							  </div>
							  <div class="modal-footer">
							    <button type="button" class="btn btn-secondary" data-dismiss="modal">Close</button>

							  </div>
							 </div><!--end modal-content-->
						      </div><!--end modal-dialog-->
						    </div><!--end modal-->
						    <div class="modal fade" id="Modal4" tabindex="-1" role="dialog" aria-labelledby="exampleModalLabel" aria-hidden="true">
						      <div class="modal-dialog" role="document">
							<div class="modal-content">
							  <div class="modal-header">
							    <h5 class="modal-title" id="exampleModalLabel">Modal title</h5>
							    <button type="button" class="close" data-dismiss="modal" aria-label="Close">
							      <span aria-hidden="true">×</span>
							    </button>
							  </div>
							  <div class="modal-body">
							    <img src="/images/patient-info.png" alt="patient info">
							  </div>
							  <div class="modal-footer">
							    <button type="button" class="btn btn-secondary" data-dismiss="modal">Close</button>
							  </div>
							</div><!--end modal-content-->
						      </div><!--end modal-dialog-->
						    </div><!--end modal-->
						</div><!--end table-responsive-->
					  </div><!--end patient tab-pane-->
					  <div class="tab-pane" id="therapies" role="tabpanel" aria-labelledby="therapies-tab">
						<h4></h4>
						      <div class="table-responsive manage-table">
							  <table class="table">
							      <thead>
								  <tr>
								      <th>Metformin combinations</th>
								      <th>Other (Metaformin intolerant/contraindicated)</th>
								      <th>No. of Patients</th>
								      <th>Actions</th>
								  </tr>
							      </thead>
							      <tbody>
								  <tr class="advance-table-row">
								      <td>Metformin plus a gliptin</td>
								      <td>A gliptin plus pioglitazone</td>
								      <td>1</td>
								      <td><!--<button type="button" class="btn btn-primary" data-toggle="tooltip" data-placement="top" title="Tooltip on top">
									Patient list
								      </button>--></td>
								  </tr>
								  <tr class="advance-table-row">
								      <td>Metformin plus pioglitazone</td>
								      <td>A gliptin plus a sulfonylurea</td>
								      <td>1</td>
								      <td><!--<button type="button" class="btn btn-primary" data-toggle="tooltip" data-placement="top" title="Tooltip on top">
									Patient list
								      </button>--></td>
								  </tr>
								  <tr class="advance-table-row">
								      <td>Metformin plus a sulfonylurea</td>
								      <td>Pioglitazone plus a sulfonylurea</td>
								      <td>2</td>
								      <td><!--<button type="button" class="btn btn-primary" data-toggle="tooltip" data-placement="top" title="Tooltip on top">
									Patient list
								      </button>--></td>
								  </tr>
								  <tr class="advance-table-row">
								      <td>Metformin plus a Sodium-glucose <br>co-transporter 2 inhibitor (SGLT-2i)</td>
								      <td>An SGLT-2i instead of a gliptin if  <br>a sulfonylurea or pioglitazone is not appropriate</td>
								      <td>1</td>
								      <td><!--<button type="button" class="btn btn-primary" data-toggle="tooltip" data-placement="top" title="Tooltip on top">
									Patient list
								      </button>--></td>
								  </tr>
							      </tbody>
							  </table>
						      </div><!--end table-responsive-->
						</div><!--end therapies tab-pane-->
					  </div><!--end mod-on-->
					  <div class="toggle-mod" style="display:none">
						 <!--Off contains no content-->       
					  </div>
				    </div>				      
				      </div>
			      <!-- PROBABLY NOT REQUIRED... TO REMOVE<script>
				$(function () {
				  $('#myTab li:first-child a').tab('show')
				})
			      </script>-->
			</div><!--end block d-->
			<div id="block-f" title="mod-10" class="section">
			      <div class="toggle-mod" style="display:none">
				     <!--On contains no content-->       
			      </div>
			      <div class="section">
				      <h2 id="blockf-header">Participation & benchmarking</h2>
				     <div class="row">
					<div class="col">
						<strong>ABOUT NDA</strong>
						    <p>The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to:</p>
						    <ul>
							<li>Assess local practice against NICE guidelines</li>
							<li>Compare their care and care outcomes with similar services and organisations</li>
							<li>Identify gaps or shortfalls that are priorities for improvement</li>
							<li>Identify and share best practice</li>
							<li>Provide comprehensive national pictures of diabetes care and outcomes in England and Wales</li>
						    </ul>Through participation in the audit, local services are able to benchmark their performance and identify where they are performing well and improve the quality of treatment and care they provide.<p></p>
					  </div>
					  <div class="col">
						<strong>National percentage of people with type 2 diabetes receiving NICE recommended care processes 2017-18.</strong>
						<ul class="list-group">
							<li class="list-group-item">HbA1c<span class="label label-default pull-right">95.3%</span></li>
							<li class="list-group-item">Blood pressure<span class="label label-default pull-right">96.3%</span></li>
							<li class="list-group-item">Serum cholesterol<span class="label label-default pull-right">92.9%</span></li>
							<li class="list-group-item">Serum creatinine<span class="label label-default pull-right">95.1%</span></li>
							<li class="list-group-item">Urine Albumin/Creatinine Ratio<span class="label label-default pull-right">66.2%</span></li>
							<li class="list-group-item">Foot Risk Surveillance<span class="label label-default pull-right">86.8%</span></li>
							<li class="list-group-item">Body Mass Index<span class="label label-default pull-right">8.0%</span>8</li>
							<li class="list-group-item">Smoking History<span class="label label-default pull-right">95.5%</span></li>
							<li class="list-group-item">All eight processes of care<span class="label label-default pull-right">58.8%</span></li>
						</ul>
					  </div>
				    </div>

			      </div>

			</div><!--end block f-->
			<div id="block-e" title="mod-16" class="patient-story section">
			      <div class="toggle-mod">
				    <h2 id="blocke-header">A patient account</h2>
				    <div class="media">
				      <img src="/images/patient.png" alt="patient photo" class="img-circle img-responsive align-self-start mr-3" style="width:64px; height:64px">
				      <div class="media-body">
					<h5 class="mt-0">Daniel Kristeen</h5>
					<p>I had struggled to keep my diabetes under control for over a year. I was taking medication already and seriously trying to improve my diet.  My Mum lost her sight because of diabetes and I was worried that this might happen to me.  My doctor prescribed me another medicine and suggested I try it for a while to see if it made an improvement.</p>
					<p>Although I had doubts about starting another medicine, I’m glad that I did because my blood sugar is better now and I haven’t had any bad side effects. I know that doctors sometimes don’t want to push lots of medicines onto people with diabetes but it is only fair to the patient that they ask.</p>
				      </div>
				    </div>
			      </div>
			      <div class="toggle-mod" style="display:none">
				     <!--Off contains no content-->       
			      </div>
			      <!--
			      <div class="col-md-1 col-sm-1">
				    <img src="" alt="patient photo" class="img-circle img-responsive">
			      </div>
			      <div class="col-md-11 col-sm-8">
				    <h2 class="m-b-0">Daniel Kristeen</h2>
				    <blockquote class="blockquote">
				      <p class="mb-0"></p>
				    </blockquote>
				    <h4></h4>
			      </div>
			      -->
			</div><!--end block e-->
			
			<div class="row section">
			       <a href="#" class="btn btn-link">Back to top</a>
			      <a href="{{ site.baseurl }}/survey" data-toggle="tooltip" data-placement="right" title="Proceed to final task!" class="btn btn-success">Next</a>
			</div>

</main>
      </div><!-- END ROW-->
</div><!-- END CONTAINER_FLUID-->
<script>
  document.getElementsByClassName("progress-bar")[0].setAttribute("style", "width:60%");
      $('#mod12Tab a').on('click', function (e) {
            e.preventDefault()
            $(this).tab('show')
      })
      function toggleSwitch() {
        var x = document.getElementByClassName("toggle-mod");
        if (x.style.display === "none") {
          x.style.display = "block";
        } else {
          x.style.display = "none";
        }
      }  
      
</script>

